US Pat. No. 10,920,111

PACKAGING FOR PREFINISHED ARTICLES

James Hardie Technology L...

1. A protective packaging system for providing temporary protection of a top coating on a prefinished building article, comprising:an outer layer, said outer layer comprising 25 to 40% by weight of a low density polyethylene (LDPE) and 60 to 75% by weight of a high density polyethylene, wherein the LDPE and the high density polyethylene are present in the outer layer in a mass ratio of about 1:3 to about 3:1;
an adhesive layer, said adhesive layer comprising ethylene methacrylate copolymer with a methyl acrylate co-monomer content of about 24% or less, acid modified ethylene acrylate terpolymer, an ethylene acrylic acid copolymer comprising 15-40% acid co-monomer, and a first roughening agent, wherein the first roughening agent comprises inorganic particulates dispersed in a polyethylene resin mixture in a manner such that at least some of the inorganic particulates protrude from the adhesive layer; and
a core layer disposed between the outer layer and the adhesive layer, wherein the core layer comprises a linear low density polyethylene, a low density polyethylene, and a dispersed second roughening agent.

US Pat. No. 10,920,110

TAPE FOR PRODUCING NON-QUILTED ARTICLES AND GARMENT USING THE TAPE

Toray Industries, Inc., ...

1. A tape for producing a non-quilted article, the tape comprising adhesive portions on outer surfaces on one side and a reverse side of the tape, the tape being a cut piece of a double-layer woven fabric comprising a fabric layer arranged on one side of the fabric and a fabric layer arranged on a reverse side of the fabric, the tape comprising adhesive portion-free surfaces arranged to face each other.

US Pat. No. 10,920,107

SELF-STOPPING POLISHING COMPOSITION AND METHOD FOR BULK OXIDE PLANARIZATION

CMC Materials, Inc., Aur...

1. A chemical-mechanical polishing composition comprising:(a) a ceria abrasive,
(b) less than about 1000 ppm of picolinic acid,
(c) a self-stopping agent selected from a compound of formula (I):
wherein R is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heterocyclic alkyl, and heterocyclic aryl, each of which may be substituted or unsubstituted:(d) a cationic polymer, wherein the cationic polymer is selected from, 2-(dimethylamino)ethyl methacrylate, diallyldimethylammonium, poly(vinylimidazolium), poly(methacryloyloxyethyltnmethylammonium) halide, poly(diallyldimethylammonium) chloride, polyquaternium-2, Polyquatemium-11, Polyquatemium-16, Polyquatemium-46, Polyquatemium-44, Luviquat Supreme, Luviquat Hold, Luviquat UltraCare, Luviquat FC 370, Luviquat FC 550, Luviquat FC 552, Luviquat Excellence, and combinations thereof, and
(e) an aqueous carrier,wherein the polishing composition has a pH of about 6 to about 9.

US Pat. No. 10,920,106

METAL CHEMICAL MECHANICAL PLANARIZATION (CMP) COMPOSITION AND METHODS THEREFORE

Versum Materials US, LLC,...

1. A metal film bulk chemical mechanical polishing (CMP) or Through Silica Via (TSV) composition comprises:a) Abrasive ranging from 0.0025 wt. % to 2.5 wt. % and is selected from the group consisting of colloidal silica or high purity colloidal silica, colloidal silica particles doped by other metal oxide within lattice of the colloidal silica, colloidal aluminum oxide, colloidal and photoactive titanium dioxide, cerium oxide, colloidal cerium oxide, nano-sized inorganic metal oxide particles, nano-sized diamond particles, nano-sized silicon nitride particles, mono-modal colloidal abrasive particles, bi-modal colloidal abrasive particles, multi-modal colloidal abrasive particles, organic polymer-based soft abrasives, surface-coated or modified abrasives, and combinations thereof;
b) at least one chelator ranging from 0.5 wt. % to 2.5 wt. % and is selected from the group consisting of amino acids, amino acid derivatives, organic amine, and combinations therefor; wherein at least one of the at least one chelator is an amino acid or an amino acid derivative;
c) corrosion inhibitor ranging from 0.01 wt. % to 0.1 wt. % and is selected from the group consisting of 1,2,4-triazole and derivatives, benzotriazole and benzotriazole derivatives, tetrazole and tetrazole derivatives, imidazole and imidazole derivatives, benzimidazole and benzimidazole derivatives, pyrazole and pyrazole derivatives, tetrazole and tetrazole derivatives, and combinations thereof;
d) a chemical additive;
e) oxidizing agent ranging from 0.25 wt. % to 3 wt. %; and is selected from the group consisting of periodic acid, hydrogen peroxide, potassium iodate, potassium permanganate, ammonium persulfate, ammonium molybdate, ferric nitrate, nitric acid, potassium nitrate, and combinations thereof; and
f) water based solvent selected from the group consisting of deionized (DI) water, distilled water, and water based alcoholic organic solvent;
optionally
g) biocide ranging from 0.0001 wt. % to 0.025 wt. % and has active ingredients of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one;
h) organic quaternary ammonium salt; and
i) pH adjusting agent;
wherein
the pH of the composition is 5.5 to 8.0;
the metal film is selected from the group consisting of Cu film, Co film, W film, Ni film, Al film, and combinations thereof; and
the chemical additive ranges from 0.0025 wt. % to 0.25 wt. % and is a morpholino compound or oligomer having a molecular structure selected from the group consisting of
wherein R is hydrogen or an organic functional group attached to the nitrogen atom in morpholino 6-member ring through covalent boding with no net charges; and R is selected from the group consisting of alkyl primary amine with a single primary amine group or two or more than 2 primary amine groups in the same molecule; alkyl primary amine with a single secondary amine group or two or more than 2 secondary amine groups in the same molecule; alkyl amide with a single amide group or two or more than 2 amide groups in the same molecule; alkene primary amine with a single primary amine group or two or more than 2 primary amine groups in the same molecule; alkene primary amine with a single secondary amine group or two or more than 2 secondary amine groups in the same molecule; alkene amide with a single amide group or two or more than 2 amide groups in the same molecule; alkyne primary amine with a single primary amine group or two or more than 2 primary amine groups in the same molecule; alkyne primary amine with a single secondary amine group or two or more than 2 secondary amine groups in the same molecule; alkyne amide with a single amide group or two or more than 2 amide groups in the same molecule; alkyl alcohol with a single hydroxyl group or two or more than 2 hydroxyl groups in the same molecule; alkene alcohol with a single hydroxyl group or two or more than 2 hydroxyl groups in the same molecule; and alkyne alcohol with a single hydroxyl group or two or more than 2 hydroxyl groups in the same molecule;wherein R? is an organic functional group attached to the nitrogen atom in morpholino 6-member ring through covalent boding with negative charges; and R? is selected from the group consisting of alkyl sulfonate with one sulfonate or two or more than 2 sulfonate groups in the same molecule, alkyl carbonate with one carbonate group or two or more than 2 carbonate groups in the same molecule, alkyl phosphate with one phosphate group or two or more than 2 phosphate groups in the same molecule, alkene sulfonate with one sulfonate group or two or more than 2 sulfonate groups in the same molecule, alkene carbonate with one carbonate group or two or more than 2 carbonate groups in the same molecule, alkene phosphate with one phosphate group or two or more than 2 phosphate groups in the same molecule, alkyne sulfonate with one sulfonate group or two or more than 2 sulfonate groups in the same molecule, alkyne carbonate with one carbonate group or two or more than 2 carbonate groups in the same molecule, alkyne phosphate with one phosphate group or two or more than 2 phosphate groups in the same molecule; and counter ion M+ for R? group is selected from the group consisting of sodium ion, potassium ion, ammonium ion, and cesium ion;wherein R+ is an organic functional group attached to the nitrogen atom in morpholino 6-member ring through covalent boding with positive charges; and R+ is selected from the group consisting of alkyl quaternary ammonium with one quaternary ammonium group or two or more than 2 quaternary ammonium groups in the same molecule, alkene quaternary ammonium with one quaternary ammonium group or two or more than 2 quaternary ammonium groups in the same molecule, alkyne quaternary ammonium with one quaternary ammonium group or two or more than 2 quaternary ammonium groups in the same molecule; and counter ions N? for R+ group is selected from the group consisting of carbonate anion, sulfate anion or phosphate anion; andcombinations thereof.

US Pat. No. 10,920,105

MATERIALS AND METHODS FOR CHEMICAL MECHANICAL POLISHING OF RUTHENIUM-CONTAINING MATERIALS

TAIWAN SEMICONDUCTOR MANU...

16. A method, comprising:providing a substrate including a ruthenium (Ru)-containing region disposed adjacent to a dielectric region;
polishing the Ru-containing region with respect to the dielectric region in a chemical-mechanical polishing (CMP) process, including:
rotating a platen configured with a polishing pad about an axis;
supplying a slurry including an oxidant and an abrasive to the substrate, wherein the abrasive includes a plurality of particles each having a first layer encapsulated by a second layer, wherein the first layer includes a first oxygen-based compound, and wherein the second layer includes a second oxygen-based compound different from the first oxygen-based compound; and
bringing the rotating platen into contact with the slurry to polish the Ru-containing region, wherein the polishing includes oxidizing Ru in the Ru-containing region and subsequently remove the oxidized Ru.

US Pat. No. 10,920,100

METHOD FOR PRODUCING A MULTI-LAYERED COATING

1. A method for producing a multicoat paint system (M) on a metallic substrate (S), comprising(1) producing a cured electrocoat (E.1) on the metallic substrate (S) by electrophoretic application of an electrocoat material (e.1) to the substrate (S) and subsequent curing of the electrocoat material (e.1),
(2) producing a basecoat (B.2.1) or two or more directly successive basecoats (B.2.2.x) directly on the cured electrocoat (E.1) by application of an aqueous basecoat material (b.2.1) directly to the electrocoat (E.1) or directly successive application of two or more basecoat materials (b.2.2.x) to the electrocoat (E.1),
(3) producing a clearcoat (K) directly on the basecoat (B.2.1) or on the topmost basecoat (B.2.2.x) by application of a clearcoat material (k) directly to the basecoat (B.2.1) or to the topmost basecoat (B.2.2.x),
(4) jointly curing the basecoat (B.2.1) and the clearcoat (K) or the basecoats (B.2.2.x) and the clearcoat (K), and
wherein
the basecoat material (b.2.1) or at least one of the basecoat materials (b.2.2.x) comprises at least one aqueous dispersion (wD),
the dispersion (wD) comprising at least one polymer having a particle size of 100 to 500 nm, wherein the at least one polymer is produced by successive radical emulsion polymerization of a mixture (A), a mixture (B), and a mixture (C) of olefinically unsaturated monomers,
the mixture (A) comprising at least 50 wt % of olefinically unsaturated monomers having a solubility in water of less than 0.5 g/l at 25° C., wherein the olefinically unsaturated monomers present in the mixture (A) are selected such that a polymer prepared from the mixture (A) possesses a glass transition temperature of 10 to 65° C.,
the mixture (B) comprising at least one polyolefinically unsaturated monomer, wherein the at least one polyolefinically unsaturated monomer present in the mixture (B) is selected such that a polymer prepared from the mixture (B) possesses a glass transition temperature of ?35 to 15° C.,
and
a polymer prepared from the mixture (C) possessing a glass transition temperature of ?50 to 15° C.,
and wherein,
i. first of all the mixture (A) is polymerized,
ii. then the mixture (B) is polymerized in the presence of the polymer prepared from the polymerization of the mixture (A),
and
iii. thereafter the mixture (C) is polymerized in the presence of the polymer prepared from the polymerization of the polymer prepared from the polymerization of the mixture (A) and the polymer prepared from the polymerization of the mixture (B).

US Pat. No. 10,920,099

POLY(METH)ACRYLAMIDE-BASED COPOLYMERS WITH CARBOXYL-TERMINATED PENDANT CHAINS

Alcon Inc., Fribourg (CH...

1. A poly(meth)acrylamide-based copolymer comprising:(a) from about 60% to about 95% by mole of first repeating units of at least one (meth)acrylamide monomer selected from the group consisting of (meth)acrylamide, N,N-dimethyl (meth)acrylamide, N-2-hydroxyethyl (meth)acrylamide, N-3-hydroxypropyl (meth)acrylamide, N-2-hydroxypropyl (meth)acrylamide, N-4-hydroxybutyl (meth)acrylamide, N-5-hydroxypentyl (meth)acrylamide, N-6-hydroxyhexyl (meth)acrylamide, N-(2,3-dihydroxypropyl) (meth)acrylamide, N,N-bis(2-hydroxyethyl) (meth)acrylamide, N-tris(hydroxymethyl)methyl (meth)acrylamide, N,N-dimethylaminopropyl (meth)acrylamide, and combinations thereof; and
(b) from about 0.01% to about 40% by mole of second repeating units each of which is an acrylic repeating unit of any one of formula (1) to (5)

in which Ro is hydrogen or methyl, Xo and X1 independent of each other are —O— or —NRn— in which Rn is hydrogen or a C1-C4 alkyl group, L1 is a C1-C4 alkylene divalent radical, L2 and L4 independent of each other are a C2-C4 alkylene divalent radical having 0 or 1 hydroxyl group, L3 is —CH2—CHOH—CH2—, t1 is an integer of 2 to 25, t2 is an integer of 2 to 4, and t3 is 0 or 1,
wherein the poly(meth)acrylamide-based copolymer comprises at least 60% by mole of repeating units which are (meth)acrylamide repeating units relative to all repeating units of the poly(meth)acrylamide-based copolymer.

US Pat. No. 10,920,098

PROCESSING OF POLYMER BASED INKS AND PASTES

1. A process of forming an electrical conductor on a substrate comprising the steps of:a) providing a substrate selected from the group consisting of plastics, polyethylene terephthalate, polyethylene, polyimide, polyvinylchloride, polystyrene, polyurethane, textile, paper, cardboard, printed circuit boards (PCB), transparent conductive oxide coated substrates and mixtures thereof;
b) providing an electrically conductive composition to at least a portion of said substrate, wherein said electrically conductive composition comprises electrically conductive particles in an amount of (i) between 15 wt. % to 75 wt. % or (ii) between 47 wt. % to 97 wt. %; and
c) exposing said electrically conductive composition on the substrate to a near infrared light having a peak wavelength of around 750 nm to form an electrical conductor.

US Pat. No. 10,920,097

DISPERSION AND INKJET INK COMPOSITION, LIGHT CONVERSION LAYER, AND LIQUID CRYSTAL DISPLAY ELEMENT USING THE DISPERSION

DIC CORPORATION, Tokyo (...

1. A dispersion comprising, as essential ingredients, light-emitting nanocrystals, a polymeric dispersant having an amine value of 5 mg KOH/g or more, and at least one stimulation-responsive curable material that cures in response to an external stimulus, whereina solubility of a coating film made from the dispersion in a 1% by mass aqueous solution of potassium hydroxide at 25° C. is 3% by mass or less.

US Pat. No. 10,920,095

INK COMPOSITIONS

Hewlett-Packard Developme...

1. An ink composition, comprising:an aqueous liquid vehicle;
from 1 wt % to 9 wt % pigment dispersed in the aqueous liquid vehicle by a polymer dispersant associated with pigment;
from 0.5 wt % to 5 wt % polymeric binder particles having a D50 particle size from 40 nm to 350 nm and a D10 particle size of 20 nm to 200 nm; and
from 0.1 wt % to 1.5 wt % monovalent salt;
wherein the polymeric binder particles and the pigment have an average particle size ratio from 0.75:1 to 1.5:1.

US Pat. No. 10,920,094

REACTIVE POLYURETHANE DISPERSIONS

Hewlett-Packard Developme...

1. A reactive polyurethane dispersion, comprising a polymer strand comprising a polymer backbone having two terminating ends comprising a first capping unit at a first terminating end and a second capping unit at a second terminating end, wherein the polymer backbone comprises polymerized monomers including:a reactive diol selected from an acrylate-containing diol, a methacrylate-containing diol, a styrene-containing diol, or combination thereof, and
a diisocyanate;
wherein the first capping unit is a styrene-containing monoalcohol reacted with an isocyanate group of the diisocyanate; and
wherein the second capping unit is an ionic stabilizing group.

US Pat. No. 10,920,093

COATING COMPOSITION FOR PREVENTING ADHESION OF ADVERTISING MATERIAL AND METHOD FOR COATING BY THEREOF

SINDO DNT CO., LTD.

1. A coating composition for forming a coating layer which inhibits adhesion of unwanted materials, the coating composition comprising:25 to 35 parts by weight of urethane synthetic resin solution, acrylic resin solution, or epoxy resin solution;
5 to 35 parts by weight of urethane pigments, acrylic or epoxy pigments;
10 to 20 parts by weight of PE-thermoplastic resin beads, phenol resin beads, melamine resin beads, epoxy resin beads, polystyrene resin beads or glass beads;
40 to 52 parts by weight of organic solvents comprising urethane thinner and toluene;
2 to 4 parts by weight of curing agent; and
particles of luminous paint comprising 10 to 15 unit weight per 100 unit weight of the coating composition, the particles of luminous paint having diameters between 50 and 250 ?m,
wherein the coating layer, on drying, has small irregularities on the dried surface, resulting in improved visibility and improved releasability of unwanted materials.

US Pat. No. 10,920,087

HYDROGENATED ISOTOPICALLY ENRICHED BORONT TRIFLUORIDE DOPANT SOURCE GAS COMPOSITION

ENTEGRIS, INC., Billeric...

12. A method comprising introducing a boron dopant source gas composition to an ion source chamber of the boron doping ion implantation system, operating the boron doping ion implantation system to ionize the boron dopant source gas composition in the ion source chamber and generate a beam of boron dopant species that is directed to a substrate in the ion implantation system for boron doping of the substrate therein with the boron dopant species, wherein the dopant source gas composition consists of (i) boron trifluoride isotopically enriched above natural abundance in boron of atomic mass 11 (11B), and (ii) hydrogen in an amount of from 4 to 6.5 vol. %, based on the total volume of boron trifluoride and hydrogen in the composition, wherein a weight change of the cathode during said operating, in relation to other hydrogen concentrations is minimized and beam stability and ion source life is enhanced.

US Pat. No. 10,920,085

ALTERATION OF CARBON FIBER SURFACE PROPERTIES VIA GROWING OF CARBON NANOTUBES

Honda Motor Co., Ltd., T...

1. A method for modifying a carbon fiber, the method comprising:providing a carbon fiber;
modifying a surface of the carbon fiber by forming a plurality of defects on the surface of the carbon fiber, wherein the plurality of defects are formed using at least one of ion bombardment and a plasma treatment with a power of from about 10 to about 50 V;
depositing a catalyst directly on the modified surface of the carbon fiber;
contacting the carbon fiber with a carbon source; and
growing carbon nanotubes on the modified surface of the carbon fiber.

US Pat. No. 10,920,084

METAL OXIDE-CONTAINING DISPERSION WITH HIGH SALT STABILITY

EVONIK OPERATIONS GMBH, ...

1. An aqueous dispersion containing a hydrophilic metal oxide powder comprising a metal oxide and a surface modification of the metal oxide, wherein:a) the metal oxide is a mixed aluminum-silicon oxide; and
b) the surface modification comprises:
b1) silicon and Al atoms;
b2) wherein the silicon atoms are at least partly bound to a hydrocarbon radical by a C atom; and
b3) wherein the Al/Si molar ratio of the surface modification is 1:2-1:20;
wherein the surface modification has the formula Si—(CH2)n—Ym—R, wherein Si is the Si atom bonded to a hydrocarbon radical via a C atom, n=1, 2 or 3 and m=0 or 1;
wherein the Al2O3/SiO2 weight ratio in the surface-modified metal oxide powder is 0.1:99.9-5:95;
and wherein:
when m=1: R=—H, —CH3, —C2H5, —OH, —OCH3, —OC2H5, —C(?O)OCH3, —C(?O)OC2H5, —O—C(?O)CH3, —O—C(?O)CH?CH2, —O—C(?O)CH?CH(CH3), —C(?O)CH3, —C(?O)H, NH2; or

when m=0: R=—OH, —OCH3, —OC2H5, —C(?O)OCH3, —C(?O)OC2H5, —O—C(?O)CH3, —O—C(?O)CH?CH2, —O—C(?O)CH?CH(CH3), —C(?O)CH3, —C(?O)H, or NH2; and
Y=—(OCR1R2—CR3R4)o—, where o=1-30, and R1, R2, R3, R4=independently of one another H or CH3, or —(OCR1R2—CR3R4—CR5R6)p—, where p=1-30, R1, R2, R3, R4, R5, R6=independently of one another H or CH3, —NHCH2CH2O—, —NH(CH2)2NH(CH2)2—, or —NH(CH2)2NH(CH2)2—.

US Pat. No. 10,920,083

LEUCO POLYMERS AS BLUING AGENTS IN LAUNDRY CARE COMPOSITIONS

1. A leuco polymer comprising a polyamine covalently bound to a leuco moiety and a red mono-azo dye moiety, wherein the polyamine is a polyalkylamine and a plurality of amine groups in the polyalkylamine are alkoxylated with polyalkylene oxide chains having from 5 to 30 alkoxy groups, wherein the alkoxy groups are selected from the group consisting of ethoxy and propoxy, wherein the leuco moiety has a maximum molar extinction coefficient in the wavelength range from 400 to 750 nm of 10 M?1 cm?1 or less, wherein the leuco moiety is a univalent or polyvalent moiety derived by removal of one or more hydrogen atoms from a structure of Formula (I)
wherein the ratio of Formula (I) to its oxidized form is at least 1:3; wherein each individual Ro, Rm and Rp group on each of rings A, B and C is independently selected from the group consisting of hydrogen, deuterium and R5; wherein each R5 is independently selected from the group consisting of halogens, nitro, alkyl, substituted alkyl, aryl, substituted aryl, alkaryl, substituted alkaryl, —C(O)R1, —C(O)OR1, —C(O)O?, —C(O)NR1R2, —OC(O)R1, —OC(O)OR1, —OC(O)NR1R2, —S(O)2R1, —S(O)2OR1, —S(O)2O—, —S(O)2NR1R2, —NR1C(O)R2, —NR1C(O)OR2, —NR1C(O)SR2, —NR1C(O)NR2R3, —OR1, —NR1R2, —P(O)2R1, —P(O)(OR1)2, —P(O)(OR1)O?, and —P(O)(O?)2; wherein at least one of the Ro and Rm groups on at least one of the three rings A, B or C is hydrogen; each Rp is independently selected from hydrogen, —OR1 and —NR1R2;
wherein G is hydrogen;
wherein R1, R2 and R3 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, alkaryl, substituted alkaryl, and R4; R4 is a organic group composed of one or more organic monomers with said monomer molecular weights ranging from 28 to 500; and
wherein any charge present in the leuco moiety is balanced with a suitable independently selected internal or external counterion.

US Pat. No. 10,920,082

BLUE-EXCITABLE WATER-SOLVATED POLYMERIC DYES

BECTON, DICKINSON AND COM...

1. A water soluble polymeric dye having a blue excitation spectrum, wherein the polymeric dye comprises a thiophene containing co-monomer described by one of formula (X)-(XVII):wherein:each R3 is independently selected from H, amino, substituted amino, halogen, cyano, alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, acyl, substituted acyl, amido, substituted amido, sulfonic acid, cyano, alkoxy, substituted alkoxy, WSG and -T2-Z2, wherein Z2 is a chemoselective functional group or a linked signaling chromophore, and T2 is a linker,
if the thiophene containing co-monomer is described by formula (X) then both R3 are a polyethylene glycol group,
if the thiophene containing co-monomer is described for formula (XIII) then at least one R3 is not hydrogen,
each * is a site for covalent attachment to the unsaturated backbone of a conjugated polymer
X1 is CR3, NR3, O or S;
X2 is O or S and each is a single bond;
R1 and R2 together form a 5- or 6-membered fused aryl or heteroaryl ring which is substituted with one or more R3 groups; and
Y4 is NR3, C(R3)2 or Si(R3)2.

US Pat. No. 10,920,081

LEUCO DYE PASTEL COLORING KIT

Nocopi Technologies, Inc....

1. A coloring kit comprising:a substrate comprising an activator of one or more leuco dyes printed or coated on at least part of a surface of the substrate with the activator in a solvent mixture; and
one or more solid pastels comprising the one or more leuco dyes dissolved in a mixture that comprises either:
a mixture of about 68-75% dimethyl adipate, about 0-25% dibenzylamide sorbitol, about 1-2% dibutyl ethyl hexanoyl glutamide, about 1-2% ethyl cellulose, about 0.1-0.5% pentaerythritol tetrakis(3-(3,5-di-tert-butyl-4-hydroxyphenyl)proprionate), and about 6% or less leuco dye, or
a mixture of about 48-70% 12 hydroxystearic acid, about 20-45% dimethyl adipate, about 4-8% ethyl cellulose, and about 6% or less leuco dye.

US Pat. No. 10,920,080

N-ALKYL GLUCAMINE-BASED UNIVERSAL PIGMENT DISPERSIONS

Clariant International Lt...

1. An aqueous, water-thinnable or solvent borne varnish comprising at least one aqueous, binder-free pigment dispersion, wherein the at least one aqueous, binder-free pigment dispersion comprises(A) at least one organic and/or inorganic pigment,
(B) one or more dispersants and/or surfactants,
(C) at least one compound of the formula (I)

in which R1 is H, C1-C4-alkyl, CH2CH2OH or CH2CH(CH3)OH, and
(F) water.

US Pat. No. 10,920,078

SILICONE-POLYETHER COPOLYMER, SEALANTS COMPRISING SAME, AND RELATED METHODS

Dow Silicones Corporation...

1. A silicone-polyether copolymer having the formula Xg[ZjYo]c,wherein each X is independently a silicone moiety having one of formulas (I) or (II):

each Y is an independently selected polyether moiety, and each Z is an independently selected siloxane moiety having the formula [R1hSiO(4-h)/2]d,
where each R1 is an independently selected substituted or unsubstituted hydrocarbyl group having from 1 to 18 carbon atoms; each R2 is an independently selected substituted or unsubstituted hydrocarbyl group having from 1 to 18 carbon atoms; each D1 is an independently selected divalent hydrocarbon group having from 2 to 18 carbon atoms; each subscript a is independently 0 or 1; each subscript b is independently 0 or 1; subscript c is from 1 to 150; each subscript d is from 1 to 1000; each subscript e is independently 1 or 2; each subscript f is independently 0 or 1, with the provisos that within each X, when f is 1, b is 1, and when b is 1, f is 1; subscript g is >1; subscript h is independently selected from 0 to 2 in each moiety indicated by subscript d; each subscript j is independently >0 and <2; each subscript o is independently >0 and <2, with the proviso that j+o=2 in each moiety indicated by subscript c; subscript t is ?0; and
subscript u is >0.

US Pat. No. 10,920,076

SILICONE RUBBER COMPOSITE AND METHOD FOR PRODUCING SAME

LG CHEM, LTD., Seoul (KR...

1. A silicone rubber composite composition comprising solid silicone rubber and carbon nanotubes having an average length/diameter (L/D) value of 500 or more and 5000 or less, wherein the silicone rubber composite has a Shore A hardness of 60 or more as measured according to ASTM D2240.

US Pat. No. 10,920,075

HYDROLYSIS-RESISTANT SILICONE COMPOUND AND A METHOD FOR PRODUCING THE SAME

SHIN-ETSU CHEMICAL CO., L...

1. A silicone of the following formula (1):
wherein Z is a radically polymerizable moiety; Q is represented by the following formula (2) or (3):

wherein “k” is an integer of from 0 to 6, “m” is an integer of from 1 to 4 when “k” equals zero, or “m” is an integer of from 1 to 17 when “k” is not zero, with the proviso that 1?3k+m?20, the site indicated by “*” is bonded to the silicon atom in the formula (1); and the site indicated by “**” is bonded to the moiety Z in the formula (1);
n is an integer of from 4 to 100; and R1, R2 and R3 are each an unsubstituted, saturated or unsaturated, monovalent hydrocarbon group having 1 to 20 carbon atoms, or a substituted form of the monovalent hydrocarbon group in which a part or all of the hydrogen atoms bonded to the carbon atoms are each substituted with a functional group and/or a halogen atom,
wherein the residue R1R2R3Si— has a steric parameter value of ?1.00 or less, the parameter indicating the steric bulkiness of the unsubstituted hydrocarbon groups bonded to the silicon atom, and in a case where at least one of R1, R2 and R3 is a substituted hydrocarbon group, the steric parameter value of the residue in which each of the functional group and halogen atom bonded to the carbon atom of the substituted hydrocarbon group is supposed to be substituted with a hydrogen atom is ?1.00 or less.

US Pat. No. 10,920,074

REACTIVE POLYURETHANE DISPERSIONS

Hewlett-Packard Developme...

1. A reactive polyurethane dispersion, comprising a polymer strand comprising a polymer backbone having two terminating ends comprising a first capping unit at a first terminating end and a second capping unit at a second terminating end, wherein the polymer backbone comprises polymerized monomers including:a reactive diol selected from an acrylate-containing diol, a methacrylate-containing diol, an acrylamide-containing diol, a methacrylamide-containing diol, or combination thereof; and
a diisocyanate,
wherein the first capping unit is an acrylamide-containing monoalcohol or methacrylamide-containing monoalcohol reacted with an isocyanate group of the diisocyanate;
wherein the second capping unit is an ionic stabilizing group; and
wherein the reactive polyurethane dispersion has a NCO/OH ratio of 1.2 to 10.

US Pat. No. 10,920,072

RECYCLED POLYETHYLENE TEREPHTHALATE COMPOSITIONS, FIBERS AND ARTICLES PRODUCED THEREFROM, AND METHODS FOR PRODUCING SAME

COLUMBIA INSURANCE COMPAN...

1. An extruded polymer composition consisting essentially of polyethylene terephthalate polymer composition, wherein the polyethylene terephthalate polymer composition has about 25% by weight to about 100% by weight of homogenized deposit post-consumer polyethylene terephthalate, or homogenized deposit post-industrial polyethylene terephthalate, or a homogenized blend of deposit post-consumer and post-industrial polyethylene terephthalate, and balance virgin polyethylene terephthalate, wherein the homogenized deposit post-consumer polyethylene terephthalate, or homogenized deposit post-industrial polyethylene terephthalate, or the homogenized blend of deposit post-consumer and post-industrial polyethylene terephthalate comprises at least one impurity not present in virgin polyethylene terephthalate.

US Pat. No. 10,920,071

RECYCLED POLYETHYLENE TEREPHTHALATE COMPOSITIONS, FIBERS AND ARTICLES PRODUCED THEREFROM, AND METHODS FOR PRODUCING SAME

COLUMBIA INSURANCE COMPAN...

1. An extruded polymer composition consisting essentially of polyethylene terephthalate polymer composition, wherein the polyethylene terephthalate polymer composition has greater than 10% by weight to about 100% by weight of homogenized curbside post-consumer polyethylene terephthalate, or homogenized curbside post-industrial polyethylene terephthalate, or a homogenized blend of curbside post-consumer and post-industrial polyethylene terephthalate, and balance virgin polyethylene terephthalate, wherein the homogenized curbside polyethylene terephthalate, or homogenized curbside post-industrial polyethylene terephthalate, or the homogenized blend of curbside post-consumer and post-industrial polyethylene terephthalate comprises at least one impurity not present in virgin polyethylene terephthalate.

US Pat. No. 10,920,069

USE OF AN ADDITIVE COMPOSITION FOR THE PREPARATION OF POLYCONDENSATION POLYMERS

1. A process for preparing a polycondensation polymer, the process comprising preparing the polycondensation polymer from a polycondensation reaction of monomers wherein an additive combination is present in the polycondensation reaction,wherein the additive combination comprises one or more compounds of the formula (A)
whereinR11, R12, R13, R14, R15, R16, R17, and R18 are independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, linear or branched pentyl, linear or branched hexyl, linear or branched heptyl, linear or branched octyl or linear and branched nonyl groups, and
R21 and R22 are independently selected from the group consisting of hydrogen, methyl, O(C1-C6-Acyl) and O—R3, wherein R3 is selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl linear or branched pentyl, linear or branched hexyl, linear or branched heptyl, linear or branched octyl or linear and branched nonyl groups, and
one or more sterically hindered organic phosphorous(III) compounds of formula (B)
whereineach R41, R42, R43, R44, R51, R52, R53 and R54, are independently selected from the group consisting of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl linear or branched pentyl, linear or branched hexyl, linear or branched heptyl, linear or branched octyl or linear or branched nonyl, and cumyl groups, and
wherein the additive combination comprises a proportion of from 95% to 98% by weight of the compounds of the formula (A) and 2% to 5% by weight of the sterically hindered organic phosphorous(III) compounds based on the total amount of the additive combination, and wherein the additive combination is used in the presence of an acid.

US Pat. No. 10,920,065

LOW MOLECULAR WEIGHT DRY POWDER POLYMER FOR USE AS PAPER-MAKING DRY STRENGTH AGENT

ECOLAB USA INC., St. Pau...

1. A powder, comprising:one or more associative polymer(s) comprising one or more associative monomer unit(s) and one or more additional monomer unit(s) selected from at least one of a cationic monomer unit, an anionic monomer unit, a nonionic monomer unit, a zwitterionic monomer unit, or a combination thereof, and one or more surfactant(s),
wherein the one or more associative polymer(s) have a weight average molecular weight of from about 10 kDa to about 2,000 kDa, and
wherein at least one of the one or more associative monomer units is derived from a monomer of Formula II:

wherein R3 is H or C1-C10 alkyl, X is O or NH, n is an integer from 1 to 100, o is an integer from 0 to 100, m is at least 5, each Y1 and Y2 are independently H or C1-C4 alkyl, and R4 is H or a hydrophobic group.

US Pat. No. 10,920,061

SELF-HEALING ACRYLIC COPOLYMER, CROSSLINKED COPOLYMER PREPARED FROM THE ACRYLIC COPOLYMER AND METHOD FOR LOW-TEMPERATURE SELF-HEALING OF THE CROSSLINKED COPOLYMER

KYUNGPOOK NATIONAL UNIVER...

1. A self-healing acrylic copolymer represented by Formula 1:
wherein R1 is
R2 and R3 are each independently H or CH3, R4 is a methyl or butyl group; andwherein K, L, and M representing the mole fractions of the corresponding repeating units are 0.08, 0.5 to 0.9, and 0.02 to 0.42, respectively, and satisfy the relation K+L+M=1.

US Pat. No. 10,920,059

COMPOSITE RESIN MATERIAL AND MOLDED ARTICLE

TOHO KASEI CO., LTD., Ya...

1. A composite resin material, comprisinga modified polytetrafluoroethylene and carbon nanotubes,
wherein the composite resin material has an average particle diameter of 500 ?m or smaller, and
wherein the composite resin material comprises the carbon nanotubes in an amount of 0.01 to 2.0% by mass based on a total amount of the composite resin material, and
wherein the modified polytetrafluoroethylene is a compound comprising:
a tetrafluoroethylene unit represented by the following Formula (I):
—CF2—CF2—  (I); and
a perfluorovinyl ether unit represented by the following Formula (II):

wherein X represents a perfluoroalkyl group having 1 to 6 carbon atoms, or a perfluoroalkoxyalkyl group having 4 to 9 carbon atoms, and
the perfluorovinyl ether unit represented by Formula (II) is contained in the modified polytetrafluoroethylene in an amount of 0.01 to 1% by mass based on a total mass of the modified polytetrafluoroethylene,
wherein the modified polytetrafluoroethylene has a crystallization heat of from 16 J/g to 25 J/g, and
wherein the modified polytetrafluoroethylene has a melting point of from 300 to 380° C.

US Pat. No. 10,920,058

MANUFACTURING PROCESS AND COMPOSITION FOR FOAMED PVC-P ROCK SHIELDS

SIKA TECHNOLOGY AG, Baar...

1. A non-woven mat that is suitable for use as a rockshield pad to protect a pipeline, the non-woven mat being formed from a plurality of foamed PVC strands that are fused together,wherein each of the plurality of strands consists of a plasticized PVC formulation, and
the non-woven mat exhibits no holidays at 4 inch rocks when tested according to ASTM G13-89 as modified to accommodate the rockshield pad.

US Pat. No. 10,920,052

PROCESS FOR REDUCING FOGGING FROM HIGH MELT STRENGTH POLYPROPYLENE

NOURYON CHEMICALS INTERNA...

1. A process for reducing fogging from high melt strength polypropylene (HMS-PP), the process comprising a step of heat treating polypropylene at a temperature between 150° C. and 300° C. in the presence of a dialkyl peroxydicarbonate to obtain a high melt strength polypropylene, introducing an anhydride into the high melt strength polypropylene, and carrying out a fogging analysis on the high melt strength polypropylene after introduction of the anhydride into the high melt strength polypropylene, wherein the anhydride is selected from the group consisting of bisanhydrides, oligoanhydrides, and mono-anhydrides of formula (I),wherein R1 is selected from hydrogen and saturated, unsaturated, linear, branched, or cyclic hydrocarbon chains with 2 to 30 carbon atoms, optionally substituted with oxygen-containing groups, R2 is selected from hydrogen and saturated, unsaturated, linear, branched, or cyclic hydrocarbon chains with 2 to 30 carbon atoms, optionally substituted with oxygen-containing groups, R3 is selected from hydrogen, hydroxyl groups, and saturated, linear, branched, and/or cyclic hydrocarbon chains with 2 to 30 carbon atoms, optionally substituted with oxygen-containing groups, R1 and R2 or R1 and R3 can be connected to form a saturated aliphatic ring or a saturated heterocyclic ring; and n=1.

US Pat. No. 10,920,042

METHOD FOR PREPARING A HYDROPHOBICALLY MODIFIED CLAY

1. A method for preparing hydrophobically modified clay comprising the steps of:a) providing a clay having at least one first cation;
b) providing at least one clay modifying agent selected from the group consisting of:

c) mixing the clay and the at least one clay modifying agent in an aqueous suspension over a period of time sufficient for the clay to become hydrophobically modified by the at least one clay modifying agent, wherein the at least one clay modifying agent is able to substantially replace the first cation on the clay surface;
wherein the at least one clay modifying agent comprises a compound represented by formula (I)

wherein, in formula (I),
X?represents a counter anion; and
R1, R2, R3, and R4 are independently selected from linear or branched, substituted or unsubstituted alkyl or alkenyl moieties with 1 to 50 carbon atoms and alkylether moieties of formula (II)
—(CHR5CH2O)nR6 (II)
wherein, in formula (II), R5 is H, methyl or ethyl, R6 is H or C1-4 alkyl, and n is an integer from 3 to 50,
wherein at least one of R1, R2, R3, and R4 represents a group of formula (II), and wherein the ratio of the number of non-hydrogen atoms of the groups of formula (II) to the number of non-hydrogen atoms of the linear or branched, substituted or unsubstituted alkyl or alkenyl moieties is 1.5 or more.

US Pat. No. 10,920,041

DISCONTINUOUS-FIBER COMPOSITES AND METHODS OF MAKING THE SAME

South Dakota Board of Reg...

1. A method for preparing a polymer composite composition comprising:mixing discontinuous fibers and one or more polymers and/or oligomers to form a mixture in an extruder; wherein the discontinuous fibers have a minimum length of about 0.16 inches when added to the extruder; wherein said polymer and/or oligomer is a thermoplastic or a thermoset; and wherein said discontinuous fibers are aramid fibers, carbon fibers, ceramic fibers, glass fibers, polymeric fibers, or mineral-based fibers, or a combination thereof
rolling the mixture to form the polymer composite composition into a sheet, wherein the rolling orients the discontinuous fibers in one direction; and
wherein one or more stages of the method minimize the fiber length attrition.

US Pat. No. 10,920,038

CROSSLINK AGENT DISPERSIBLE IN OIL OR WATER FOR POLYMER MODIFIED ASPHALT

DENNIS D. KRIVOHLAVEK AND...

1. A crosslinking composition, for vulcanizing polymer modified asphalt or bitumen, that can be used as a powder or dispersed into either a hydrocarbon oil or water, which crosslinking composition consisting of:(a). elemental sulfur;
(b). hexamethylenetetramine;
(c). at least one suspension agent configured to promote suspension in both oil and water;
(d). at least one wetting or dispersing chemical to aid dispersion in oils or water;
(e). optionally dust suppressant oils; and
(f). optionally at least one vulcanization co-reactant.

US Pat. No. 10,920,035

TUNING DEFORMATION HYSTERESIS IN TIRES USING GRAPHENE

LytEn, Inc., San Jose, C...

1. A method for manufacturing a tire, the method comprising:determining a hysteretic curve indicative of one or more mechanical properties of the tire, the one or more mechanical properties including at least a deformation of the tire;
selecting a carbon structure based at least in part on the hysteretic curve;
generating a post-treatment carbon based on the carbon structure;
combining the post-treatment carbon and one or more materials;
curing the combination of the post-treatment carbon and the one or more materials; and
forming the tire based on the cured combination.

US Pat. No. 10,920,028

PLEXIFILAMENTARY SHEETS

1. A sheet comprising a plexifilamentary film-fibril network consisting of high density polyethylene in an overlapping multi-directional configuration, the sheet, as-produced from a spin cell, having a normalized Frazier air permeability of between 0.002 and 0.2 m3/m2·minute at 50 gsm, a BET surface area of between 9 and 20 m2/gm, and a normalized hydrohead of between 150 and 250 cm at 50 gsm wherein the plexifilamentary film-fibril network in an overlapping multi-directional configuration is flash-spun from a spin fluid comprising polymer and spin agent, the spin fluid temperature being 190° C. to 195° C.,the spin agent consisting of dichloromethane and 2,3-dihydrodecafluoropentane, and the polymer concentration in the spin fluid being 12 to 14 weight percent.

US Pat. No. 10,920,024

POLYSULFIDE COPOLYMER PARTICLE AND METHOD OF PREPARING THE SAME

1. A method of preparing a polysulfide copolymer particle, comprising:preparing a mixture including a surfactant, a phase transfer catalyst, a polyfunctional monomer, and a polysulfide salt represented by the formula X2Sm, in which X is an alkali metal cation or ammonium cation and m is a number from 1 to 10, the surfactant and the phase transfer catalyst being different; and
polymerizing the polysulfide salt with the polyfunctional monomer in the presence of the surfactant and the phase transfer catalyst to form a polysulfide polymer particle in the mixture.

US Pat. No. 10,920,021

SILICONE COMPOSITIONS

Saint-Gobain Performance ...

16. A polymerized composition that is the polymerization product of a polymerizable composition comprisingone or more organosiloxanes or organosilanes, the one or more organosiloxanes or organosilanes comprising one or more of
one or more first organosiloxanes or organosilanes, each comprising a plurality of silicon hydride functional groups but lacking reactive heterocycloalkyl functional groups, present in an amount within the range of about 0.05 wt % to about 99.95 wt %;
one or more second organosiloxanes or organosilane, each comprising a plurality of reactive heterocycloalkyl functional groups but lacking reactive silicon hydride functional groups, present in an amount within the range of about 0.05 wt % to about 99.95 wt %; and
one or more third organosiloxanes or organosilanes, each comprising at least about one silicon hydride functional group and at least about one reactive heterocycloalkyl functional group, present in an amount within the range of about 0.05 wt % to about 99.9999 wt %,
wherein if the one or more third organosiloxanes or organosilanes is absent, then both one or more first organosiloxanes or organosilanes and one or more second organosiloxanes or organosilanes are present in the polymerizable composition, and
an effective amount of a borane catalyst, present in an amount within the range of 0.0005 wt % to about 10 wt %,
wherein the ratio of reactive heterocycloalkyl functional groups to reactive silicon hydride functional groups in the composition is in the range of 1:5 to 5:1, and
wherein the polymerization causes silicon hydrides to hydrosilylate reactive heterocycloalkyl groups with ring opening to form silyl ethers, thereby providing crosslinks to the crosslinked silicone material.

US Pat. No. 10,920,020

3D-PRINTING OF ULTRA-HIGH REFRACTIVE INDEX POLYMERS

ARIZONA BOARD OF REGENTS ...

1. A method of producing a substrate using 3D printing, said method comprising:a. providing a print material comprising a sulfur copolymer, said sulfur copolymer formed from polymerization of:
i. one or more chalcogenic monomers at a level of at least 50 wt % of the sulfur copolymer, wherein the chalcogenic monomers contain sulfur and selenium; and
ii. one or more comonomers each selected from a group consisting of amine comonomers, thiol comonomers, sulfide comonomers, alkynylly unsaturated comonomers, epoxide comonomers, nitrone comonomers, aldehyde comonomers, ketone comonomers, thiirane comonomers, ethylenically unsaturated comonomers, styrenic comonomers, vinylic comonomers, methacrylate comonomers, acrylonitrile comonomers, allylic monomers, acrylate monomers, vinylpyridine monomers, isobutylene monomers, maleimide monomers, norbornene monomers, monomers having at least one vinyl ether moiety, and monomers having at least one isopropenyl moiety, at a level in the range of about 5-50 wt % of the sulfur copolymer;
b. introducing said print material into a 3D printer; and
c. dispensing said print material by successively applying layers of said print material to form the substrate;
wherein the substrate produced from the print material has a refractive index of about 1.75-2.6 at a wavelength in a range of about 500 nm to about 8 ?m.

US Pat. No. 10,920,018

POLYIMIDE RESIN AND POLYIMIDE RESIN COMPOSITION

MITSUBISHI GAS CHEMICAL C...

1. A polyimide resin comprising a structural unit A derived from a tetracarboxylic dianhydride and a structural unit B derived from a diamine compound,wherein the structural unit A comprises
a structural unit (A-1) derived from a compound represented by the following formula (a-1)
and a structural unit (A-2) derived from a compound represented by the following formula (a-2)whereinthe proportion of the structural unit (A-2) in the structural unit A is 60 mol % or less; andthe structural unit B comprises 85 mol % or more of a structural unit (B-1) derived from a compound represented by the following formula (b-1):

wherein m and n in the formula (b-1) each independently is an integer of 0 or 1, and
wherein the structural unit (B-1) comprises 50 mol % or more of a structural unit (B-1-1) derived from a compound represented by the following formula (b-1-1):

US Pat. No. 10,920,017

POLYIMIDE RESIN AND RESIN COMPOSITION

KANEKA CORPORATION, Osak...

1. A polyimide resin comprising a repeating unit represented by the following formula (1) and a repeating unit represented by the following formula (2):
wherein X1 is a tetravalent organic group comprising at least one ring structure, and each two of four carbonyl groups bonded to X1 form a pair and, together with X1 and a nitrogen atom, form a five-membered ring, R2 is a hydrogen, an alkyl group having 1 to 9 carbon atoms, or an alkoxy group comprising 1 to 10 carbon atoms, and Y is a divalent organic group selected from the group consisting of 2,6-dimethylene-4-methyl-phenol; 2,6-dimethylene-4-t-butyl-phenol; bis(2-hydroxy-3-methylene-5-methylphenyl) methane; and bis(4-hydroxy-5-methylene-3-methylphenyl) methane,

wherein X2 is a tetravalent organic group comprising at least one ring structure, and each two of four carbonyl groups bonded to X2 form a pair and, together with X2 and a nitrogen atom, form a five-membered ring, R3 and R4 are each independently a divalent organic group, R5-R8 are each independently an alkyl group comprising 1 to 9 carbon atoms, an alkoxy group comprising 1 to 10 carbon atoms, or a substituted or unsubstituted aryl group, and r is an integer equal to or greater than 1.

US Pat. No. 10,920,016

POLYMERIZABLE COMPOSITION

LG CHEM, LTD., Seoul (KR...

1. A polymerizable composition comprising a phthalonitrile compound and a compound of Formula 1 below:
wherein, X1 to X3 are each the same or different aromatic divalent radical, Y1 and Y2 are each the same or different aryl group substituted with at least one amine group, R1 to R4 are each independently a hydrogen atom, an alkyl group, an alkoxy group or an aryl group and n is a number in a range of 0 to 20.

US Pat. No. 10,920,014

COMPOUNDS, COMPOSITIONS INCLUDING THE SAME, AND LAYERED STRUCTURES AND DEVICES PREPARED FROM THE COMPOSITIONS

SAMSUNG ELECTRONICS CO., ...

1. A composition, comprising:a perfluoropolyether compound; and
an organic solvent configured to dissolve or disperse the perfluoropolyether compound,
wherein the perfluoropolyether compound comprises a first end and a second end facing each other and a perfluoropolyether moiety disposed between the first end and the second end,
wherein the first end comprises an organic group comprising 5 or more carbon atoms, and does not include fluorine, and
the second end comprises a hydrolysable silicon-containing moiety,
wherein the organic group comprises a C5 to C60 substituted or unsubstituted aromatic hydrocarbon group, or a C6 to C60 substituted or unsubstituted aliphatic hydrocarbon group wherein at least one methylene is replaced by sulfonyl (—S(?O)2—), carbonyl (—C(?O)—), sulfide (—S—), sulfoxide (—S(?O)—), ester (—C(?O)O—), amide (—C(?O)NR—) (wherein, R is hydrogen or a C1 to C10 linear or branch alkyl group), imine (—NR—) (wherein, R is hydrogen or a C1 to C10 linear or branch alkyl group), or a combination thereof, a substituted or unsubstituted poly(alkylene oxide) residual group, a substituted or unsubstituted polyester residual group, or a combination thereof.

US Pat. No. 10,920,013

ALKOXYLATION PROCESS USING TUBULAR REACTOR

Dow Global Technologies L...

1. A process for manufacturing a polyether by polymerizing at least one alkylene oxide in a tubular reactor having an inlet end and an outlet end, wherein an initiator composition containing at least one initiator compound and an alkylene oxide polymerization catalyst is continuously introduced into said inlet end and the polyether is continuously removed from the outlet end, wherein the tubular reactor includes at least one monomer feed section wherein at least one alkylene oxide is continuously introduced under polymerization conditions through multiple alkylene oxide ports arranged along the length of said monomer feed section to form a reaction mixture, the process being further characterized in that the concentration of unreacted alkylene oxide is maintained in the range 0.1 to 12 weight percent at each point along the length of the monomer feed section.

US Pat. No. 10,920,012

COPOLYMER AND COMPOSITION

FUJIFILM Corporation, To...

1. A copolymer comprising:a repeating unit represented by the following formula (III); and
a repeating unit represented by the following formula (V),

wherein, in the formula (III), R1 represents a hydrogen atom or an alkyl group having 1 to 20 carbon atoms; ma represents an integer of 1 to 20; na represents an integer of 5 to 7; and X represents a hydrogen atom or a fluorine atom, and

wherein, in the formula (V), R10 represents a hydrogen atom or an alkyl group having 1 to 20 carbon atoms: R11 and R12 each independently represent a hydrogen atom, a substituted or unsubstituted aliphatic hydrocarbon group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group: R11 and R12 may be linked to each other: X11 represents a divalent linking group comprising at least one selected from the group consisting of —(C?O)O—, —O(C?O)—, —(C?O)NH—, —O—, —CO— and —CH2—; and X12 represents a divalent linking group including at least one linking group selected from —(C?O)O—, —O(C?O)—, —(C?O)NH—, —O—, —CO—, —NH—, —O(C?O)—NH—, —O(C?O)—O— and —CH2— and including 2 to 4 substituted or unsubstituted aromatic rings; and a total number of carbon atoms of X11 and X12 is 7 or more.

US Pat. No. 10,920,011

WATER SOLUBLE POLYMERS AND POLYMER ADDUCTS ALONG WITH AQUEOUS SOLUTIONS THEREOF

Arkema Inc., King of Pru...

1. A latex comprising an anionically-stabilized latex and a polymer that is the product of at least one multifunctional amine compound reacted with one or more polyfunctional epoxy compounds;wherein the polyfunctional epoxy compounds comprise epoxides of unsaturated hydrocarbons and fatty acids/oils, epoxy ethers of multifunctional alcohols, or combinations thereof,
wherein the epoxides of unsaturated hydrocarbons and fatty acids/oils are selected from the group of the epoxides of vinyl cyclohexene, dicyclopentadiene, cyclohexadiene, cyclododecadiene, cyclododecatriene, isoprene, 1,6-hexadiene, butadiene, polybutadiene, divinyl benzene, castor oil, soybean oil, and combinations thereof,
wherein the epoxy ethers of multifunctional alcohols are selected from the group consisting of trimethyol propane triglycidyl ether, pentaerythritol tetraglycidyl ether, trimethyol ethane triglycidyl ether, ethylene glycol diglycidyl ether, sorbitol glycidyl ethers, 2-methyl-1,3-propane diol diglycidyl ether, neopentyl glycol diglycidyl ether, 2,2,4-trimethyl pentanediol diglycidyl ether, propylene glycol diglycidyl ether, hydrogenated bisphenol A diglycidyl ether, 1,4-butanediol diglycidyl ether, 1,6-hexanediol diglycidyl ether, and combinations thereof,
wherein the amine compound and the one or more epoxy compounds provide 1.3 to 3.8 amine functional groups per epoxy functional group; and
wherein the polymer is water soluble, has a number average molecular weight in the range of about 500 to about 1,000,000 Daltons, and comprises a nitrogen atom percentage of 5 to about 35%.

US Pat. No. 10,920,010

EPOXY RESIN, EPOXY RESIN COMPOSITION, EPOXY RESIN CURED PRODUCT, AND COMPOSITE MATERIAL

Showa Denko Materials Co....

1. An epoxy resin, comprising a reaction product of a first diepoxy compound having a single mesogenic structure and a reactive compound having two functional groups capable of reacting with the epoxy groups of the first diepoxy compound, said reaction product comprising a first epoxy compound and a second epoxy compound,wherein the first epoxy compound is the first diepoxy compound which has not undergone reaction with the reactive compound,
wherein the second epoxy compound is a reaction product of the first diepoxy compound and the reactive compound, the second epoxy compound having two or more mesogenic structures that are the same as the mesogenic structure of the first epoxy compound,
a proportion, determined by liquid chromatography, of the first epoxy compound being from 40% to 50% with respect to a total amount of the epoxy resin, and
an epoxy equivalent amount of the epoxy resin being 500 g/eq or less; and
wherein the second epoxy compound has a reaction residue structure of the reactive compound represented by the following Formula (A) or Formula (B):

wherein, in Formula (A) and Formula (B), each * refers to a bonding site to an adjacent atom of the functional groups, each of R1 to R3 independently represents an alkyl group having from 1 to 8 carbon atoms, and each of n, m, and 1 independently represents an integer of from 0 to 4.

US Pat. No. 10,920,006

HYBRID POLYMERS

SOLVAY SPECIALTY POLYMERS...

1. A polyurethane fluoropolymer (FP) obtained by reacting:(i) at least one fluoropolymer (F) selected from:
a polymer (F1), wherein polymer (F1) is manufactured by aqueous suspension polymerization or by an aqueous emulsion polymerization process and wherein polymer (F1) comprises recurring units derived from vinylidene fluoride (VDF) and from 0.01% to 10% by moles, based on the total moles of recurring units in polymer (F1), of recurring units derived from at least one (meth)acrylic monomer (MA) of formula (I):

wherein:
R1, R2, and R3, equal to or different from each other, are independently selected from a hydrogen atom and a C1-C3 hydrocarbon group,
RH is a C1-C10 hydrocarbon group optionally comprising one or more functional groups selected from double bonds, epoxy, ester, ether and carboxylic acid groups, and
x is an integer between 1 and 5; or
a polymer (F2), wherein polymer (F2) is manufactured by aqueous suspension polymerization or by an aqueous emulsion polymerization process and wherein polymer (F2) comprises recurring units derived from ethylene (E), from at least one fluorinated monomer (F) selected from tetrafluoroethylene (TFE), chlorotrifluoroethylene (CTFE), and mixtures thereof, and from 0.01% to 10% by moles, based on the total moles of recurring units in polymer (F2), of recurring units derived from at least one (meth)acrylic monomer (MA) of formula (I),
with
(ii) at least one isocyanate compound (I) comprising at least one isocyanate functional group,
(iii) in the presence of one or more chain extenders selected from polyethylene glycols,
said polyurethane fluoropolymer (FP) comprising at least one bridging group selected from bridging groups of formula (a):

wherein:
RH is a C1-C10 hydrocarbon group optionally comprising one or more functional groups selected from double bonds, epoxy, ester, ether and carboxylic acid groups, and
x is an integer between 1 and 5.

US Pat. No. 10,920,004

METHOD FOR PREPARING MODIFIED CONJUGATED DIENE-BASED POLYMER

LG Chem, Ltd.

1. A method for preparing a modified conjugated diene-based polymer comprising:polymerizing a conjugated diene-based monomer in the presence of an organometal compound in a hydrocarbon solvent to prepare an active polymer which is coupled with an organometal (S1); and
a step of reacting or coupling the active polymer prepared in step (S1) with a modifier (S2),
wherein step (S1) is continuously performed in two or more polymerization reactors, and
a polymerization conversion ratio in a first polymerization reactor among the polymerization reactors is 50% or less.

US Pat. No. 10,920,002

3D PRINTING OF THERMOSET POLYMERS AND COMPOSITES

THE BOARD OF TRUSTEES OF ...

1. A method for fabricating a printed thermoset polymer comprising:a) extruding a thermoset gel from a dispensing apparatus to provide an extruded thermoset gel, the thermoset gel having a storage modulus of about 10 Pascals to about 10,000 Pascals and comprising a mixture of an organic phosphite, a ruthenium(II) catalyst, a dicyclopentadiene, and an organic solvent; and
b) triggering a frontal polymerization of the extruded thermoset gel, wherein the frontal polymerization propagates and cures the extruded thermoset gel;
wherein a printed thermoset polymer is printed by steps comprising steps a) and b).

US Pat. No. 10,920,001

PROCESS FOR OBTAINING A CATIONIC POLYMER WITH AN AT LEAST BIMODAL MOLECULAR WEIGHT DISTRIBUTION

BASF SE, Ludwigshafen am...

1. A process for obtaining a cationic polymer by polymerization ofa) at least one cationic monomer and at least one nonionic monomer (monomer component a), wherein
the cationic monomer according to monomer component a) in the cationic polymer is selected from a compound of the formula (II)

where
R1 is H or C1-C4-alkyl,
R2 is H or methyl,
R3 is C1-C4-alkylene,
R4, R5 and R6 are each independently H or C1-C30-alkyl,
X is —O— or —NH— and
Y is Cl; Br; I; hydrogensulfate or methosulfate,
wherein monomer component a) in the cationic polymer comprises 30 to 99.5% by weight of at least one cationic monomer and 0.5 to 70% by weight of at least one nonionic monomer,
b) at least one crosslinker (monomer component b),
c) optionally at least one chain transfer agent (monomer component c),
wherein the cationic polymer has an at least bimodal molecular weight distribution with at least one first peak (P1) with an average sedimentation coefficient of ?100 Sved and with at least one second peak (P2) with an average sedimentation coefficient of ?1000 Sved, and
wherein the polymerization is carried out in two steps I) and II) with:
I) polymerization of monomer component a) and monomer component b),
II) polymerization of monomer component a), optionally monomer component c) and in a complete absence or in a presence of <10 ppm (related to a total amount of cationic polymer) of monomer component b),
wherein step II) is carried out after the polymerization of step I) is finished or step I) is carried out after the polymerization of step II) is finished.

US Pat. No. 10,920,000

LIGHT DIFFUSING AGENT, LIGHT DIFFUSING RESIN COMPOSITION AND MOLDED BODY

MITSUBISHI GAS CHEMICAL C...

1. A polymer microparticle consisting of a copolymer which contains:a (meth)acrylate structural unit (A) represented by formula (1); and
a polyvalent vinyl structural unit (B) that is copolymerized with the structural unit (A)

wherein:
X represents a divalent group selected from the group consisting of a single bond, —C(R2)(R3)—, —C(?O)—, —O—, —OC(?O)—, —OC(?O)O—, —S—, —SO—, —SO2— and any combination thereof, wherein R2 and R3 each independently represent a hydrogen atom, a linear alkyl group having 1 to 10 carbon atoms, a branched alkyl group having 3 to 10 carbon atoms, a cyclic alkyl group having 3 to 10 carbon atoms, a linear alkoxy group having 1 to 10 carbon atoms, a branched alkoxy group having 3 to 10 carbon atoms, a cyclic alkoxy group having 3 to 10 carbon atoms, a phenyl group or a phenylphenyl group; or R2 and R3 may be bonded to each other so as to form a cyclic alkyl group having 3 to 10 carbon atoms together with a carbon atom to which they are attached;
Y represents a branched or unbranched alkylene group having 2 to 6 carbon atoms, a cycloalkylene group having 6 to 10 carbon atoms or an arylene group having 6 to 10 carbon atoms;
R1 represents a hydrogen atom or a methyl group;
R4 and R5 each independently represent a linear alkyl group having 1 to 10 carbon atoms, a branched alkyl group having 3 to 10 carbon atoms, a cyclic alkyl group having 3 to 10 carbon atoms, a linear alkoxy group having 1 to 10 carbon atoms, a branched alkoxy group having 3 to 10 carbon atoms, a cyclic alkoxy group having 3 to 10 carbon atoms, a halogen atom, a phenyl group or a phenylphenyl group;
m represents an integer of 0 to 10;
n represents an integer of 1 or 2;
p represents an integer of 0 to 4; and
q represents an integer of 0 to 5;
wherein the structural unit (A) is contained in an amount of 10 to 90% by mass relative to the copolymer, and wherein the structural unit (B) is contained in an amount of 10 to 90% by mass relative to the copolymer, and any other structural units are contained in an amount 10% by mass or less; and
wherein the structural unit (B) comprises a structural unit derived from a compound represented by formula (2) or a structural unit derived from a compound represented by formula (3)

wherein in formula (2):
X represents a divalent group selected from a single bond, —[C(R6)(R7)]n—, —C(?O)—, —O—, —SO— and —SO2—, wherein R6 and R7 are each independently selected from a hydrogen atom, a phenyl group and a phenylphenyl group; or R6 and R7 are bonded to each other so as to form a cyclic alkyl group having 3 to 13 carbon atoms together with a carbon atom to which they are attached; and n represents an integer of 1 to 10;
R8 and R9 are each independently selected from a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, an alkoxyl group having 1 to 20 carbon atoms, a cycloalkyl group having 3 to 20 carbon atoms, a cycloalkoxyl group having 5 to 20 carbon atoms, an aryl group having 6 to 20 carbon atoms, an aryloxy group having 6 to 20 carbon atoms, and a halogen atom;
R10 represents a hydrogen atom or a methyl group;
Y and Z each independently represent a branched or unbranched alkylene group having 2 to 6 carbon atoms, a cycloalkylene group having 6 to 10 carbon atoms or an arylene group having 6 to 10 carbon atoms; and
p and q each independently represent an integer of 0 to 4; and
in formula (3):
X represents a divalent group selected from a single bond, —[C(R6)(R7)]n—, —C(?O)—, —O—, —SO— and —SO2—, wherein R6 and R7 are each independently selected from a hydrogen atom, a methyl group, a phenyl group and a phenylphenyl group; or R6 and R7 are bonded to each other so as to form a cyclic alkyl group having 3 to 13 carbon atoms together with a carbon atom to which they are attached; and n represents an integer of 1 to 10;
R8 and R9 are each independently selected from a hydrogen atom, an alkyl group having 1 to 20 carbon atoms, an alkoxyl group having 1 to 20 carbon atoms, a cycloalkyl group having 3 to 20 carbon atoms, a cycloalkoxyl group having 5 to 20 carbon atoms, an aryl group having 6 to 20 carbon atoms, an aryloxy group having 6 to 20 carbon atoms, and a halogen atom;
R10 represents a hydrogen atom or a methyl group;
Y and Z each independently represent a branched or unbranched alkylene group having 2 to 6 carbon atoms, a cycloalkylene group having 6 to 10 carbon atoms or an arylene group having 6 to 10 carbon atoms; and
p and q each independently represent an integer of 0 to 4.

US Pat. No. 10,919,998

COLOR-CONVERSION PHOTONIC CRYSTAL STRUCTURE AND COLOR-CONVERSION PHOTONIC CRYSTAL SENSOR USING SAME

KOREA RESEARCH INSTITUTE ...

1. A color-conversion photonic crystal structure, comprising:a first refractive index layer which includes a first polymer having a first refractive index; and a second refractive index layer which includes a second polymer having a second refractive index, wherein these refractive index layers are alternately laminated,
wherein the first refractive index is higher than the second refractive index; and
the second polymer comprises a structure unit represented by Formula 3:

wherein R3 is selected from hydrogen and C1-3 alkyl;
X2 is C1-10 alkyl substituted by at least one fluorine atom; and
n is independently an integer of 1 or more.

US Pat. No. 10,919,997

ETHYLENE ?-OLEFIN NON-CONJUGATED POLYENE COPOLYMER, USE THEREOF, AND MANUFACTURING METHOD THEREOF

MITSUI CHEMICALS, INC., ...

1. An ethylene.?-olefin.non-conjugated polyene copolymer comprising a structural unit derived from an ethylene [A], a structural unit derived from a C4-C20 ?-olefin [B] and a structural unit derived from a non-conjugated polyene [C], and satisfying the following (1) to (4):(1) a molar ratio ([A]/[B]) of the structural units derived from the ethylene [A] to the structural units derived from the ?-olefin [B] is 48.3/51.7 to 70.2/29.8;
(2) a content of the structural units derived from the non-conjugated polyene [C] is 1.24 to 3.22 mol % based on the total of the structural units of [A], [B] and [C] as 100 mol %;
(3) a Mooney viscosity ML(1+4)125° C. at 125° C. is 5 to 100; and
(4) a B value represented by the following formula (i) is in the range of 1.28 to 1.29:
B value=([EX]+2[Y])/[2×[E]×([X]+[Y])]  (i),
wherein [E], [X] and [Y] represent a mole fraction of the ethylene [A], the C4-C20 ?-olefin [B] and the non-conjugated polyene [C] respectively, and [EX] represents an ethylene [A]-C4-C20 ?-olefin [B] diad chain fraction,
wherein the ethylene.?-olefin.non-conjugated polyene copolymer is obtained by copolymerizing an ethylene, a C4-C20 ?-olefin and a non-conjugated polyene in the presence of an olefin polymerization catalyst containing:
(a) a transition metal compound represented by the following general formula [VII]:

wherein M is a titanium atom, a zirconium atom, or a hafnium atom;
R5 and R6 are substituted aryl groups wherein one or more of the hydrogen atoms of an aryl group are substituted with an electron-donating substituent having a substituent constant ? of ?0.2 or less in the Hammett's rule; wherein when the substituted aryl group has a plurality of the electron-donating substituents, each of the electron-donating substituents may be the same or different; wherein the substituted aryl group optionally comprises a substituent selected from C1-C20 hydrocarbon groups, silicon-containing groups, nitrogen-containing groups, oxygen-containing groups, halogen atoms and halogen-containing groups other than the electron-donating substituents; and wherein when the substituted aryl group comprises a plurality of the substituents, each of the substituents may be the same or different;
Q is selected in an identical or different combination from halogen atoms, C1-C20 hydrocarbon groups, anionic ligands, and neutral ligands capable of being coordinated with a lone electron pair; and
j is an integer of 1 to 4; and
(b) at least one compound selected from
(b-1) organometallic compounds,
(b-2) organoaluminum oxy-compounds, and
(b-3) components which react with the transition metal compound (a) to form an ion pair,
wherein the C4-C20 ?-olefin [B] is 1 butene, and
wherein the non-conjugated polyene [C] is 5-ethylidene-2-norbornene.

US Pat. No. 10,919,996

SILICA-COATED ALUMINA ACTIVATOR-SUPPORTS FOR METALLOCENE CATALYST COMPOSITIONS

Chevron Phillips Chemical...

1. An activator-support comprising a silica-coated alumina treated with an electron-withdrawing anion, wherein:the silica-coated alumina has a weight ratio of alumina to silica in a range from about 1:1 to about 2:1 and a surface area in a range from about 200 to about 600 m2/g.

US Pat. No. 10,919,995

OLEFIN POLYMERIZATION CATALYST SYSTEMS AND METHODS OF USE THEREOF

Dow Global Technologies L...

1. An olefin polymerization catalyst system comprising a procatalyst component chosen from metal-ligand complexes according to Formula (I):where:M is titanium, zirconium, or hafnium;
each X is independently a monodentate or polydentate ligand that is neutral, monoanionic, or dianionic;
n is an integer;
the metal-ligand complex of Formula (I) is overall charge-neutral;
each of Y1-4 is independently selected from C or N with the proviso that exactly one of Y1-4 is N or exactly two of Y1-4 are N;
each of Y7-10 is independently selected from C or N with the proviso that exactly one of Y7-10 is N or exactly two of Y7-10 are N;
R1 and R10 are both independently selected from the group consisting of (C1-C40) hydrocarbyl, substituted (C1-C40) hydrocarbyl, (C1-C40) heterohydrocarbyl, substituted (C1-C40) heterohydrocarbyl, and an electron pair;
each of R2, R3, R4, R7, R8, and R9 is independently selected from the group consisting of hydrogen, (C1-C40) hydrocarbyl, substituted (C1-C40) hydrocarbyl, (C1-C40) heterohydrocarbyl, substituted (C1-C40) heterohydrocarbyl, halogen, nitro, and an electron pair; and
R5 and R6 are both independently selected from the group consisting of (C1-C40) hydrocarbyl, substituted (C1-C40) hydrocarbyl, (C1-C40) heterohydrocarbyl, and substituted (C1-C40) heterohydrocarbyl;
any two or more of R1-5 optionally may be taken together to form at least one ring structure having from 5 to 16 atoms in the ring excluding any hydrogen atoms;
any two or more of R6-10 optionally may be taken together to form at least one ring structure having from 5 to 16 atoms in the ring excluding any hydrogen atoms; and
any two or more of R1-10 optionally may be taken together form a linked tetradentate chelant structure.

US Pat. No. 10,919,994

METALLOCENE COMPOUND, CATALYST COMPONENT FOR OLEFIN POLYMERIZATION AND CATALYST FOR OLEFIN POLYMERIZATION CONTAINING THE SAME, AND METHOD FOR PRODUCING OLEFIN POLYMER USING CATALYST FOR OLEFIN POLYMERIZATION

JAPAN POLYETHYLENE CORPOR...

1. A metallocene compound represented by the following general formula (3):wherein M1 represents any transition metal of Ti, Zr, and Hf; X1 and X2 represent each independently a hydrogen atom, a halogen, a hydrocarbon group having a carbon number of 1 to 20, an oxygen- or nitrogen-containing hydrocarbon group having a carbon number of 1 to 20, an amino group substituted with a hydrocarbon group having a carbon number of 1 to 20, or an alkoxy group having a carbon number of 1 to 20; Q1 represents a carbon atom, a silicon atom, or a germanium atom; R1 and R2 represent each independently a hydrogen atom or a hydrocarbon group having a carbon number of 1 to 10, and optionally form a ring together with Q1 bonded thereto; R5, R6, R7, R8, R9, R10, and R12 represent each independently a hydrogen atom, a halogen, a hydrocarbon group having a carbon number of 1 to 20, a silicon-containing hydrocarbon group having a carbon number of 1 to 18, which contains a silicon number of 1 to 6, a halogen-containing hydrocarbon group having a carbon number of 1 to 20, an oxygen-containing hydrocarbon group having a carbon number of 1 to 20, or a silyl group substituted with a hydrocarbon group having a carbon number of 1 to 20; Z1 represents an oxygen atom or a sulfur atom; R23, R24, and R25 represent each independently a hydrogen atom, a halogen, a hydrocarbon group having a carbon number of 1 to 20, a silicon-containing hydrocarbon group having a carbon number of 1 to 18, which contains a silicon number of 1 to 6, a halogen-containing hydrocarbon group having a carbon number of 1 to 20, an oxygen-containing hydrocarbon group having a carbon number of 1 to 20, or a silyl group substituted with a hydrocarbon group having a carbon number of 1 to 20, and adjacent substituents of R23, R24, and R25 optionally form a ring together with carbon atoms bonded thereto.

US Pat. No. 10,919,993

INJECTION MOLDED ARTICLE BASED ON PROPYLENE HOMOPOLYMER

BOREALIS AG, Vienna (AT)...

1. A process for producing an injection molded article comprising a propylene homopolymer, the process comprising:polymerizing propylene to obtain the propylene homopolymer, wherein the propylene is polymerized in the presence of:
(a) a Ziegler-Natta catalyst (ZN-C) comprising compounds (TC) of a transition metal of Group 4 to Group 6 of IUPAC, a Group 2 meal compound (MC), and an internal donor (ID), wherein said internal donor (ID) is a non-phthalic compound;
(b) a co-catalyst (Co); and
(c) an external donor (ED);
wherein the ratio of co-catalyst (Co) to external donor (ED) [Co/ED] is 5 to 45; and
wherein the propylene homopolymer has:
(a) a melt flow rate MFR2 (230° C./2.16 kg) measured according to ISO 1133 in the range of 40 to 120 g/10 min;
(b) a pentad isotacticity (mmmm) of more than 92.5% determined by 13C-NMR;
(c) a meso sequence length (MSL4) of equal or more than 90.0; MSL4 is calculated by formula (1)

wherein
“[mmmm]” is % of mmmm pentads
“[mmmr]” is % of mmmr pentads,
determined by 13C-NMR spectroscopy; and
(d) a molecular weight distribution (MWD) of 7.5 or less; and injection molding the propylene homopolymer.

US Pat. No. 10,919,992

INDENE-BASED TRANSITION METAL COMPOUND, TRANSITION METAL CATALYST COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING ETHYLENE HOMOPOLYMER OR COPOLYMER OF ETHYLENE AND ALPHA-OLEFIN BY USING SAME

SABIC SK NEXLENE COMPANY ...

1. A compound represented by the following Chemical Formula Int-1:
wherein
R1 is (C1-C20)alkyl or (C2-C20)alkenyl, in which the alkyl or alkenyl of R1 may be further substituted by one or more substituents selected from the group consisting of halogen, (C6-C30)aryl and (C1-C20)alkyl(C6-C30)aryl;
Ar1 is (C6-C30)aryl, in which the aryl of Ar1 may be further substituted by one or more substituents selected from the group consisting of (C1-C20)alkyl, halo(C1-C20)alkyl and (C6-C30)aryl(C1-C20)alkyl;
R2 to R5 are each independently hydrogen, (C1-C20)alkyl, (C1-C20)alkoxy, halo(C1-C20)alkyl, (C3-C20)cycloalkyl, (C1-C20)alkyl(C6-C30)aryl, (C6-C30)aryl, (C6-C30)aryloxy, (C1-C20)alkyl(C6-C30)aryloxy, (C6-C30)aryl(C1-C20)alkyl or ((C1-C20)alkyl(C6-C30)aryl)(C1-C20)alkyl, or R2 to R5 are linked with an adjacent substituent to form a fused ring, in which the formed fused ring may be further substituted by one or more substituents selected from the group consisting of (C1-C20)alkyl, (C1-C20)alkoxy, halo(C1-C20)alkyl, (C3-C20)cycloalkyl, (C1-C20)alkyl(C6-C30)aryl, (C6-C30)aryl, (C6-C30)aryloxy, (C1-C20)alkyl(C6-C30)aryloxy, (C6-C30)aryl(C1-C20)alkyl and ((C1-C20)alkyl(C6-C30)aryl)(C1-C20)alkyl;
R9 is (C1-C20)alkyl, (C3-C20)cycloalkyl or (C6-C30)aryl(C1-C20)alkyl;
R6 and R7 are each independently (C1-C20)alkyl, halo(C1-C20)alkyl, (C3-C20)cycloalkyl, (C6-C30)aryl, (C1-C20)alkyl(C6-C30)aryl, (C1-C20)alkoxy(C6-C30)aryl or (C6-C30)aryl(C1-C20)alkyl, or R6 and R7 are linked to each other to form a ring, in which the formed ring may be further substituted by one or more substituents selected from the group consisting of (C1-C20)alkyl, halo(C1-C20)alkyl, (C6-C30)aryl(C1-C20)alkyl, (C1-C20)alkoxy, (C3-C20)cycloalkyl, (C6-C20)aryl, (C1-C20)alkyl(C6-C30)aryl and (C6-C20)aryloxy; and
R8 is hydrogen or (C1-C20)alkyl.

US Pat. No. 10,919,990

LATEX COMPOSITION FOR DIP-FORMING AND DIP-FORMED ARTICLE PRODUCED THEREFROM

LG Chem, Ltd.

1. A latex composition for dip-molding comprising: a carbonic acid-modified nitrile-based copolymer latex; and an alkenyl succinic acid compound,wherein the alkenyl succinic acid compound is represented by the following formula (1) or a sodium (Nat+), potassium (K+), or lithium (Li+) salt thereof:

wherein R is a linear or branched C12-C20 alkenyl group, and
the alkenyl succinic acid compound is included in an amount of 0.01 to 10 parts by weight based on 100 parts by weight of the total amount of monomers used at the time of copolymerization of the carbonic acid-modified nitrile-based copolymer latex.

US Pat. No. 10,919,989

END GROUP FUNCTIONALIZATION AGENTS FOR POLYDIENE

IOWA STATE UNIVERSITY RES...

1. A modified polymer having the structure of Formula (I):
wherein
is a polymer;A is selected from the group consisting of
C1-15 alkyl, C1-15 alkylene, C3-8 cycloalkyl, aryl, arylene, andwherein C1-15 alkyl, C1-15 alkylene, C3-8 cycloalkyl, aryl, and arylene can be optionally substituted from 1 to 4 times with a substituent independently selected from the group consisting of H, halogen, C1-6 alkyl, and —NR7R8;is a point of attachment of A togroup;R1 is C1-6 alkyl;
R2 is H or C1-6 alkyl;
R3 is H or C1-6 alkyl;
R4 is C1-6 alkyl;
R5 is H or C1-6 alkyl;
R6 is H or C1-6 alkyl;
R7 is H or C1-6 alkyl;
R8 is H or C1-6 alkyl;
R9 is C1-6 alkyl;
R10 is C1-6 alkyl;
X1 is C1-6 alkylene;
X2 is C1-15 alkylene;
Y is O or N;
Z is H, R9, or Si(R10)3;
a is 0 to 2;
b is 1 or 2; and
n is 1 to 3.

US Pat. No. 10,919,988

PROCESS FOR MAKING SUGAMMADEX

Synthon B.V., Nijmegen (...

1. A process for preparation of Sugammadex comprising:a) mixing of ?-cyclodextrin with CX4, in the presence of triphenylphosphine and N-methyl-2-pyrrolidone;
b) treating the reaction product with a base to provide corresponding 6-per-deoxy-6-per-halo-?-cyclodextrin compound of formula (3),
wherein X is Cl or Br or I; andc) reacting compound of formula (3) with 3-mercaptopropionic acid in the presence of a sodium base to provide Sugammadex of formula (1),

US Pat. No. 10,919,987

SYSTEMS AND METHODS FOR DEWATERING A SLURRY THAT INCLUDES LIGNOCELLULOSIC BIOMASS AND LIQUID

POET Research, Inc., Sio...

1. A system for dewatering a lignocellulosic biomass slurry, wherein the system comprises:a) a source of a lignocellulosic biomass slurry, wherein the lignocellulosic biomass slurry comprises:
i) lignocellulosic biomass; and
ii) water;
b) a dewatering system in fluid communication with the source of the lignocellulosic biomass slurry, and adapted to receive the lignocellulosic biomass slurry to separate at least a portion of the water from the lignocellulosic biomass slurry, wherein the dewatering system comprises at least a solids transfer device having a housing including an inlet and an outlet, wherein the solids transfer device is adapted to convey and accumulate dewatered lignocellulosic biomass proximal to the outlet of the solids transfer device, wherein the solids transfer device is configured to have a first headspace occupied by a gas is present at least at the inlet of the solids transfer device when conveying and accumulating dewatered lignocellulosic biomass, wherein the first headspace is at a first pressure; and
c) at least one vessel in fluid communication with the outlet of the solids transfer device, wherein the vessel is configured to receive the accumulated dewatered lignocellulosic biomass and process the dewatered lignocellulosic biomass, wherein the vessel has a second headspace that is occupied by a gas that is at a second pressure, wherein the second pressure is greater than atmospheric pressure when receiving the accumulated dewatered lignocellulosic biomass, and wherein the first pressure has a value that inhibits the gas in the vessel from flowing back through the solids transfer device.

US Pat. No. 10,919,982

ANTIBODIES TO SYMMETRICALLY DIMETHYLATED ARGININE ANALYTES AND USE THEREOF

ARK Diagnostics, Inc., F...

1. A nucleic acid encoding a variable heavy chain (VH) polypeptide, a variable light chain (VL) polypeptide, or both, of an antibody that specifically binds to a compound of Formula 1:
wherein:
R1 is —Y—Z;
Y is a linking group; and
Z is selected from the group consisting of hydrogen, OH, SH, S-acyl, O-alkyl, halogen, NH2, epoxy, maleimidyl, haloacetamide, carboxyl, activated carboxyl, an immunogenic carrier, a protein, a label, and a solid support, and wherein the antibody is selected from the group consisting of:
an antibody comprising:
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GFSLSSY (SEQ ID NO:2),
a VH CDR2 comprising the amino acid sequence DIKTGDR (SEQ ID NO:3), and
a VH CDR3 comprising the amino acid sequence ARVYVSGNDHYDL (SEQ ID NO:4); and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence QSISNY (SEQ ID NO:6),
a VL CDR2 comprising the amino acid sequence RAS (SEQ ID NO:7), and
a VL CDR3 comprising the amino acid sequence QLGYTYSNVENA (SEQ ID NO:8);
an antibody comprising:
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GFSLSSY (SEQ ID NO:2),
a VH CDR2 comprising the amino acid sequence DIKTGDR (SEQ ID NO:3), and
a VH CDR3 comprising the amino acid sequence ARVYVSGNDHYDL (SEQ ID NO:4); and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence QSISNY (SEQ ID NO:6),
a VL CDR2 comprising the amino acid sequence RAS (SEQ ID NO:7), and
a VL CDR3 comprising the amino acid sequence QLGYTYTNVENA (SEQ ID NO:10);
an antibody comprising:
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GFSFSSTK (SEQ ID NO:12),
a VH CDR2 comprising the amino acid sequence CIGTDT (SEQ ID NO:13), and
a VH CDR3 comprising the amino acid sequence ARSSSTGYYNL (SEQ ID NO:14); and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence QSIRSY (SEQ ID NO:16),
a VL CDR2 comprising the amino acid sequence YAS (SEQ ID NO:17), and
a VL CDR3 comprising the amino acid sequence HDYYTFTDND (SEQ ID NO:18);
an antibody comprising:
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GFSFSSTK (SEQ ID NO:12);
a VH CDR2 comprising the amino acid sequence CIGVGSRGS (SEQ ID NO:20); and
a VH CDR3 comprising the amino acid sequence ARSSTTGYYIL (SEQ ID NO:21); and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence ESIYSY (SEQ ID NO:23);
a VL CDR2 comprising the amino acid sequence KAS (SEQ ID NO:24); and
a VL CDR3 comprising the amino acid sequence QNYYTFTEND (SEQ ID NO:25); and
an antibody comprising:
a variable heavy chain (VH) polypeptide comprising
a VH CDR1 comprising the amino acid sequence GFSFWR (SEQ ID NO:27);
a VH CDR2 comprising the amino acid sequence CIDGGNTNR (SEQ ID NO:28); and
a VH CDR3 comprising the amino acid sequence ARVRLGNNDYIDL (SEQ ID NO:29); and
a variable light chain (VL) polypeptide comprising
a VL CDR1 comprising the amino acid sequence QSISNY (SEQ ID NO:6);
a VL CDR2 comprising the amino acid sequence RAS (SEQ ID NO:7); and
a VL CDR3 comprising the amino acid sequence QQGYNWDLDGA (SEQ ID NO:31).

US Pat. No. 10,919,973

GENERATION OF A CANCER-SPECIFIC IMMUNE RESPONSE TOWARD MUC1 AND CANCER SPECIFIC MUC1 ANTIBODIES

KOBENHAVNS UNIVERRSITET, ...


wherein the cancer is selected from the group consisting of breast cancer, ovarian cancer, pancreatic cancer, or lung cancer.

US Pat. No. 10,919,969

ANTI-CD123 ANTIBODIES AND CONJUGATES AND DERIVATIVES THEREOF

IMMUNOGEN, INC., Waltham...

1. An immunoconjugate represented by the following formula:
or a pharmaceutically acceptable salt thereof, wherein:
wC is 1 or 2;
the double line between N and C represents a single bond or a double bond, provided that when it is a double bond, X is absent and Y is —H, and when it is a single bond, X is —H, and Y is -SO3M, and M is H+ or a cation; and
CBA is an antibody or an antigen-binding fragment thereof that (i) binds an epitope within amino acids 101 to 346 of human CD123/IL3-R? antigen, and (ii) inhibits IL3-dependent proliferation in antigen-positive TF-1 cells, and wherein the antibody or antigen-binding fragment thereof comprises:
a) an immunoglobulin heavy chain variable region comprising a CDR1 having the amino acid sequence set forth in SEQ ID NO: 5, a CDR2 having the amino acid sequence set forth in SEQ ID NO: 8, and a CDR3 having the amino acid sequence set forth in SEQ ID NO: 11; and
b) an immunoglobulin light chain variable region comprising a CDR1 having the amino acid sequence set forth in SEQ ID NO: 20, a CDR2 having the amino acid sequence set forth in SEQ ID NO: 21, and a CDR3 having the amino acid sequence set forth in SEQ ID NO: 22.

US Pat. No. 10,919,956

POLYSACCHARIDE VACCINE FOR STAPHYLOCOCCAL INFECTIONS

1. A composition comprisingan isolated ?-1,6-glucosamine polymer conjugated to a protein or peptide carrier, wherein less than 40% of glucosamine amino groups in the isolated polymer are substituted with acetate, and
wherein the isolated polymer has the structure of
wherein n is an integer that is at least four, wherein R is selected from the group consisting of —NH—CO—CH3 and —NH2.

US Pat. No. 10,919,955

RODENT COMBINATORIAL ANTIBODY LIBRARIES

MORPHOSYS AG, Planegg (D...

1. A collection of nucleic acid molecules encoding a synthetic rodent antibody library, wherein the synthetic rodent antibody library comprises variable heavy (VH) and variable light (VL) chain combinations, wherein the VH-VL combinations consist of a) VH1/Vk3, b) VH2/Vk1, and c) VH5Nk3, wherein a variable heavy chain or variable light chain comprises an amino acid sequence modification as compared to amino acid sequences encoded by germline genes, wherein said amino acid sequence modification results from modifying nucleic acids encoding the variable heavy chain or variable light chain to include a restriction site.

US Pat. No. 10,919,941

FUNCTIONAL LIPID CONSTRUCTS

KODE BIOTECH LIMITED, Au...

1. A construct of the structure:
where h is the integer 1, 2, 3 or 4, v is the integer 3, 4, or 5, x is the integer 2, 3 or 4, y is the integer 1, 2 or 3, L is phosphatidylethanolamine and R3 is O of a substituted hydroxyl of a glycan.

US Pat. No. 10,919,938

MODIFIED CYCLOPENTAPEPTIDES AND USES THEREOF

1. A compound having a structure according to formula I
or a pharmaceutically acceptable salt thereof,
wherein Xaa1 is selected from the group consisting of iodo-substituted D-Tyr; iodo-substituted L-Tyr; D-Tyr, which is methyl-substituted at the aromatic ring; L-Tyr, which is methyl-substituted at the aromatic ring; iodo-substituted or methyl-substituted D-homotyrosine; iodo-substituted or methyl-substituted L- homotyrosine; iodo-substituted or methyl-substituted D-Phe; iodo-substituted or methyl-substituted L-Phe iodo-substituted or methyl-substituted D-p-OH-phenylglycine; iodo-substituted or methyl-substituted p-OH-phenylglycine; iodo-substituted or methyl-substituted D-Trp; and iodo-substituted or methyl-substituted L- Trp;
Xaa2 is arginine (Arg),
Xaa3 is naphthylalanine (Nal),
Xaa4 is glycine,
R is H or methyl,
L is a linker moiety selected from,

Ar is selected from the group consisting of
ABS-Avs: N-(5-aminoveratryl)-4-aminobenzoyl
ABS-Ahx: N-(5-aminohexanyl)-4-aminobenzoyl
AMBS-Gly: N-(glycinyl)-4-aminomethylbenzoyl
AMBS-Avs: N-(5-aminoveratryl)-4-aminomethylbenzoyl
AMBS: 4-aminomethylbenzoyl
wherein the free amino group of Ar is linked to D and the free acyl function of Ar is linked to L
and
D is
i) an organic complexation agent selected from NODASA, NODAGA, TETA, TRITA, TRAP, DTPA, CHX-DTPA EDTA, CDTA, CPTA, DOTP, DOTPI, EGTA, HBED, DTPA, DOT A, DOTAGA, NOTA, HP-DOA3, CBTE2a, TE2A, TMT, DPDP, HYNIC, DFO, HEDTA, NOPO, MAG3, NCS-MP-NODA, NH2-MPAA-NODA, and NODA;
ii) a nuclide or radionuclide selected from 11C, 18F, 47Sc, 51Cr, 52mMn, 58Co, 52Fe, 56Ni, 57Ni, 62Cy, 64Cu, 67Cu, 66Ga, 68Ga, 67Ga 72As, 77As, 75Br, 76Br, 77Br, 82Br, 89Zr, 90Y, 94mTc, 99mTc, 97Ru, 105Rh, 109Pd, 111Ag, 110mIn, 111In, 113mIn, 114mIn, 120I, 123I, 124I, 125I,127I, 131I, 117mSn, 121Sn, 127Te, 142Pr, 143Pr, 149Pm, 151Pm, 149Tb, 153Sm, 157Gd, 161Tb, 166Ho, 165Dy, 169Er, 169Yb, 175Yb, 172Tm, 177Lu, natLu, 186Re, 188Re, 191Pt, 197Hg, 198Au, 199Au, 201Tl, 203Pb, 211At, 212Bi and 225Ac and radioactive ion Al18F2+;
iii) a combination of a nuclide or radionuclide of ii) and a complexation agent of i), with the complexation agent being covalently bound to Ar;
iv) detectable label;
v) a combination of a detectable label and a nuclide or radionuclide of ii) or a complexation agent of i); or
vi) an active substance selected from cytotoxic agents, lipids, sugars, sugar conjugates, proteins and combinations thereof.

US Pat. No. 10,919,937

BICYCLIC PEPTIDE LIGANDS AND USES THEREOF

BicycleTx Limited, Cambr...

1. A compound of formula I:or a pharmaceutically acceptable salt thereof, wherein:each of L1, L2, and L3 is independently a covalent bond or a C1-8 bivalent hydrocarbon chain wherein one, two or three methylene units of the chain are optionally and independently replaced by -Cy1-, —S, —N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —C(O)N(R)—, —N(R)C(O)—, —OC(O)N(R)—, —N(R)C(O)O—, —S(O)—, —S(O)2—, —C(CH3)?N—N(R)—, —N(R)N?C(CH3)—, —N(R)CH2C(O)—, —(CH2CH2O)1-10—,

L4 is a covalent bond, —O—, —N(R)—, or —N(R)CH2CH2N(R)—;
each R is independently hydrogen or C1-4 aliphatic;
each -Cy1- is independently an optionally substituted bivalent ring selected from phenylene, 3-7 membered saturated or partially unsaturated carbocyclylene, 4-7 membered saturated or partially unsaturated heterocyclylene having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10-12 membered saturated or partially unsaturated bicyclic heterocyclylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10-12 membered saturated or partially unsaturated tricyclic heterocyclylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10-12 membered partially saturated bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 10-12 membered partially saturated tricyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 9-12 membered bicyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 19-20 membered partially unsaturated tetracyclic heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 5-6 membered heteroarylene having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
Scaffold is a trivalent group that connects and orients a cyclic peptide selected from the group consisting of

Loop A is a bivalent natural or unnatural amino acid residue or peptide attached to the amino acid residue linked to L1 and the amino acid residue linked to L2;
Loop B is a bivalent natural or unnatural amino acid residue or peptide attached to the amino acid residue linked to L1 and the amino acid residue linked to L3;
Spacer1 is a covalent bond, a natural or unnatural amino acid wherein the amino group is connected to the C-terminus of the Bicycle via an amide bond, or a peptide wherein the N-terminal amino group of the peptide is connected to the C-terminus of the Bicycle via an amide bond;
Spacer2 is a covalent bond, a natural or unnatural amino acid wherein the acid is connected to the N-terminus of the Bicycle via an amide bond, or a peptide wherein the C-terminal acid of the peptide is connected to the N-terminus of the Bicycle via an amide bond;
each of R1 and R2 is independently R,
or -Linker-Conjugate;each Linker is independently a covalent bond, or a C1-8 bivalent hydrocarbon chain wherein one, two or three methylene units of the chain are optionally and independently replaced by -Cy1-, —S—, —N(R)—, —O—, —C(O)—, —OC(O)—, —C(O)O—, —C(O)N(R)—, —N(R)C(O)—, —OC(O)N(R)—, —N(R)C(O)O—, —S(O)—, —S(O)2—, —C(CH3)?N—N(R)—, —N(R)N?C(CH3)—, —N(R)CH2C(O)—, —(CH2CH2O)1-10—,

each Conjugate is independently a half life extension motif, a solubilizing group, a transporter recognition motif, a cell penetrant motif, a drug payload, or a detectable moiety;
each R3 is independently hydrogen or C1-4 aliphatic;
m is 0 or 1; and
n is 0 or 1.

US Pat. No. 10,919,929

GLUCOCORTICOID INHIBITORS FOR TREATMENT OF PROSTATE CANCER

Sloan-Kettering Institute...

1. A method of treating castration resistant prostate cancer or doubly resistant prostate cancer comprising administering to a subject in need thereof a compound having the structure of formula I or III:
or a pharmaceutically acceptable salt thereof, wherein:
each R1 is —OR, wherein R is optionally substituted phenyl;
R2 is optionally substituted unsaturated C2-6 aliphatic;
Rs is —H, —OH, —NH2, —CH3, —Br, —Cl, —F, —I, or —O—C1-6alkyl;
m is an integer between 1-8; and
n is 1.

US Pat. No. 10,919,928

OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE

AJINOMOTO CO., INC., Tok...

1. A method for producing an oligonucleotide, comprising:(1) condensing, in a non-polar solvent,
a nucleoside, nucleotide or oligonucleotide (b), and
a nucleoside, nucleotide or oligonucleotide (a), or
a substituted nucleotide or oligonucleotide (?)
by adding said nucleoside, nucleotide or oligonucleotide (b) to a reaction solution comprising said nucleoside, nucleotide or oligonucleotide (a) or said substituted nucleotide or oligonucleotide (?) to obtain a reaction solution comprising a phosphite triester product (c) wherein a 5?-hydroxy group is protected by a temporary protecting group;
(3) oxidizing or sulfurizing said phosphite triester product (c) by adding an oxidant or a sulfurizing agent to said reaction solution comprising said phosphite triester product (c) to obtain a reaction solution comprising an oligonucleotide (d) wherein the 5?-hydroxy group is protected by the temporary protecting group;
(4) removing the temporary protecting group of the 5?-hydroxy group by adding an acid to said reaction solution after the oxidation or sulfurization to obtain a reaction solution comprising an oligonucleotide (e) wherein the 5?-hydroxy group is not protected; and
(6) adding a polar solvent to said reaction solution comprising said oligonucleotide (e) and purifying said oligonucleotide (e) by solid-liquid separation,
wherein said non-polar solvent is at least one member selected from the group consisting of chloroform, dichloromethane, 1,2-dichloroethane, benzene, toluene, xylene, mesitylene, ethyl acetate, isopropyl acetate, hexane, pentane, heptane, octane, nonane, cyclohexane, diethyl ether, cyclopentyl methyl ether, tert-butyl methyl ether, and mixtures thereof;
wherein said nucleoside, nucleotide or oligonucleotide (a) or said substituted nucleotide or oligonucleotide (a) is a compound represented by formula (a-i):
whereinm is an integer of not less than 0 and not more than 49;
each Base in each number of m+1 is independently an optionally protected nucleic acid base;
each X in each number of m+1 is independently a hydrogen atom, a halogen atom, or an optionally protected hydroxy group;
each R10 in each number of m is independently an oxygen atom or a sulfur atom;
each Rp1 in each number of m is independently a protecting group of phosphoric acid group;
L is a single bond, or a group represented by formula (a1) or (a1?):
wherein* is the bonding position to Y;
** is the bonding position to an oxygen atom;
R1 and R2 are each independently a C1-22 hydrocarbon group;
L1 is an optionally substituted divalent C1-22 hydrocarbon group;
L2 is a single bond or a group represented by ***C(?O)N(R3)—R4—N(R5)**** wherein *** is the bonding position to L1, **** is the bonding position to C?O, R4 is a C1-22 alkylene group, R3 and R5 are each independently a hydrogen atom or a C1-22 alkyl group, or R3 and R5 are optionally joined to form a ring;
Y is a single bond, an oxygen atom or NR wherein R is a hydrogen atom, an alkyl group or an aralkyl group; and
Z is a group represented by formula (a2), formula (a2?) or formula (a2?):
wherein* indicates a bonding position;
R6 is a hydrogen atom, or when Rb is a group represented by the following formula (a3), R6 of ring A or ring B is optionally shows, together with R8, a single bond or —O— to form, together with ring A or ring B and ring C, a fused ring;
k is an integer of 1 to 4;
each Q in each number of k is independently —O—, —C(?O)—, —C(?O)O—, —OC(?O)—, —C(?O)NH— or —NHC(?O)—;
each R7 in each number of k is independently a hydrocarbon group wherein a linear aliphatic hydrocarbon group selected from a linear C10-40 alkyl group and a linear C10-40 alkenyl group is bonded via a single bond or a linker;
ring A and ring B, each independently, optionally has, in addition to QR7 in the number of k, a substituent selected from the group consisting of a halogen atom, a C1-6 alkyl group optionally substituted by a halogen atom, and a C1-6 alkoxy group optionally substituted by a halogen atom;
Ra is a hydrogen atom; and
Rb is a hydrogen atom, or a group represented by formula (a3):
wherein* indicates a bonding position;
j is an integer of 0 to 4;
each Q in each number of j is independently as defined above;
each R9 in each number of j is independently a hydrocarbon group wherein a linear aliphatic hydrocarbon group selected from a linear C10-40 alkyl group and a linear C10-40 alkenyl group is bonded via a single bond or a linker;
R8 is a hydrogen atom, or optionally shows, together with R6 of ring A or ring B, a single bond or —O— to form, together with ring A or ring B and ring C, a fused ring; and
ring C optionally has, in addition to QR9 in the number of j, a substituent selected from the group consisting of a halogen atom, a C1-6 alkyl group optionally substituted by a halogen atom, and a C1-6 alkoxy group optionally substituted by a halogen atom, or
Ra and Rb are joined to form an oxo group;
a compound represented by formula (a-vi):
whereinat least one of Base? in the number of m+1 is a nucleic acid base protected by -L-Y—Z, and the rest is an optionally protected nucleic acid base;
Rn4 is a hydroxy-protecting group;
m, X in the number of m+1, R10 in the number of m, Rp1 in the number of m, L, Y and Z are each independently as defined above; or
a compound represented by formula (a-vii):
whereinLn1 is a C2-6 alkylene group;
m, Base in the number of m+1, X in the number of m+1, R10 in the number of m+1, Rp1 in the number of m+1, L, Y and Z are each independently as defined above;
wherein said nucleoside, nucleotide or oligonucleotide (b) is a compound represented by formula (b-i):
whereinq is an integer of not less than 0 and not more than 49;
each Base3 in each number of q+1 is independently an optionally protected nucleic acid base;
X in the number of q+1, Rp1 in the number of q+1, and R10 in the number of q are each independently as defined above;
Q? is the temporary protecting group;
R36 and R37 are each independently an alkyl group, or a 5- or 6-membered saturated cyclic amino group formed together with the adjacent nitrogen atom, and the saturated cyclic amino group, optionally has, as a ring-constituting atom, one oxygen atom or sulfur atom besides nitrogen atom;
wherein said temporary protecting group is a trityl group, a 9-(9-phenyl)xanthenyl group, a 9-phenylthioxanthenyl group, a bis(C1-6 alkoxy)trityl group, or a mono(C1-18 alkoxy)trityl group;
wherein said acid in said (4) removing the temporary protecting group is at least one member selected from the group consisting of trifluoroacetic acid, dichloroacetic acid, trifluoromethanesulfonic acid, trichloroacetic acid, methanesulfonic acid, hydrochloric acid, acetic acid, p-toluenesulfonic acid, and mixtures thereof; and
wherein said polar solvent in said (6) adding a polar solvent to said reaction solution is at least one member selected from the group consisting of methanol, ethanol, isopropanol, acetonitrile, propionitrile, acetone, 2-butanone, 1,4-dioxane, tetrahydrofuran, dimethylformamide, dimethylacetamide, N-methylpiperidone, dimethyl sulfoxide, water, and mixtures thereof.

US Pat. No. 10,919,927

IMMUNE STIMULATING MACROLIDE

ISR IMMUNE SYSTEM REGULAT...

1. A compound having the structure of Formula (I):

US Pat. No. 10,919,926

COMPOUND OR SALT THEREOF, NATURAL KILLER T CELL ACTIVATOR, AND PHARMACEUTICAL COMPOSITION

KEIO UNIVERSITY, Tokyo (...

1. A compound represented by formula (1):
or a salt thereof,
wherein
Y is a group represented by any of formulae (A) to (E)

R1 is a C2-45 monovalent aliphatic group or a C2-45 monovalent aryl group, each of which is optionally substituted with a halogen atom, an optionally substituted alkoxy group, a group derived from a heterocycle, or a group represented by formula (XIII)

R11 is an alkyl group or an alkenyl group,
R2 is a monovalent hydrocarbon group optionally having a substituent,
Ra is a monovalent hydrocarbon group having a carbon number of 1 to 5,
X1 is a divalent hydrocarbon group,
X2 is —NHCO—, —NMeCO—, —O—, or —OCO—, wherein Me represents a methyl group,
X3 is —CH2—, —CHOH—, or —CHNH2—,
X4 is —OCH2—, —CH2—CH2—, —CH?CH—, —SCH2—, or —NHCH2—, and
either
(A) R3, R6, and R8 are hydrogen atoms,
R4 is hydrogen atom, hydroxy group, —NH2 or —NHCOCH3,
R5 is hydroxy group, an alkoxy group, an arylalkoxy group, or —OSO3Na,
R7 is hydroxy group, an alkoxy group, an arylalkoxy group, or —OSO3Na, and
R9 is hydrogen atom, hydroxymethyl group, methyl group, an alkoxymethyl group, an arylalkoxymethyl group, —CH2SO3Na, a group represented by formula (VII), or a group represented by formula (VIII),

or
(B) R3, R6, and R7 are hydrogen atoms,
R4 is hydrogen atom, hydroxy group, —NH2 or —NHCOCH3,
R5 is hydroxy group, an alkoxy group, an arylalkoxy group, or —OSO3Na,
R8 is hydroxy group, an alkoxy group, an arylalkoxy group, or —OSO3Na, and
R9 is hydrogen atom, hydroxymethyl group, methyl group, an alkoxymethyl group, an arylalkoxymethyl group, —CH2OSO3Na, a group represented by formula (VII), or a group represented by formula (VIII).

US Pat. No. 10,919,923

ORGANIC PHOSPHORUS-BASED COMPOUND, AND FLAME RETARDANT AND FLAME-RETARDANT PRODUCT COMPRISING THE SAME

TEIJIN LIMITED, Osaka (J...

1. An organic phosphorus-based compound which satisfies the following requirements (i) to (viii) and is represented by the following formula (1):(i) the organic purity is not lower than 98%;
(ii) the solubility in 20° C. water is not higher than 0.1 g/100 g of water;
(iii) the total halogen component content is not higher than 1,000 ppm;
(iv) the total volatile organic matter content is not higher than 800 ppm;
(v) the ? pH value is not larger than 1.0;
(vi) the volume standard median diameter is not larger than 30 ?m;
(vii) the maximum particle diameter is not larger than 200 ?m; and
(viii) the standard deviation represented by the following formula (6) is not larger than 15 ?m;
Standard deviation=(d84%+d16%)/2  (6)
 d84%: particle diameter at a point where the cumulative curve becomes 84% (?m)
 d16%: particle diameter at a point where the cumulative curve becomes 16% (?m)

wherein, in formula (1),
R2 and R5 may be the same or different and are each a phenyl group which may have a substituent, naphthyl group which may have a substituent, anthryl group which may have a substituent, or branched or linear alkyl group having 1 to 4 carbon atoms which may have an aromatic substituent, and
R1, R3, R4 and R6 may be the same or different and are each a hydrogen atom, branched or linear alkyl group having 1 to 4 carbon atoms, phenyl group which may have a substituent, naphthyl group which may have a substituent, or anthryl group which may have a substituent.

US Pat. No. 10,919,922

BROAD SPECTRUM ANTIVIRAL COMPOUNDS

University of Southern Ca...

1. A compound of the following formula:
or a salt or a pharmaceutically acceptable salt thereof,
wherein B is a naturally occurring or non-naturally occurring base; R1 is a C2-C14 alkyl group; X is O, S, CH?CH (cis) or CH?CH (trans); and R2 is a C2-C14 alkyl group.

US Pat. No. 10,919,921

P-CHIRAL PHOSPHINE LIGANDS AND USE THEREOF FOR ASYMMETRIC SYNTHESIS

BASF SE

1. A chiral compound of the general formula (I)
in which
A1 is O, S, CRaRb, NRa, S(?O), S(?O)2, BRa, PRa or P(?O)Ra, where Ra and Rb, independently of one another, are hydrogen, C1-C30-alkyl, C3-C12-cycloalkyl, heterocycloalkyl with 3 to 12 ring atoms, C6-C14-aryl or hetaryl with 5 to 14 ring atoms, where the cycloalkyl, heterocycloalkyl, aryl and hetaryl groups are unsubstituted or carrying one, two or three substituents selected from C1-C10-alkyl and C1-C10-alkoxy,
A2 and A3, independently of one another, are hydrogen, C1-C20-alkyl, C1-C20-alkoxy, C3-C12-cycloalkyl, C3-C12-cycloalkyloxy, heterocycloalkyl with 3 to 12 ring atoms, heterocycloalkyloxy with 3 to 12 ring atoms, C6-C14-aryl, C6-C14-aryloxy, hetaryl with 5 to 14 ring atoms, hetaryloxy with 5 to 14 ring atoms, C1-C20-hydroxyalkyl, C1-C20-aminoalkyl, C1-C20-haloalkyl, hydroxy, mercapto, cyano, nitro, polyalkylene oxide, polyalkyleneimine, halogen, carboxyl, carboxylate, formyl, acyl, sulfo, sulfonate or NE1E2, in which E1 and E2 are in each case identical or different radicals selected from hydrogen, C1-C30-alkyl, C3-C12-cycloalkyl and C6-C14-aryl,
or
A2 and A3 together are a chemical bond between the two benzene rings,
or
A2 and A3 together are O, S, CRcRd, NRc, SiRcRd, S(?O), S(?O)2, BRc, PRc or P(?O)Rc, where Rc and Rd, independently of one another, are hydrogen, C1-C30-alkyl, C3-C12-cycloalkyl, heterocycloalkyl with 3 to 12 ring atoms,
C6-C14-aryl or hetaryl with 5 to 14 ring atoms, where cycloalkyl, heterocycloalkyl, aryl and hetaryl groups are unsubstituted or carry one, two or three substituents selected from C1-C10-alkyl or C1-C10-alkoxy,
or
A1, A2 and A3 together are a bridging group

where
each of the variables #1 and #2 is a binding site, where the binding sites #1 are bonded to two adjacent carbon atoms of the one benzene ring and the binding sites #2 are bonded to two adjacent carbon atoms of the other benzene ring,
Re1, Re2, Re3 and Re4, independently of one another, are hydrogen, C1-C20-alkyl, C3-C12-cycloalkyl, C6-C14-aryl, halogen, trifluoromethyl, carboxyl or carboxylate,
where Re1, also together with Re3, can be the binding fraction of a double bond between the two carbon atoms to which Re1 and Re3 are bonded, or
Re1, Re2, Re3 and Re4 together with the carbon atoms of the bridging group to which they are bonded can also be a benzene ring or a condensed aromatic ring system with 1, 2 or 3 benzene rings, where the benzene rings are unsubstituted or where each of the benzene rings can have 1 or 2 substituents which are selected, independently of one another, from C1-C20-alkyl, C1-C20-alkoxy, C3-C12-cycloalkyl, C3-C12-cycloalkyloxy, heterocycloalkyl with 3 to 12 ring atoms, heterocycloalkyloxy with 3 to 12 ring atoms, C6-C14-aryl, C6-C14-aryloxy, hetaryl with 5 to 14 ring atoms, hetaryloxy with 5 to 14 ring atoms, C1-C20-hydroxyalkyl, C1-C20-aminoalkyl, C1-C20-haloalkyl, hydroxy, mercapto, cyano, nitro, polyalkylene oxide, polyalkyleneimine, halogen, carboxyl, carboxylate, formyl, acyl, sulfo, sulfonate or NE3E4, in which E3 and E4 are in each case identical or different radicals selected from hydrogen, C1-C30-alkyl, C3-C12-cycloalkyl and C6-C14-aryl,
Ar1 is C6-C14-aryl or hetaryl with 5 to 14 ring atoms, where aryl and hetaryl are unsubstituted or carry 1, 2 or 3 identical or different substituents which are selected from C1-C6-alkyl, C1-C6-alkoxy or NE5E6, in which E5 and E6 are in each case identical or different radicals selected from hydrogen, C1-C30-alkyl, C3-C12-cycloalkyl and C6-C14-aryl,
Ar2 is C6-C14-aryl or hetaryl with 5 to 14 ring atoms, where aryl and hetaryl are unsubstituted or carry 1, 2 or 3 identical or different substituents which are selected from C1-C6-alkyl, C1-C6-alkoxy or NE5E6, in which E5 and E6 are in each case identical or different radicals selected from hydrogen, C1-C30-alkyl, C3-C12-cycloalkyl and C6-C14-aryl,
Ar3 is C6-C14-aryl or hetaryl with 5 to 14 ring atoms, where aryl and hetaryl are unsubstituted or carry 1, 2 or 3 identical or different substituents which are selected from C1-C6-alkyl, C1-C6-alkoxy or NE5E6, in which E5 and E6 are in each case identical or different radicals selected from hydrogen, C1-C30-alkyl, C3-C12-cycloalkyl and C6-C14-aryl,
Ar4 is C6-C14-aryl or hetaryl with 5 to 14 ring atoms, where aryl and hetaryl are unsubstituted or carry 1, 2 or 3 identical or different substituents which are selected from C1-C6-alkyl, C1-C6-alkoxy or NE5E6, in which E5 and E6 are in each case identical or different radicals selected from hydrogen, C1-C30-alkyl, C3-C12-cycloalkyl and C6-C14-aryl,
with the proviso that Ar1 and Ar2 do not have the same meaning, and that Ar3 and Ar4 do not have the same meaning,
R1, R2, R3, R4, R5 and R6, independently of one another, are hydrogen, C1-C20-alkyl, C1-C20-alkoxy, C3-C12-cycloalkyl, C3-C12-cycloalkyloxy, heterocycloalkyl with 3 to 12 ring atoms, heterocycloalkyloxy with 3 to 12 ring atoms, C6-C14-aryl, C6-C14-aryloxy, hetaryl with 5 to 14 ring atoms, hetaryloxy with 5 to 14 ring atoms, C1-C20-hydroxyalkyl, C1-C20-aminoalkyl, C1-C20-halo alkyl, hydroxy, mercapto, cyano, nitro, polyalkylene oxide, polyalkyleneimine, halogen, carboxyl, carboxylate, formyl, acyl, sulfo, sulfonate or NE5E6, in which E5 and E6 are in each case identical or different radicals selected from hydrogen, C1-C20-alkyl, C3-C12-cycloalkyl and C6-C14-aryl,
where two adjacent radicals R1 to R6, together with the carbon atoms of the benzene ring to which they are bonded, can also be a condensed ring system with 1, 2 or 3 further benzene rings, where the benzene rings of the condensed ring system are unsubstituted or each of the benzene rings can have 1 or 2 substituents which are selected, independently of one another, from C1-C20-alkyl, C1-C20-alkoxy, C3-C12-cycloalkyl, C3-C12-cycloalkyloxy, heterocycloalkyl with 3 to 12 ring atoms, heterocycloalkyloxy with 3 to 12 ring atoms, C6-C14-aryl, C6-C14-aryloxy, hetaryl with 5 to 14 ring atoms, hetaryloxy with 5 to 14 ring atoms, C1-C20-hydroxyalkyl, C1-C20-aminoalkyl, C1-C20-halo alkyl, hydroxy, mercapto, cyano, nitro, polyalkylene oxide, polyalkyleneimine, halogen, carboxyl, carboxylate, formyl, acyl, sulfo, sulfonate or NE7E8, in which E7 and E8 are in each case identical or different radicals selected from hydrogen, C1-C20-alkyl, C3-C12-cycloalkyl and C6-C14-aryl.

US Pat. No. 10,919,919

EPOXY-FUNCTIONAL ALKOXYSILANES, METHOD FOR THE PRODUCTION AND USE THEREOF

Evonik Operations GmbH, ...

1. An epoxy-functional alkoxysilane of formulae II, I, IV, V, and/or VI:
wherein R represents a methyl or an ethyl group.

US Pat. No. 10,919,918

TETRACARBOXYLIC DIANHYDRIDE, POLYIMIDE RESIN AND METHOD FOR PRODUCING THE SAME, PHOTOSENSITIVE RESIN COMPOSITIONS, PATTERNING PROCESS, METHOD FOR FORMING CURED FILM, INTERLAYER INSULATING FILM, SURFACE PROTECTIVE FILM, AND ELECTRONIC PARTS

SHIN-ETSU CHEMICAL CO., L...

4. A polyimide resin comprising a structural unit shown by the following general formula (5),
wherein Z represents a linear or branched divalent hydrocarbon group having 4 to 100 carbon atoms optionally containing an oxygen atom therein; R1 to R4 each represent an identical or different monovalent hydrocarbon group having 1 to 8 carbon atoms; R5 represents a trivalent organic group; “n” represents an integer of 1 to 100; and X represents a divalent organic group.

US Pat. No. 10,919,917

SILYLATED DERIVATIVES OF AROMATIC HETEROCYCLES

California Institute of T...

1. A method of preparing silylated compound comprising a moiety of Formula (I) or Formula (II):the method comprising:contacting a substrate containing a
moiety with a hydrosilane of formula (R1)3?mSi(H)m+1 and potassium hydroxide (KOH), under conditions to form the silylated compound, the method resulting in the formation of the silylated compound comprising the moiety of Formula (I) or Formula (II);wherein
m is 0, 1, or 2;
R1 is independently optionally substituted C1-12 alkyl, C1-12 heteroalkyl, or an optionally substituted 5- or 6-membered aryl or heteroaryl, and, if substituted, the substituents are independently alkyl, alkenyl, aryl, heteroaryl, hydroxyl, C1-C20 alkoxy, C5-C20 aryloxy, C2-C20 alkoxycarbonyl, C5-C20 aryloxycarbonyl, amino, optionally protected carboxyl, carboxylato, cyano, halo, phosphonato, phosphoryl, phosphanyl, phosphino, sulfonato, C1-C20 alkylsulfanyl, C5-C20 arylsulfanyl, C1-C20 alkylsulfonyl, C5-C20 arylsulfonyl, C1-C20 alkylsulfinyl, C5-C20 arylsulfinyl, sulfonamido, amido, imino, nitro, nitroso, mercapto, optionally protected formyl, C1-C20 thioester, cyanato, thiocyanato, isocyanate, thioisocyanate, carbamoyl, epoxy, styrenyl, silyl, silyloxy, silanyl, siloxazanyl, boronato, or boryl;
X is NR2, O, or S;
R2 is an amine protecting group, an optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkaryl or optionally substituted alk-heteroaryl;
is a heteroaromatic moiety containing y additional nitrogens in the ring structure, where y=0 or 1 when X is O or S, or y=0, 1, or 2 when X is NR2; andis an aromatic moiety containing x nitrogen atoms in the ring structure, where x=0, 1, or 2.

US Pat. No. 10,919,916

BORON-CONTAINING SMALL MOLECULES

1. A compound, or a salt or a hydrate or a solvate thereof, having a structure which is:whereinX is H or F or OH;
Y is selected from the group consisting of a bond, O, —S—, —NH—, substituted or unsubstituted alkylene, and substituted or unsubstituted heteroalkylene; and
Z is a substituted or unsubstituted heterocyclic ring or ring system containing at least one endocyclic boron; and
the substituted alkyl, substituted heteroalkyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted alkylene, substituted heteroalkylene, substituted aryl, and substituted heteroaryl are respectively alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl respectively substituted with one or more substituents selected from the group consisting of —R?, —OR?, ?O, ?NR?, ?N—OR?, —NR?R?, —SR?, halogen, —SiR?R?R??, —OC(O)R?, —C(O)R?, —CONR?R?, —OC(O)NR?R?, —NR?C(O)R?, —NR?—C(O)NR?R??, —NR?C(O)2R?, —NR???-C(NR?R?R??)?NR??, —NR??—C(NR?R?)?NR??, —S(O)R?, —S(O)2R?, —S(O)2NR?R?, —NR?SO2R?, —CN, —NO2, —N3, —CH(Ph)2, fluoro(C1-C4)alkoxy, and fluoro(C1-C4)alkyl,
wherein R?, R?, R??, R?? and R??? are each independently selected from the group consisting of hydrogen, substituted or unsubstituted heteroalkyl, substituted or unsubstituted aryl, aryl substituted with 1-3 halogens, substituted or unsubstituted alkyl, alkoxy or thioalkoxy groups, and arylalkyl groups.

US Pat. No. 10,919,915

COMPOUNDS AS GPR119 AGONISTS

MANKIND PHARMA LTD., New...

1. A compound which is 2-(1-(1-(5-ethylpyrimidin-2-yl)piperidin-4-ypethoxy)-5-(6-(methylsulfonyl)pyridin-3-yl)thiazolo[5,4-b]pyridine represented by the following structural formula:or a physiologically acceptable salt thereof.

US Pat. No. 10,919,914

HETEROCYCLIC COMPOUNDS AND USES THEREOF

Infinity Pharmaceuticals,...

1. A compound of Formula I?:
or a pharmaceutically acceptable form thereof,
wherein R is halo, C1-C8 alkyl optionally substituted with one or more halo, or
is a (5-14 membered fused bicyclic saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of N, O, and S) or (5-14 membered fused bicyclic saturated, unsaturated, or aromatic carbocycle); wherein the heterocycle or carbocycle is optionally substituted with one or more substituents selected from R2a, R3a, R4a, R6a, (R5a)n, and R1d;n is 1, 2, or 3;
L is a bond or —NR1e;
Wd is

R1a is selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, OH, OR10, NH2, NHR10, NR10R10, NR10COR10, COH, C(O)R10, COOH, COOR10, CONH2, CONHR10, CONR10R10, CN, halo, NO2, haloalkyl, (3-14 membered saturated, unsaturated, or aromatic carbocycle), and (3-14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of N, O, and S); wherein each of alkyl, alkenyl, alkynyl, haloalkyl, carbocycle, or heterocycle is optionally substituted with one or more R11;
each instance of R10 is independently selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, halo, OH, O(C1-C8 alkyl), NH2, NH(C1-C8 alkyl), N(C1-C8 alkyl)2, haloalkyl, CN, NO2, CONH2, CONH(C1-C8 alkyl), CON(C1-C8 alkyl)2, COH, CO(C1-C8 alkyl), COOH, COO(C1-C8 alkyl), NHCO(C1-C8 alkyl), N(C1-C8 alkyl)CO(C1-C8 alkyl), (3-14 membered saturated, unsaturated, or aromatic carbocycle), and (3-14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of N, O, and S);
each instance of R11 is independently selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, halo, OH, O(C1-C8 alkyl), OCF3, OCF2H, OCFH2, NH2, NH(C1-C8 alkyl), N(C1-C8 alkyl)2, haloalkyl, CN, NO2, CONH2, CONH(C1-C8 alkyl), CON(C1-C8 alkyl)2, COH, CO(C1-C8 alkyl), COOH, COO(C1-C8 alkyl), NHCO(C1-C8 alkyl), N(C1-C8 alkyl)CO(C1-C8 alkyl), (3-14 membered saturated, unsaturated, or aromatic carbocycle), and (3-14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of N, O, and S);
each instance of R2a, R3a, R4a, R5a, and R6a is independently selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, halo, oxo, OH, O(C1-C8 alkyl), OCF3, OCF2H, OCFH2, NH2, NH(C1-C8 alkyl), N(C1-C8 alkyl)2, haloalkyl, CN, NO2, CONH2, CONH(C1-C8 alkyl), CON(C1-C8 alkyl)2, COH, CO(C1-C8 alkyl), COOH, COO(C1-C8 alkyl), NHCO(C1-C8 alkyl), N(C1-C8 alkyl)CO(C1-C8 alkyl), (3-14 membered saturated, unsaturated, or aromatic carbocycle), and (3-14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of N, O, and S);
R1b, R2b, R3b, R4b, and R5b each is independently selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, halo, OH, O(C1-C8 alkyl), OCF3, OCF2H, OCFH2, NH2, NH(C1-C8 alkyl), N(C1-C8 alkyl)2, haloalkyl, CN, NO2, CONH2, CONH(C1-C8 alkyl), CON(C1-C8 alkyl)2, COH, CO(C1-C8 alkyl), COOH, COO(C1-C8 alkyl), NHCO(C1-C8 alkyl), N(C1-C8 alkyl)CO(C1-C8 alkyl), (3-14 membered saturated, unsaturated, or aromatic carbocycle), and (3-14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of N, O, and S);
R1c is selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, halo, OH, O(C1-C8 alkyl), OCF3, OCF2H, OCFH2, NH2, NH(C1-C8 alkyl), N(C1-C8 alkyl)2, haloalkyl, CN, NO2, CONH2, CONH(C1-C8 alkyl), CON(C1-C8 alkyl)2, COH, CO(C1-C8 alkyl), COOH, COO(C1-C8 alkyl), NHCO(C1-C8 alkyl), N(C1-C8 alkyl)CO(C1-C8 alkyl), (3-14 membered saturated, unsaturated, or aromatic carbocycle), and (3-14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of N, O, and S);
R2 is selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, halo, OH, O(C1-C8 alkyl), OCF3, OCF2H, OCFH2, NH2, NH(C1-C8 alkyl), N(C1-C8 alkyl)2, haloalkyl, CN, NO2, CONH2, CONH(C1-C8 alkyl), CON(C1-C8 alkyl)2, COH, CO(C1-C8 alkyl), COOH, COO(C1-C8 alkyl), NHCO(C1-C8 alkyl), N(C1-C8 alkyl)CO(C1-C8 alkyl), (3-14 membered saturated, unsaturated, or aromatic carbocycle), and (3-14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of N, O, and S); and
R1d is selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, and C2-C8 alkynyl;
R1e is selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, and C2-C8 alkynyl;
Rif is selected from the group consisting of NH2, NH(C1-C8 alkyl), N(C1-C8 alkyl)2, C2-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, halo, OH, O(C1-C8 alkyl), OCF3, OCF2H, OCFH2, haloalkyl, CN, NO2, CONH2, CONH(C1-C8 alkyl), CON(C1-C8 alkyl)2, COH, CO(C1-C8 alkyl), COOH, COO(C1-C8 alkyl), NHCO(C1-C8 alkyl), N(C1-C8 alkyl)CO(C1-C8 alkyl), (3-14 membered saturated, unsaturated, or aromatic carbocycle), and (3-14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of N, O, and S);
R2f, R3f, R4f, and R5f each is independently selected from the group consisting of hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, halo, OH, O(C1-C8 alkyl), OCF3, OCF2H, OCFH2, NH2, NH(C1-C8 alkyl), N(C1-C8 alkyl)2, haloalkyl, CN, NO2, CONH2, CONH(C1-C8 alkyl), CON(C1-C8 alkyl)2, COH, CO(C1-C8 alkyl), COOH, COO(C1-C8 alkyl), NHCO(C1-C8 alkyl), N(C1-C8 alkyl)CO(C1-C8 alkyl), (3-14 membered saturated, unsaturated, or aromatic carbocycle), and (3-14 membered saturated, unsaturated, or aromatic heterocycle containing one or more heteroatoms selected from the group consisting of N, O, and S).

US Pat. No. 10,919,913

SPIRO[3H-INDOLE-3,2?-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS

Boehringer Ingelheim Inte...

1. A compound of formula (I)whereinR1 is a group, optionally substituted by one or more, identical or different Rb1 and/or
Rc1, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rb1 is independently selected from among —ORc1, —NRc1Rc1, halogen, —CN, —C(O)Rc1, —C(O)ORc1, —C(O)NRc1Rc1, —S(O)2Rc1, —S(O)2NRc1Rc1, —NHC(O)Rc1 and —N(C1-4alkyl)C(O)Rc1;
each Rc1 independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different Rd1 and/or Re1, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rd1 is independently selected from among —ORe1, —NRe1Re1, halogen, —CN, —C(O)Re1, —C(O)ORe1, —C(O)NRe1Re1, —S(O)2Re1, —S(O)2NRe1Re1, —NHC(O)Re1 and —N(C1-4alkyl)C(O)Re1;
each Re1 independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different Rf1 and/or Rg1, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rf1 is independently selected from among —ORg1, —NRg1Rg1, halogen, —CN, —C(O)Rg1, —C(O)ORg1, —C(O)NRg1Rg1, —S(O)2Rg1, —S(O)2NRg1Rg1, —NHC(O)Rg1 and —N(C1-4alkyl)C(O)Rg1;
each Rg1 is independently selected from among hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
R2 and R3, each independently, is selected from among hydrogen, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl, wherein this C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl is optionally substituted by one or more, identical or different Rb2 and/or Rc2;
each Rb2 is independently selected from among —ORc2, —NRc2Rc2, halogen, —CN, —C(O)Rc2, —C(O)ORc2, —C(O)NRc2Rc2, —S(O)2Rc2, —S(O)2NRc2Rc2, —NHC(O)Rc2 and —N(C1-4alkyl)C(O)Rc2;
each Rc2 independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different Rd2 and/or Re2, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-6cycloalkyl, C4-6cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rd2 is independently selected from among —ORe2, —NRe2Re2, halogen, —CN, —C(O)Re2, —C(O)ORe2, —C(O)NRe2Re2, —S(O)2Re2, —S(O)2NRe2Re2, —NHC(O)Re2 and —N(C1-4alkyl)C(O)Re2;
each Re2 independently of one another denotes hydrogen or a group selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-6cycloalkyl, C4-6cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
A is selected from among phenyl and 5-6 membered heteroaryl;
each R4 is independently selected from among Ra4 and Rb4;
each Ra4 independently of one another is a group, optionally substituted by one or more, identical or different Rb4 and/or Rc4, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rb4 is independently selected from among —ORc4, —NRc4Rc4, halogen, —CN, —C(O)Rc4, —C(O)ORc4, —C(O)NRc4Rc4, —C(O)NRg4ORc4, —S(O)2Rc4, —S(O)2NRc4Rc4, —NHSO2Rc4, —N(C1-4alkyl)SO2Rc4, —NHC(O)Rc4 and —N(C1-4alkyl)C(O)Rc4;
each Rc4 independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different Rd4 and/or Re4, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rd4 is independently selected from among —ORe4, —NRe4Re4, halogen, —CN, —C(O)Re4, —C(O)ORe4, —C(O)NRe4Re4, —C(O)NRg4ORe4, —S(O)2Re4, —S(O)2NRe4Re4, —NHC(O)Re4 and —N(C1-4alkyl)C(O)Re4;
each Re4 independently of one another denotes hydrogen or a group, optionally substituted by one or more, identical or different Rf4 and/or Rg4, selected from among C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
each Rf4 is independently selected from among —ORg4, —NRg4Rg4, halogen, —CN, —C(O)Rg4, —C(O)ORg4, —C(O)NRg4Rg4, —C(O)NRg4ORg4, —S(O)2Rg4, —S(O)2NRg4Rg4, —NHC(O)Rg4 and —N(C1-4alkyl)C(O)Rg4;
each Rg4 is independently selected from among hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6haloalkyl, C3-7cycloalkyl, C4-7cycloalkenyl, C6-10aryl, 5-10 membered heteroaryl and 3-10 membered heterocyclyl;
r denotes the number 0, 1, 2 or 3
R5 and R6, each independently, is selected from among hydrogen, C1-4alkyl and C1-4haloalkyl;
n denotes the number 1;
each R7 is independently selected from among halogen, C1-4alkyl, —CN, C1-4haloalkyl, —OC1-4alkyl and —OC1-4haloalkyl;
q denotes the number 0, 1, 2 or 3;
W, X and Y is each independently selected from —N? and —CH?
with the proviso that the hydrogen in each —CH? may be replaced by a substituent R7 if present and that a maximum of two of W, X and Y can be —N?;
V is oxygen or sulfur;
or a salt thereof.

US Pat. No. 10,919,912

TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS

Incyte Holdings Corporati...

1. A method of treating BET-mediated cancer, wherein the cancer is leukemia, lymphoma, multiple myeloma, brain cancer, neuroblastoma, carcinoma, skin cancer, lung cancer, or a prostate cancer, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt thereof, wherein:
represents a single bond;
L is O;
Cy1 is selected from isoxazolyl and pyrazolyl, wherein said isoxazolyl and pyrazolyl of Cy1 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R11;
R1 is selected from H, methyl, —CH2OH, —C(?O)OCH2CH3, —C(?O)N(H)CH2CH3, —C(?O)N(H)CH3, —C(?O)NH2, —C(?O)N(H)CH2CH2OH, and —C(?O)N(CH3)2;
R2 is H or methyl;
Cy3 is selected from phenyl, pyridinyl, oxidopyridinyl, thiazolyl, cyclohexyl, dihydrobenzofuranyl, tetrahydrofuranyl, and piperidinyl wherein said phenyl, pyridinyl, oxidopyridinyl, thiazolyl, cyclohexyl, dihydrobenzofuranyl, tetrahydrofuranyl, and piperidinyl of Cy3 is optionally substituted with 1, 2, 3, or 4 groups independently selected from R3;
R4 is H, —C(?O)NH2, —CH2NH2, —CH2N(H)C(?O)CH3, —C(?O)N(H)CH3, —CH2CH3, or —CH3;
R5 is ?O;
R6 is selected from H, C1-6 alkyl, C1-6 alkoxy, and C1-6 haloalkyl, wherein said C1-6 alkyl of R6 is optionally substituted by 1, 2, 3, or 4 groups independently selected from R16;
R7 is selected from H, F, Cl, Br, CN, NRRd, C1-4 alkyl, C2-4 alkenyl, pyrazolyl, pyridinyl, pyrimidinyl, and 1,2,3,6-tetrahydropyridinyl, wherein said C1-6 alkyl, C2-6 alkenyl, pyrazolyl, pyridinyl, pyrmimidinyl, and 1,2,3,6-tetrahydropyridinyl of R7 are optionally substituted with 1, 2, or 3 groups independently selected from R7;
R8 is H;
R11 is independently at each occurrence selected from H, C1-3 alkyl, C1-3 haloalkyl, halo, CN, OR, NRCRd, SR, and C(?O)NRRd, wherein said C1-3 alkyl is optionally substituted by OH;
R11 is independently at each occurrence selected from H, halo, CN, OH, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, ORa3, SRa3, C(?O)Rb3, C(?O)NRc3Rd3, C(?O)ORa3, OC(?O)Rb3, =)NRc3Rd3, NRc3Rd3, NRc3C(?O)Rd3, NRc3C(?O)NRc3Rd3, NRc3C(?O)ORa3, S(?O)Rb3, S(?O)NRc3Rd3, S(?O)2Rb3, NRc3S(?O)2Rb3 and S(?O)2NRc3Rd3, wherein said C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl of R13 is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, OH, ORa3, SRa3, C(?O)Rb3, C(?O)NRc3Rd3, C(?O)ORa3, OC(?O)Rb3, OC(?O)NRc3Rd3, NRc3Rd3, NRc3C(?O)Rb3, NRc3C(?O)NRc3Rd3, NRc3C(?O)ORa3, S(?O)Rb3, S(?O)NR3cR3d, S(?O)2Rb3, NRc3S(?O)2Rb3 and S(?O)2NRc3Rd3;
R16 is independently at each occurrence selected from morpholinyl and piperidinyl;
R17 is independently at each occurrence selected from halo, C1-4 alkyl, CN, OR, NRcRd, SRb, C(?O)NRcRd, C(?O)ORa, and NRc(?O)Ra;
Ra, Rc, and Rd are independently at each occurrence selected from H, C1-6 alkyl, C(O)R, S(?O)2Rf, C(?O)NRgRh, and phenyl optionally substituted by C1-4 alkoxy;
Rb is at each occurrence C1-6 alkyl;
Rc is at each occurrence C1-4 alkyl optionally substituted by a group selected from phenyl, C1-4 alkoxy, amino, C1-4 alkylamino, and C2-8 dialkylamino;
Rf is C1-4 alkyl;
Rg and Rh are independently at each occurrence selected from H and C1-4 alkyl;
Ra3, Rb3, Rc3 and Rd3 are independently at each occurrence selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C34 cycloalkyl, and C1 haloalkyl, wherein said C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl forming Ra3, Rb3, Rc3 and Rd3 are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, OH, ORa4, SRa4, C(?O)Rb4, C(?O)NRc4Rd4, C(?O)ORa4, OC(?O)Rb4, OC(?O)NR4cRd4, NRc4Rd4, NRc4C(?O)Rb4, NR4C(?O)NRc4Rd4, NRc4C(?O)ORa4, S(?O)Rb4, S(?O)NRc4Rd4, S(?O)2Rb4, NRc4S(?O)2Rb4 and S(?O)2NRc4Rd4;
Ra4, Rb4, Rc4 and Rd4 are independently at each occurrence selected from H, C1-6 alkyl, C2-4 alkenyl, C2-4 alkynyl, and C1-4 haloalkyl, wherein said C1-4 alkyl, C2-4 alkenyl, and C2-4 alkynyl forming Ra4, Rb4, Rc4 and Rd4 are each optionally substituted with 1, 2, or 3 substituents independently selected from R20; and
R20 is at each occurrence independently selected from H, halo, OH, CN, amino, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-4 haloalkyl, C1-4 haloalkoxy, C1-4 alkyl-C(?O)—, C1-4 alkyl-C(?O)O—, C1-4 alkyl-OC(?O)—, HOC(?O)—, H2NC(?O)—, C1-4 alkyl-NHC(?O)—, di(C1-4 alkyl)NC(?O)—, C1-4 alkyl-C(?O)NH—, C1-4 alkyl-O—C(?O)NH—, C1-4 alkyl-S(?O)—, H2NS(?O)—, C1-4 alkyl-NHS(?O)—, di(C1-4 alkyl)NS(?O)—, C1-4 alkyl-S(?O)2—, C1-4 alkyl-S(?O)2NH—, H2NS(?O)2—, C1-4 alkyl-NHS(?O)2—, and di(C1-4 alkyl)NS(?O)2—.

US Pat. No. 10,919,911

TRICYCLIC ASK1 INHIBITORS

TERNS, INC., Foster City...

1. A compound of formula (IA):
or a pharmaceutically acceptable salt thereof, wherein:
ring A is a triazole, a tetrazole, or an imidazole optionally substituted with halo or C1-C6 alkyl;
ring B is phenyl or 6 membered heteroaryl containing 1-2 ring nitrogen atoms;
L1 is

R100 and R101 are independently H; C1-C6 alkyl optionally substituted with 1-3 hydroxyl or halo; halo; C3-C5 cycloalkyl optionally substituted with 1-3 C1-C6 alkyl, hydroxyl, or halo; 4- to 5-membered heterocyclyl optionally substituted with 1-3 C1-C6 alkyl, hydroxyl, or halo; or 5-membered heteroaryl optionally substituted with 1-3 C1-C6 alkyl, hydroxyl, or halo;
or R100 and R101 are taken together with the carbon atom or carbon atoms to which they are attached to form a C3-C5 cycloalkyl;
L2 is —CO—NH—;
R1 is C3-C8 cycloalkyl, 6-membered aryl, 5- to 6-membered heteroaryl, or 4- to 6-membered heterocyclyl, each of which is optionally substituted with 1-2 C1-C6 alkyl or with one C3-C6 cycloalkyl which is optionally substituted with 1-2 substituents selected from the group consisting of C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl; —CONR11R12; or —SO2NR11R12;
R11 and R12 are independently selected from the group consisting of hydrogen, C1-C6 alkyl, and C3-C8 cycloalkyl;
or R11 and R12 are taken together with the nitrogen atom to which they are attached to form a 4- to 7-membered heterocyclyl;
X1 is CR2 or N;
X2 is CR2;
X3 is CR2;
each R2 is independently hydrogen; C1-C6 alkyl optionally substituted with 1-3 halo, —CF3, —OCF3, hydroxy, —CN or —N(R3)(R4); C1-C6 alkoxy optionally substituted with 1-3 halo, —CF3, —OCF3, hydroxy, —CN or —N(R3)(R4); C3-C8 cycloalkyl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxy, —CN or —N(R3)(R4); 6-membered aryl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxy, —CN or —N(R3)(R4); 5- to 10-membered heteroaryl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxy, —CN or —N(R3)(R4); 4-10 membered heterocyclyl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxy, —CN or —N(R3)(R4); or halo; and
R3 and R4 are independently hydrogen; C1-C6 alkyl optionally substituted with 1-3 halo, —CF3, —OCF3, hydroxyl, or —CN; C3-C8 cycloalkyl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, or —CN; 6-membered aryl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, or —CN; 5- to 10-membered heteroaryl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, or —CN; or 5- to 10-membered heterocyclyl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, or —CN;
or R3 and R4 are taken together with the nitrogen atom or with the intervening atoms to which they are attached to form a 4- to 10-membered heterocyclyl optionally substituted with 1-3 halo, C1-C6 alkyl, —CF3, —OCF3, hydroxyl, or —CN.

US Pat. No. 10,919,910

SECO MACROLIDE COMPOUNDS

FIDELTA D.O.O., Zagreb (...

1. A process for preparation of seco (opened ring) macrolide compound of Formula (I) or a salt or solvate thereof,wherein,X1p is
—C(?O)OH, —C(?O)NH2, —C(?S)NH2, —C(?O)NHNH2, —CH2NH2, —CH2OH, —C(?O)H, —CN or —NH2;X2p is hydrogen, —CH(CH3)C(?O)H, —C(?S)NH2 or —C(?O)NH2;
Z1 and Z2
(i) are both hydrogen, or
(ii) together with carbon atom to which they are attached form a keto group provided RN is hydrogen and A1 is OC1-6alkyl,
A1 is OH, OC1-6alkyl, OC2-6alkenyl, OC2-6alkynyl, ORp, or A1 together with R2b forms cyclic hemiketal or ether;
A2 is CH3 or H;
B1 and B2 are independently H, C1-6alkyl or halogen, or
B2 together with R2a forms a double bond;
R1 is S1, OH, OC1-6alkyl or ORp;
S1 is sugar group of formula (b1):
wherein,

R3 is OH, H, ORp, —O-L1-G or —OC(?O)G, provided when R3 is —O-L1-G or —OC(?O)G group then R4 is —N(CH3)2 and R5 is H, wherein
L1 —(CH2)a1-U1-(CH2)b1—;
U1 is —N(R6)—, —NHC(?O)—or —C(?O)NH—;
R6 is H or C1-3alkyl;
a1 is an integer from 2 to 6;
b1 is an integer from 0 to 6;
G is selected from:
(i) G1, wherein G1 is C1-8alkyl, wherein alkyl may be optionally interrupted by 1 to 3 bivalent radical groups selected from —O—, —S— and —N(Rg1)—, where gg1 is H or C1-6alkyl, and where alkyl may be optionally substituted by one or more groups independently selected from halogen, OH, keto, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, OC1-6alkyl, haloC1-6alkyl, haloC1-6alkyloxy, —C(?O)OC1-6 alkyl, —C1-6alkyl-OH, NH2, N—(C1-6-alkyl)amino, N,N-di(C1-6alkyl)amino; aryl or heteroaryl wherein said aryl and heteroaryl may be mono or biyclic and independently each may be optionally substituted by one or more groups independently selected from halogen, CN, OH, NO2, OC1-6alkyl, NH2, N—(C1-6-alkyl)amino, N,N-di(C1-6alkyl)amino, —C(?O)C1-6alkyl, —OC(?O)C1-6alkyl, —C(?O)OH, —C(?O)OC1-6alkyl, —C(?O)NHC1-6alkyl and —NHC(?O)C1-6alkyl;
(ii) G2, wherein G2 is 3-7 membered cycloalkyl which may be optionally substituted by one or more groups independently selected from OH, halogen, CN, NH2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, —OC1-6alkyl, haloC1-6alkyloxy, —C1-6alkyl-OH, —C(?O)C1-6alkyl, —C(?O)OC1-6alkyl, —C(?O)OH, —C(?O)NH2, —C0-6alkyl-aryl or C0-6alkyl-heteroaryl wherein aryl and heteroaryl independently from each other may be optionally substituted by one or more groups independently selected from halogen, CN, OH, NO2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, —OC1-6alkyl, haloC1-6alkyloxy, —C1-6alkyl-OH, NH2, N—(C1-6-alkyl)amino, N,N-di(C1-6alkyl)amino, —C(?O)C1-6alkyl, —OC(?O)C1-6alkyl, —C(?O)OH, —C(?O)OC1-6alkyl, —C(?O)NHC1-6alkyl and —NHC(?O)C1-6alkyl;
(iii) G3, wherein G3 is 3-7 membered heterocycloalkyl containing one or two heteroatoms independently selected from N, O and S, where heterocycloalkyl may be optionally substituted by one or more groups independently selected from OH, halogen, CN, NH2, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, —OC1-6alkyl, haloC1-6alkyloxy, —C1-6alkyl-OH, —C(?O)C1-6alkyl, —C(?O)OC1-6alkyl, —C(?O)OH and —C(?O)NH2;
(iv) G4, wherein G4 is aryl wherein aryl may be optionally substituted by one or more groups independently selected from halogen, CN, OH, NO2, C1-6alkyl, C2-6 alkenyl, C2-6alkynyl, haloC1-6alkyl, —OC1-6alkyl, haloC1-6alkyloxy, —C1-6alkyl-OH, NH2, N—(C1-6-alkyl)amino, N,N-di(C1-6alkyl)amino, —C(?O)C1-6alkyl, —O(C?O)C1-6alkyl, —C(?O)OH, —C(?O)OC1-6alkyl, —C(?O)NHC1-6alkyl and —NHC(?O)C1-6alkyl;
(v) G5, wherein G5 is heteroaryl wherein heteroaryl may be optionally substituted by one or more groups independently selected from halogen, CN, OH, NO2, C1-6 alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, —OC1-6alkyl, haloC1-6alkyloxy, —C1-6alkyl-OH, NH2, N—(C1-6-alkyl)amino, N,N-di(C1-6alkyl) amino, —C(?O)C1-6alkyl, —O(C?O) C1-6alkyl, —C(?O)OH, —C(?O)OC1-6 alkyl, —C(?O)NHC1-6alkyl and —NHC(?O)C1-6alkyl;
R4 is —N(R7)R8, wherein
R7 is CH3,
R8 is C1-6alkyl, H, —C(?O)R9 or Rp wherein R9 is C1-6alkyl or H;
R5 is hydrogen;
or both R4 and R5 are hydrogen or together form a bond;
or S1 is sugar group of formula (b2):
wherein:

R5 is H;
d is an integer from zero to 3;
R10 is C1-4alkyl;R2a is:(i) S2;
(ii) —OH;
(iii) —OC1-6 alkyl,
(iv) H;
(v) together with R2b forms a keto group (?O);
(vi) together with B2 forms a double bond;
(vii) —OC(?O)Y1, wherein Y1 is G1, G2, G3, G4, G5 or H; or
(viii) —ORp;R2b is H, together with R2a forms a keto group, together with A1 forms cyclic hemiketal and R2a is OH, or together with A1 forms cyclic ether group and R2a is H;S2 is sugar group of formula (d)
wherein,

R11 is:
(i) H;
(ii) together with R12 and carbon atom to which they are attached forms a keto or epoxy group;
(iii) one of R11 and R12 is OH and the other is —CH2N(R13)R14, wherein one of R13 and R14 is C1-6alkyl and the other is H, G1, G2, G3, G4, G5 or Rp, or wherein R13 and R14 taken together with the nitrogen atom to which they are attached form a non-aromatic heterocyclic ring containing between 2 and 6 carbon atoms which is:
a. saturated or unsaturated and contains zero or 1 additional heteroatom selected from O, S and N; and/or
b. unsubstituted or substituted by from 1 to 2 groups selected from C1-5alkanoyl; C1-6alkyl wherein alkyl is uninterrupted or is interrupted by 1-3 bivalent radical groups selected from —O—, —S— and and —N(R18)—, and/or wherein C1-6alkyl is unsubstituted or substituted by from 1 to 2 groups selected from OH, NH2, a non-aromatic heterocyclic ring containing between 2 and 6 carbon atoms which is unsubstituted or is substituted by a group selected from C1-4alkyl, halogen, NH2, OH, SH, C1-6alkoxy and C1-4hydroxyalkyl, and C3-7cycloalkyl which is unsubstituted or is substituted by a group selected from C1-4alkyl, halogen, NH2, OH, SH, C1-6alkoxy, C1-4hydroxyalkyl; and C1-4dialkylamino;
R12 is:
(i) OH,
(ii) together with R11 and carbon atom to which they are attached forms a keto or epoxy group;
(iii) —OC(?O)Y3, wherein Y3 is H, G1, G2, G3, G4, or G5; or
(iv) ORp;RN is hydrogen, G1, G2, G3, G4, G5, Rp, or R15 wherein R15 is —C1-4alkyl-G, —C(?O)G, —C(?O)NH—C0-4alkyl-G, wherein G is G1, G2, G3, G4 or G5;Rp is a protective group;or a salt or solvate thereof;wherein process comprises:(a) reacting a 9a-aza-9a-homoerythromycin compound of formula (II)
wherein,

Z1, Z2, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) above, with an oxidative cleavage reactant in a solvent or mixture of solvents to give:

(i) a seco macrolide compound of formula (I-A), which is subset of formula (I), wherein X1p is
X2p is hydrogen, Z1 and Z2 are both hydrogen, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) when starting from compound of formula (II), wherein Z1 and Z2 are both hydrogen, or(ii) a seco macrolide compound of formula (I-A), which is subset of formula (I) wherein X1p is
X2p is —CH(CH3)C(?O)H, Z1 and Z2 together with carbon atom to which they are attached form a keto group, RN is hydrogen, A1 is —OC1-6alkyl, A2,R1, R2a, R2b, B1 and B2, are as defined for formula (I) when starting from compound of formula (II) wherein Z1 and Z2 together with carbon atom to which they are attached form a keto group;(b) hydrolyzing a compound of formula (I-A) wherein X1p is
obtained in step (a) to give compound of formula (I-B), which is subset of formula (I) wherein X1p is —C(?O)OH, X2p is hydrogen, Z1, Z2, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) above; and optionally subjecting a compound of formula (I-B) wherein X1p is —C(?O)OH, X2p is hydrogen, RN is hydrogen and Z1 and Z2 together with carbon atom to which they are attached form a keto group to a further hydrolyzing conditions to give di-carboxylic acid of formula (XC), wherein A1, A2, B1, B2, R1, R2a and R2b are as defined for formula (I); or
(c) reacting a compound of formula (IA) wherein X1p is
X2p is hydrogen obtained in step (a) or compound of formula (I-B) wherein X1p is —C(?O)OH and X2p is hydrogen obtained in step (b) with ammonium salt in the presence of base and coupling agent or with ammonia in organic solvents, or with ammonia hydroxide to give a compound of formula (I-C), which is subset of formula (I) wherein X1p is —C(?O)NH2, X2p is hydrogen, Z1, Z2, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) above; or
(d) reducing amide compound of formula (I-B) wherein X1p is —C(?O)NH2, and X2p is hydrogen obtained in step (c) using reducing agent to compound of formula (I-D), which is subset of formula (I) wherein X1p is —CH2NH2, X2p is hydrogen, Z1, Z2, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) above; or

(e) reacting a compound of formula (I-A) obtained in step (a) wherein X1p is
with hydrazine hydrate in a solvent to give compound of formula (I-E), which is subset of formula (I) wherein X1p is —C(?O)—NH—NH2 group, X2p is hydrogen, Z1, Z2, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) above; or
(f) reacting a compound of formula (I-A) obtained in step (a) wherein X1p is
or a compound of formula (I-B) obtained in step (b) wherein X1p is —C(?O)OH with thiocarbonyldiimidazole followed by the amonolysis reaction conditions (provided when starting from compound of formula (I-A) then C/1-keto ester hydrolysis step (b) is usually performed prior amonolysis), or in alternative with thiocyanates or isothiocyanates to give compound of formula (I-FA), which is subset of formula (I) wherein X1p is —C(?O)OH group, X2p is —C(?S)NH2 group, Z1, Z2, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) above; or
(g) reacting a compound of formula (I-A) obtained in step (a) wherein X1p is
or a compound of formula (I-B) obtained in step (b) wherein X1p is —C(?O)OH with carbonyldiimidazole followed by the amonolysis reaction conditions (provided when starting from compound of formula (I-A) then C/1-keto ester hydrolysis step (b) is usually performed prior amonolysis), or in alternative with alkali metal cyanates or isocyanates to give compound of formula (I-FB), which is subset of formula (I) wherein X1p is —C(?O)OH group, X2p is —C(?O)NH2 group, Z1, Z2, A1, A2, R2a, R2b, B1, B2 and RN are as defined for formula (I) above; or
(h) subjecting a compound of formula (I-A) obtained in step (a) wherein X1p is
or a compound of formula (I-B) obtained in step (b) wherein X1p is —C(?O)OH to the standard carboxylic acid reduction conditions to give compound of formula (I-KA-a), which is subset of formula (I) wherein X1p is —CH2OH group, X2p is hydrogen, Z1, Z2, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) above; or
(i) reacting a compound of formula (I-KA-a) obtained in step (h) wherein X1p is —CH2OH group and X2p is hydrogen with the standard oxidizing reagents to give compound of formula (I-KA), which is subset of formula (I) wherein X1p is —C(?O)H group, X2p is hydrogen, Z1, Z2, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) above; or

(j) subjecting compound of formula (I-C) obtained in step (c) where X1p is —C(?O)NH2 group and X2p is hydrogen to dehydration reaction to give compound of formula (I-MN), which is subset of formula (I) wherein X1p is —CN, X2p is hydrogen, Z1, Z2, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) above; or

(k) reacting
a. a compound of formula (I-C) obtained in step (c) where X1p —C(?O)NH2, and X2p is hydrogen with Lawesson's or Bellau's reagents or with P4S10 alone or in combination with hexamethyldisiloxane, or in alternative
b. a compound of formula (I-MN) obtained in step (j) where X1p —CN, and X2p is hydrogen using alkali metal hydrogen sulfide or ammonium sulfide under high pressure, phosphorus decasulfide, thioacids, thioacetic acid in combination with Lewis acid or benzylamine or calcium hydride, thioacetamide, DowexSH, O-dialkyldithiophosphates, diphenylphosphinodithioacids, sodium trimethylsilanethiolate, sodium hydrosulfide hydrate and diethyl amine hydrochloride, sodium hydrosulfide hydrate and magnesium chloride hexahydrate, and (P4S11)Na2
to give compound of formula (I-M), which is subset of formula (I) wherein X1p is —C(?S)NH2, X2p is hydrogen, Z1, Z2, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) above; or

(l) subjecting
a. a compound of formula (I-B) obtained in step (b) where X1p —C(?O)OH, and X2p is hydrogen to the modified Curtius rearrangement followed by mild acidic hydrolysis or hydrogenation of the carbamate group, or
b. a compound of formula (I-A) obtained in step (a) where X1p is
and X2p is hydrogen to the modified Lossen rearrangement followed by mild acidic hydrolysis or hydrogenation of the carbamate group,to give compound of formula (I-RE), which is subset of formula (I) wherein X1p is —NH2, X2p is hydrogen, Z1, Z2, A1, A2, R1, R2a, R2b, B1, B2 and RN are as defined for formula (I) above; and

(m) if required after any of previous steps (a)-(l), subjecting the resulting compound to one or more of the following operations:
(i) removal of the protecting group Rp,
(ii) removal of S2 sugar group and/or S1 sugar group,
(iii) conversion of the resulting compound of formula (I) into a salt or solvate thereof.

US Pat. No. 10,919,909

PHOTOINITIATED REACTIONS

LINTFIELD LIMITED, Kent ...

18. A composition comprising:a transformable reactive substrate;
a species capable of generating acid; and
one or more protected ketone photoinitiators, wherein the one or more ketone photoinitiators are derived from coumarins, and wherein the ketone group of the photoinitiator is protected by an unsubstituted 1,3 dioxolane group.

US Pat. No. 10,919,908

THIENOPYRIMIDINONE DERIVATIVE AND APPLICATION THEREOF IN PREPARING ANTICANCER DRUG

HENAN GENUINE BIOTECH CO....

1. A compound having a formula (I), or a pharmaceutically acceptable salt, or a solvate thereof:
wherein:
R represents hydrogen (H) or deuterium (D);
R1 and R2 independently, at each occurrence, represent H, D, F, Cl, I, cyano group (CN), or N3, and when R represents H, R1 and R2 do not synchronously represent H; and
R3, R4 and R5 independently, at each occurrence, represent an alkyl group, a cycloalkyl group, a heterocyclic group, an aromatic ring group, or a heteroaryl ring group.

US Pat. No. 10,919,906

CONFORMATIONALLY-CONSTRAINED BIOISOSTERES OF CAFFEIC ACID, AND SYNTHESIS AND THERAPEUTIC USES

Board of Supervisors of L...

3. A chemical comprising:a bioisoter of caffeic acid having one of the following chemical structures where R is one of an alkyl group, an aryl group, an aryl/alkyl group, and a H:

or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof.

US Pat. No. 10,919,904

NORTHERN-SOUTHERN ROUTE TO SYNTHESIS OF BACTERIOCHLORINS

North Carolina State Univ...

1. A method of making a compound of Formula I:
or a metal conjugate thereof, wherein:
each R1, R2, R3, R4, R5, R6, R7 and R8 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, heterocyclo, heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl, aryl, aryloxy, arylalkyl, arylalkenyl, arylalkynyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, alkoxy, halo, mercapto, azido, cyano, formyl, carboxylic acid, hydroxyl, nitro, acyl, alkylthio, amino, alkylamino, arylalkylamino, disubstituted amino, acylamino, acyloxy, ester, amide, sulfoxyl, sulfonyl, sulfonate, sulfonic acid, sulfonamide, urea, alkoxylacylamino, aminoacyloxy, a hydrophilic group, a linking group, a surface attachment group, and a targeting group, wherein the hydrophilic group is selected from the group consisting of a polyol, polyalkylene oxide group, ionic group, polar group, and any combination thereof, wherein the linking group is selected from the group consisting of aryl, alkyl, heteroaryl, heteroalkyl, a peptide, a polysaccharide, and any combination thereof, and wherein the targeting group is selected from the group consisting of an antibody, a ligand, one member of a ligand-receptor binding pair, a nucleic acid, a protein, a liposomal suspension, and any combination thereof;
or R1 and R2 together are ?O or spiroalkyl;
or R3 and R4 together are ?O or spiroalkyl;
where R6 and R7, or R7 and R8, together represent a fused aromatic or heteroaromatic ring systems;
said method comprising condensing a pair of compounds of Formula II:

in an organic solvent in the presence of an acid,
where each R? independently represents C1-C4 alkyl, or both R? together represent C2-C4 alkylene; to produce a compound of Formula I wherein R5 is H or alkoxy,
wherein condensing the pair of compounds of Formula II comprises performing two successive Pd-coupling reactions.

US Pat. No. 10,919,903

NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AS FXR MODULATORS

Hepagene Therapeutics (HK...

1. A compound according to formula I
a stereoisomer thereof, a salt thereof, or a salt of the stereoisomer; wherein
L and M are both N;
Z is a substituted or unsubstituted C1-C4 alkylene;
W is

X is

D is N or CR9;
one of G1, G2, G3, and G4 is CR13, one of G1, G2, G3, and G4 is C bonded to R4, and the remaining two are selected from the group consisting of CH and CR11;
Q is O, S, or NR12;
R1 and R2 are independently H, OH, halo, CN, carboxyl, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, or hydroxyalkyl group;
R3 is a substituted or unsubstituted alkyl or cycloalkyl group;
R4 is CN, SO3H, CONRaRb, SO2NRaRb, NHSO2Rb, SO2NHCORa, CO2Rc, or a substituted or unsubstituted tetrazolyl or 1,2,4-oxadiazol-5(4H)-one-3-yl group;
R9 and R13 are independently H, halo, or a substituted or unsubstituted C1-C6 alkyl, or O—(C1-C6 alkyl) group;
R10 at each occurrence is independently halo, CO2Rc, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group;
R11 at each occurrence OH, halo, CF3, CN, carboxyl, NRaRb, or a substituted or unsubstituted alkyl, alkoxy group, or phenyl group;
R12 is H or a substituted or unsubstituted C1-C6 alkyl group; and
Ra at each occurrence is independently H, or a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, or SO2-alkyl group;
Rb at each occurrence is H or a substituted or unsubstituted alkyl, or haloalkyl group;
Rc is H or a substituted or unsubstituted alkyl, alkenyl, alkynyl, or cycloalkyl group;
n is 1, 2, 3, or 4; and
r and t are each independently 1, 2, or 3.

US Pat. No. 10,919,902

HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE

Alkermes, Inc., Waltham,...

1. A compound having the formula:or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,919,900

ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND USES THEREOF

Magenta Therapeutics Inc....

1. A method of producing an expanded population of hematopoietic stem cells ex vivo, comprising contacting a population of hematopoietic stem cells with a compound represented by formula (I) or (II):
wherein L is selected from the group consisting of —NR7a(CR8aR8b)n—, —O(CR8aR8b)n—, —C(O)(CR8aR8b)n—, —C(S)(CR8aR8b)n—, —S(O)0-2(CR8aR8b)n—, —(CR8aR8b)n—, —NR7aC(O)(CR8aR8b)n—, —NR7aC(S)(CR8aR8b)n—, —OC(O)(CR8aR8b)n—, —OC(S)(CR8aR8b)n—, —C(O)NR7a(CR8aR8b)n—, —C(S)NR7a(CR8aR8b)n—, —C(O)O(CR8aR8b)n—, —C(S)O(CR8aR8b)n—, —S(O)2NR7a(CR8aR8b)n—, —NR7aS(O)2(CR8aR8b)n—, —NR7aC(O)NR7b(CR8aR8b)n—, and —NR7aC(O)O(CR8aR8b)n—, wherein R7a, R7b, R8a, and R8b are each independently selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl, and each n is independently an integer from 2 to 6;
R1 is selected from the group consisting of —S(O)2NR9aR9b, —NR9aC(O)R9b, —NR9aC(S)R9b, —NR9aC(O)NR9bR9c, —C(O)R9a, —C(S)R9a, —S(O)0-2R9a, —C(O)OR9a, —C(S)OR9a, —C(O)NR9aR9b, —C(S)NR9aR9b, —NR9aS(O)2R9b, —NR9aC(O)OR9b, —OC(O)CR9aR9bR9c, —OC(S)CR9aR9bR9c, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl, wherein R9a, R9b, and R9c are each independently selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;
R2 is selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl;
R3 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;
R4 is selected from the group consisting of hydrogen and optionally substituted C1-4 alkyl;
R5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl; and
R6 is selected from the group consisting of hydrogen, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted heteroalkyl, optionally substituted cycloalkyl, and optionally substituted heterocycloalkyl;
or a salt thereof.

US Pat. No. 10,919,899

IMIDAZOPYRAZINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

DONGGUAN ZHENXING-BEITE M...

1. A compound having a structure as represented by formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof:
wherein,
A is selected from CH or N;
n is 0, 1, 2, or 3;
R1 is selected from the following groups:

wherein R3 and R4 are each independently selected from H and C1-C6 alkyl;
R5 is selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C4 alkyl substituted with C1-C3 alkoxy, C1-C4 alkyl substituted with amino, C1-C4 alkyl substituted with C1-C3 alkyl amino, C1-C4 alkyl substituted with di(C1-C3 alkyl) amino, and C1-C4 alkyl substituted with heterocyclic group;
X1, X2, X3 and X4 are each independently selected from the group consisting of C(R2) and N;
R2 is selected from the group consisting of H, halogen atom, C1-C6 alkyl, C1-C6 alkoxy, and halogenated C1-C6 alkyl;
W and Y are each independently selected from the group consisting of O, N(R6), S and C1-C6 alkylene, and at least one of W and Y is selected from C1-C6 alkylene;
R6 is selected from H or C1-C6 alkyl; and
Ar is selected from phenyl or 5 to 6 membered heteroaryl, optionally, the phenyl or 5 to 6 membered heteroaryl is substituted with a group selected from the group consisting of halogen atom, C1-C6 alkyl, C1-C6 alkoxy, and halogenated C1-C6 alkyl.

US Pat. No. 10,919,898

MEDICAL USE OF COMPOUND III

Boehringer Ingelheim Inte...

1. A crystalline form b of Compound IIIcharacterized by(i) an X-ray powder diffraction reflection peak having a 2-theta of 6.4° ±0.2°, wherein the X-ray powder diffraction reflections are measured using monochromatic CuKal radiation of ?=1.54056 Å, 40kV, 40mA, or
(ii) a Raman spectrum having at least one characteristic peak at the following Raman shifts selected from the group consisting of 1182 ±2 cm-1, 1394 ±2 cm-1, and 1663 ±2 cm-1.

US Pat. No. 10,919,897

[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUND

Janssen Pharmaceutica NV,...

1. A compound having the formula (1)or a pharmaceutically acceptable salt or a solvate thereof.

US Pat. No. 10,919,896

PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES

Cancer Research Technolog...

1. A compound of Formula I
and/or a salt thereof wherein,
X is chosen from halogen, haloC1-C2alkyl, and CN;
Each R1 is independently chosen from C1-C2alkyl, —CN, haloC1-C4alkyl, halogen, —NO2, —NR3R4, and —C0-C4alkylOR3
R2 is:
i) a group A-B-C wherein:
A is a bond or is C1-C10alkyl;
B is absent or is chosen from S(O)p, NR3, O, C2-C10alkenyl, and C2-C10alkynyl; and
C is a 3 to 15 membered heterocycloalkyl or a 4 to 11 membered cycloalkyl either of which is optionally substituted with one or more R5; or
ii) a group D-E-F wherein:
D is chosen from NR3 or;
E is a bond or is C1-C10alkyl; and
F is a 3 to 15 membered heterocycloalkyl or an aryl, each of which is optionally substituted with one or more groups chosen from C1-C10alkyl, halogen, amino or alkoxy;
R3 and R4 are each independently chosen from H, C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, haloC1-C6alkyl, C0-C6alkylaryl, C0-C6alkylcycloalkyl, C0-C6alkylheteroaryl, C0-C6alkylheterocycloalkyl, wherein any of the foregoing, except for H, is optionally substituted with one or more R5; or
R3 and R4 may be taken together to form a 3 to 15 membered carbocyclic or heterocyclic ring system, wherein said ring system is optionally substituted with one or more R5;
Each R5 is independently chosen from C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C0-C6alkylaryl, C0-C6alkylcycloalkyl, C0-C6alkylheterocycloalkyl, C0-C6alkylheteroaryl, —C0-C6alkylCN, —C0-C6alkylC(?O)C0-C6alkylR6, —C0-C6alkyC(?O)C0-C6alkylOR6, —C0-C6alkylC(?O)C0-C6alkylNR6R6, —C0-C6alkylC(?O)C0-C6alkylNR6C(?O)OR6, —C0-C6alkylC(?O)C0-C6alkylC(?O)R6, haloC1-C6alkyl, halogen, —NO2, —C0-C6alkyNR6R6, —C0-C6alkylNR6NR6R6, —C0-C6alkylN?NR6, —C0-C6alkyNR6C0-C6alkylOR6, —C0-C6alkylNR6C0-C6alkylC(?O)R6, —C0-C6alkylNR6C(?O)C0-C6alkylC(?O)R6, —C0-C6alkylNR6C0-C6alkyl C(?O)OR6, —C0-C6alkylNR6C0-C6alkylC(?O)C(?O)OR6, —C0-C6alkylNR6C0-C6alkylC(?O)NR6R6, —C0-C6alkyNR6C(?O)C0-C6alkyNR6C(?O)R6, —C0-C6alkylNR6C(?O)C0-C6alkylNR6C(?O)OR6, —C0-C6alkylNR6C(?O)C0-C6alkylC(?O)NR6R6, —C0-C6alkyNR6C0-C6alkyS(?O)2R6, —C0-C6alkylNR6S(?O)2C0-C6alkylNR6R6, —C0-C6alkylOR6, (?O),—C0-C6alkylOC(?O)C0-C6alkyR6, —C0-C6alkylOC(?O)C0-C6alkylNR6R6, —C0-C6alkylOC(?O)C0-C6alkylOR6, —C0-C6alkylOS(?O)R6, —C0-C6alkylOS(?O)2R6, —C0-C6alkylOS(?O)2C0-C6alkylOR6, —C0-C6alkylOS(?O)2C0-C6alkylNR6R6, —C0-C6alkylOP(?O)R6R6, —C0-C6alkylOP(?O)(NR6R6)(NR6R6), —C0-C6alkylOP(?O)(OR6)(OR6), —C0-C6alkylOP(?O)(SR6)(SR6), —C0-C6alkyP(?O)R6R6, —C0-C6alkyP(?O)(NR6R6)(NR6R6), —C0-C6alkylP(?O)(OR6)(OR6), —C0-C6alkyP(?O)(SR6)(SR6), —C0-C6alkyS(?O)pR6, —C0-C6alkylS(?O)2C0-C6alkylNR6R6, —C0-C6alkylS(?O)C0-C6alkylNR6R6, and —C0-C6alkylSCN,
wherein any of the foregoing is optionally substituted with one or more R7; or
together with carbon atoms to which they are attached, two R5 groups may be linked to form a fused aryl, heteroaryl, 3 to 6 membered heterocycloalkyl or a 3 to 6 membered cycloalkyl;
Each R6 is independently chosen from H, C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, haloC1-C6alkyl, C0-C6alkylaryl, C0-C6alkylcycloalkyl, C0-C6alkylheteroaryl, C0-C6alkylheterocycloalkyl, wherein any of the foregoing except for H is optionally substituted with one or more R7; or
Two R6 may be taken together to form a 3 to 15 membered carbocyclic or heterocyclic ring system, wherein said ring system is optionally substituted with one or more R7;
Each R7 is independently chosen from C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, C0-C6alkylaryl, C0-C6alkylcycloalkyl, C0-C6alkylheterocycloalkyl, C0-C6alkylheteroaryl, —C0-C6alkylCN, —C0-C6alkylC(?O)C0-C6alkylR8, —C0-C6alkylC(?O)C0-C6alkylOR8, —C0-C6alkylC(?O)C0-C6alkylNR8R8, —C0-C6alkylC(?O)C0-C6alkylNR8C(?O)OR8, —C0-C6alkylC(?O)C0-C6alkylC(?O)R8, haloC1-C6alkyl, halogen, —NO2, —C0-C6alkyNR8R8, —C0-C6alkylNR8NR8R8, —C0-C6alkylN?NR8, —C0-C6alkyNR8C0-C6alkylOR8, —C0-C6alkylNR8C0-C6alkylC(?O)R8, —C0-C6alkylNR8C(?O)C0-C6alkylC(?O)R8, —C0-C6alkylNR8C0-C6alkyl C(?O)OR8, —C0-C6alkylNR8C0-C6alkylC(?O)C(?O)OR8, —C0-C6alkylNR8C0-C6alkylC(?O)NR8R8, —C0-C6alkylNR8C(?O)C0-C6alkylNR8C(?O)R8, —C0-C6alkylNR8C(?O)C0-C6alkylNR8C(?O)OR8, —C0-C6alkylNR8C(?O)C0-C6alkylC(?O)NR‘R’, —C0-C6alkyNR8C0-C6alkylS(?O)2R8, —C0-C6alkylNR8S(?O)2C0-C6alkylNR8R8, —C0-C6alkylOR8, (?O), —C0-C6alkylOC(?O)C0-C6alkylR8, —C0-C6alkylOC(?O)C0-C6alkyNR8R8, —C0-C6alkylOC(?O)C0-C6alkylOR8, —C0-C6alkylOS(?O)R8, —C0-C6alkylOS(?O)2R8, —C0-C6alkylOS(?O)2C0-C6alkylOR8, —C0-C6alkylOS(?O)2C0-C6alkyNR8R8, —C0-C6alkylOP(?O)R8R8, —C0-C6alkylOP(?O)(NR8R8)(NR8R8), —C0-C6alkylOP(?O)(OR)(OR8), —C0-C6alkylOP(?O)(SR8)(SR8), —C0-C6alkyP(?O)R8R8, —C0-C6alkyP(?O)(NR8R8)(NR8R8), —C0-C6alkylP(?O)(OR8)(OR8), —C0-C6alkylP(?O)(SR8)(SR8), —C0-C6alkyS(?O)pR8, —C0-C6alkylS(?O)2C0-C6alkylNR8R8, —C0-C6alkylS(?O)C0-C6alkylNR8R8, and —C0-C6alkylSCN;
Each R8 is independently chosen from H, C1-C10alkyl, C2-C10alkenyl, C2-C10alkynyl, haloC1-C6alkyl, C0-C6alkylaryl, C0-C6alkylcycloalkyl, C0-C6alkylheteroaryl, and C0-C6alkylheterocycloalkyl;
Each p is independently 0, 1 or 2; and
Each n is independently 0, 1, 2, 3 or 4;
With the proviso that the compound is not one of the following:

US Pat. No. 10,919,895

TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A PYRIDINE OR PYRAZINE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR

Bristol-Myers Squibb Comp...

1. A compound having a structure according to formula (Ic-04)

US Pat. No. 10,919,894

ADENINE DERIVATIVES WHICH ARE USEFUL IN THE TREATMENT OF ALLERGIC DISEASES OR OTHER INFLAMMATORY CONDITIONS

GLAXOSMITHKLINE BIOLOGICA...

1. An immunogenic composition comprising:(i) a compound of formula (I):

wherein;
R1 is methylbutoxy;
R2 is a group having the structure:

where n is an integer having a value of five;
Het is a six-membered saturated heterocycle containing five carbon atoms and one nitrogen atom, wherein Het is attached to the —(CH2)n— moiety at the carbon 4 position of the heterocycle; and
R3 is hydrogen;
or a pharmaceutically acceptable salt thereof;
(ii) an antigen or antigen composition.

US Pat. No. 10,919,891

HETEROCYCLIC COMPOUND

TAKEDA PHARMACEUTICAL COM...

1. A compound represented by formula (I):
wherein
Ring A represents an optionally further substituted aromatic ring;
R1 represents a hydrogen atom, an optionally substituted alkyl group, an optionally substituted alkylthio group, or an optionally substituted alkoxy group;
R2 and R3 each independently represent an optionally substituted alkyl group, or R2 and R3 may form an optionally further substituted ring together with an adjacent carbon atom;
R4 represents an optionally substituted aromatic ring group or optionally substituted alkyl group;
R5 and R6 each independently represent a hydrogen atom or a halogen atom,
or a salt thereof.

US Pat. No. 10,919,890

SALTS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

GALAPAGOS NV, Mechelen (...

1. A method of treating rheumatoid arthritis in a subject comprising administering an effective amount of a pharmaceutically acceptable salt of a compound according to Formula (I):
wherein the salt is a 1:1 free base/maleic acid salt in a crystalline form characterized at least by an X-ray powder diffraction peak at each of the following positions: 4.3, 8.3, 12.0, 15.0, 16.3, 18.1, 18.7, 19.3, 20.0, 20.4, 22.6, 23.5, 23.9, 24.0, 24.5, 25.4, 25.8, and 28.7±0.2° 2?, to a subject suffering from rheumatoid arthritis.

US Pat. No. 10,919,889

CHIRAL HETEROCYCLIC COMPOUND WITH HEDGEHOG PATHWAY ANTAGONIST ACTIVITY, METHOD AND USE THEREOF

SUZHOU KINTOR PHARMACEUTI...

1. A compound of Formula III:or a pharmaceutically acceptable salt, stereoisomer, or solvate thereof, whereinR2 and R?2 are independently H, C1-3 alkyl, CD3, or CF3, with the proviso that at least one of R2 and R?2 is not H;
R1 is —NRxRy, wherein Rx and Ry are independently H, alkyl, cycloalkyl, alkylcycloalkyl, C(O)R?, or —NRxRy together to form
wherein W10 is H or D;R? is C1-5 alkyl;
W1, W2, W3, W4, W5, W6, W7, W8 and W9 are independently H or D; and
A is N or CH.

US Pat. No. 10,919,888

BENZYL AMINE-CONTAINING HETEROCYCLIC COMPOUNDS AND COMPOSITIONS USEFUL AGAINST MYCOBACTERIAL INFECTION

UNIVERSITY OF NOTRE DAME ...

1. A compound, having one of the following formulas:

US Pat. No. 10,919,886

SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR

UNIVERSITY HEALTH NETWORK...

1. A method of treating a subject with cancer, comprising administering to the subject an effective amount of a fumarate salt of compound (I) represented by the following structural formula:
wherein the molar ratio between compound (I) and fumaric acid is 1:1,
wherein the cancer is selected from the group consisting of lung cancer, breast cancer and colon cancer.

US Pat. No. 10,919,885

COMPOUNDS AND USES THEREOF

Yumanity Therapeutics, In...

13. A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of claim 1, and a pharmaceutically acceptable excipient.

US Pat. No. 10,919,884

AMIDE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS

Achillion Pharmaceuticals...

1. A compound of Formula:
or a pharmaceutically acceptable salt thereof, wherein
A is A1;
B is B1 or B4;
L is L1;
L3 is L4 or L5;
A1 is

B1 is selected from the group consisting of a monocyclic or bicyclic carbocyclic; a monocyclic or bicyclic carbocyclic-oxy group; a monocyclic, bicyclic, or tricyclic heterocyclic group having 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S and from 4 to 7 ring atoms per ring; —(C0-C4alkyl)(aryl); —(C0-C4alkyl)(heteroaryl); and —(C0-C4alkyl)(biphenyl), each of which B1 is unsubstituted or substituted with one or more substituents independently selected from the group consisting of R33 and R34, and 0 or 1 substituents selected from the group consisting of R35 and R36;
B4 is selected from the group consisting of:
(i) a 4-membered carbocyclic fused to a 5- or 6-membered heteroaryl having 1, 2, or 3 heteroatoms independently chosen from N, O, and S;
(ii) a 4-membered carbocyclic fused to a 6-membered aryl ring; and
(iii) (cycloalkyl)-(aryl), (cycloalkyl)-(heteroaryl), (cycloalkyl)-(heterocycle), (alkyl)-alkenyl, and cycloalkyl-alkenyl;
wherein B4 can be substituted 1, 2, 3 or 4 times with the substituents independently selected from the group consisting of R33, R34, R35, R36 and R48;
L1 is a bond or is selected from the group consisting of formulas

L4 is —C(O)—;
L5 is —C(S)—, —P(O)OH—, —S(O)—, —S(O)2— or —C(R52)2—;
X11 is N or CR11;
X12 is CR12;
X13 is CR13;
X14 is N or CR14;
R6 is selected from the group consisting of hydrogen, -JCHO, -JC(O)NH2, -JC2-C6alkanoyl, -JC(O)NH(CH3), -J-COOH, -JP(O)(OR9)2, -JOC(O)R9, -JC(O)OR9, -JC(O)N(CH2CH2R9)(R10), -JNR9C(O)R10, -JSO2NH2, -JS(O)NH2, -JC(CH2)2F, -JCH(CF3)NH2, -JC(O)C0-C2alkyl(C3-C7cycloalkyl), -JNR9(C2-C6alkanoyl), -JNR9C(O)NR9R10, -JSO2(C1-C6alkyl), -JSO2(C1-C6haloalkyl), -JSO2NR7R7, -JSO=NH(C1-C6alkyl), -J-nitro, -J-halogen, -J-hydroxyl, -J-phenyl, a 5- to 6-membered heteroaryl, -J-cyano, -J-cyanoimino, -J-amino, -J-imino, —C1-C6alkyl, —C0-C4alkyl(C3-C7heterocycloalkyl), —C0-C4alkyl(C3-C7cycloalkyl),
each R6 other than hydrogen, nitro, halogen, cyano, cyanoimino, or —CHO is unsubstituted or substituted with one or more substituents selected from the group consisting of amino, imino, halogen, hydroxyl, cyano, cyanoimino, C1-C2alkyl, C1-C2alkoxy, —C0-C2alkyl(mono- and di-C1-C4alkylamino), C1-C2haloalkyl, and C1-C2haloalkoxy;R7 is hydrogen, C1-C6alkyl, or —C0-C4alkyl(C3-C7cycloalkyl);
R8 and R8? are independently selected from the group consisting of hydrogen, halogen, hydroxyl, C1-C6alkyl, —C0-C4alkyl(C3-C7cycloalkyl), C1-C6alkoxy, and (C1-C4alkylamino)C0-C2alkyl; or R8 and R8? are taken together to form an oxo group; or R8 and R8? can be taken together with the carbon that they are bonded to form a 3-membered carbocyclic ring;
R9 and R10 are independently selected at each occurrence from the group consisting of hydrogen, C1-C6alkyl, (C3-C7cycloalkyl)C0-C4alkyl, —C0-C4alkyl(C3-C7cycloalkyl), and —O—C0-C4alkyl(C3-C7cycloalkyl);
R11 and R14 are independently selected at each occurrence from the group consisting of hydrogen, halogen, hydroxyl, nitro, cyano, —O(PO)(OR9)2, —(PO)(OR9)2, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C2-C6alkenyl(aryl), C2-C6alkenyl(cycloalkyl), C2-C6alkenyl(heterocycle), C2-C6alkenyl(heteroaryl), C2-C6alkynyl, C2-C6alkynyl(aryl), C2-C6alkynyl(cycloalkyl), C2-C6alkynyl(heterocycle), C2-C6alkynyl(heteroaryl), C2-C6alkanoyl, C1-C6alkoxy, C1-C6thioalkyl, —C0-C4alkyl(mono- and di-C1-C6alkylamino), —C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkoxy(C3-C7cycloalkyl), C1-C2haloalkyl, and C1-C2haloalkoxy;
one of R12 and R13 is chosen from R31 and the other of R12 and R13 is chosen from R32 or both R12 and R13 are each independently selected from a R32;
R17 is hydrogen, C1-C6alkyl, or —C0-C2alkyl(C3-C7cycloalkyl);
R18 and R18? are independently selected from the group consisting of hydrogen, halogen, hydroxymethyl, and methyl;
m is 0, 1, 2, or 3;
R21 and R22 are independently selected at each occurrence from the group consisting of hydrogen, hydroxyl, cyano, amino, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, (C3-C7cycloalkyl)C0-C4alkyl, (phenyl)C0-C4alkyl, —C1-C4alkylOC(O)OC1-C6alkyl, —C1-C4alkylOC(O)C1-C6alkyl, —C1-C4alkylC(O)OC1-C6alkyl, (4- to 7-membered heterocycloalkyl)C0-C4alkyl having 1, 2, or 3 heteroatoms independently chosen from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle)Co-C4alkyl having 1, 2, or 3 heteroatoms independently chosen from N, O, and S;
R23 is independently selected at each occurrence from the group consisting of C1-C6alkyl, C1-C6haloalkyl, (aryl)C0-C4alkyl, (C3-C7cycloalkyl)C0-C4alkyl, (phenyl)C0-C4alkyl, (4- to 7-membered heterocycloalkyl)Co-C4alkyl having 1, 2, or 3 heteroatoms independently chosen from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle)C0-C4alkyl having 1, 2, or 3 heteroatoms independently chosen from N, O, and S;
R24 and R25 are taken together with the nitrogen to which they are attached to form a 4- to 7-membered monocyclic heterocycloalkyl group, or a 6- to 10-membered bicyclic heterocyclic group having fused, spiro, or bridged rings;
R31 is selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, cyano, amino, —COOH, C1-C2haloalkyl, C1-C2haloalkoxy, C1-C6alkyl, —C0-C4alkyl(C3-C7cycloalkyl), C2-C6alkenyl, C2-C6alkanoyl, C1-C6alkoxy, C2-C6alkenyloxy, —C(O)OR9, C1-C6thioalkyl, —C0-C4alkyINR9R10, —C(O)NR9R10, —SO2R9, —SO2NR9R10, —OC(O)R9, and —C(NR9)NR9R10, each of which R31 other than hydrogen, halogen, hydroxyl, nitro, cyano, C1-C2haloalkyl, and C1-C2haloalkoxy is unsubstituted or substituted with one or more substituents independently selected from the group consisting of halogen, hydroxyl, nitro, cyano, amino, —COOH, —CONH2 C1-C2haloalkyl, and C1-C2haloalkoxy, and each of which R31 is also optionally substituted with one substituent chosen from phenyl and 4- to 7-membered heterocycle containing 1, 2, or 3 heteroatoms independently chosen from N, O, and S; which phenyl or 4- to 7-membered heterocycle is unsubstituted or substituted with one or more substituents independently chosen from the group consisting of halogen, hydroxyl, nitro, cyano, C1-C6alkyl, C2-C6alkenyl, C2-C6alkanoyl, C1-C6alkoxy, (mono- and di-C1-C6alkylamino)C0-C4alkyl, C1-C6alkylester, —C0-C4alkyl(C3-C7cycloalkyl), C1-C2haloalkyl, and C1-C2haloalkoxy;
R32 is selected from the group consisting of C(O)NR21R71, —C(O)NR24R25, —C(O)NR9R71, —C(O)NR21SO2R22, —NR9C(O)OR10, —NR9C(O)OR23, —NR9C(O)R21, —NR9C(O)NR9R10, —NR9C(O)NR10R23, and —NR9C(O)NR24R25;
R71 is selected at each occurrence from the group consisting of hydroxyl, C1-C6alkoxy, (C3-C7cycloalkyl)C0-C4alkyl, (phenyl)C0-C4alkyl, —C1-C4alkylOC(O)OC1-C6alkyl, —C1-C4alkylOC(O)C1-C6alkyl, —C1-C4alkylC(O)OC1-C6alkyl, (4- to 7-membered heterocycloalkyl)C0-C4alkyl having 1, 2, or 3heteroatoms independently chosen from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle)C0-C4alkyl having 1, 2, or 3 heteroatoms independently chosen from N, O, and S;
R33 is independently selected from the group consisting of halogen, hydroxyl, —COOH, cyano, C1-C6alkyl, C2-C6alkanoyl, C1-C6alkoxy, —C0-C4alkyINR9R10, —SO2R9, C1-C2haloalkyl, and C1-C2haloalkoxy;
R34 is independently selected from the group consisting of nitro, C2-C6alkenyl, C2-C6alkynyl, C1-C6thioalkyl, -JC3-C7cycloalkyl, —B(OH)2, -JC(O)NR9R23, -JOSO2OR21, —C(O)(CH2)1-4S(O)R21, —O(CH2)1-4S(O)NR21R22, -JOP(O)(OR21)(OR22), -JP(O)(OR21)(OR22), -JOP(O)(OR21)R22, -JP(O)(OR21)R22, -JOP(O)R21R22, -JP(O)R21R22, -JSP(O)(OR21)(OR22), -JSP(O)(OR21)(R22), -JSP(O)(R21)(R22), -JNR9P(O)(NHR21)(NHR22), -JNR9P(O)(OR21)(NHR22), -JNR9P(O)(OR21)(OR22), -JC(S)R21, -JNR21SO2R22, -JNR9S(O)NR10R22, -JNR9SO2NR10R22, -JSO2NR9COR22, -JSO2NR9CONR21R22, -JNR21SO2R22, -JC(O)NR21SO2R22, -JC(NH2)=NR22, -JCH(NH2)NR9S(O)2R22, -JOC(O)NR21R22, -JNR21C(O)OR22, -JNR21OC(O)R22, —(CH2)1-4C(O)NR21R22, -JNR9C(O)R21, -JC(O)R21, -JNR9C(O)NR10R22, —CCR21, —(CH2)1-4OC(O)R21, and -JC(O)OR23;
R35 is independently selected from the group consisting of naphthyl, naphthyloxy, indanyl, (4- to 7-membered heterocycloalkyl)C0-C4alkyl containing 1 or 2 heteroatoms chosen from N, O, and S, and bicyclic heterocycle containing 1, 2, or 3 heteroatoms independently chosen from N, O, and S, and containing 4- to 7-ring atoms in each ring; each of which R35 is unsubstituted or substituted with one or more substituents independently chosen from the group consisting of halogen, hydroxyl, nitro, cyano, C1-C6alkyl, C2-C6alkenyl, C2-C6alkanoyl, C1-C6alkoxy, (mono- and di-C1-C6alkylamino)C0-C4alkyl, C1-C6alkylester, —C0-C4alkyl(C3-C7cycloalkyl), —SO2R9, C1-C2haloalkyl, and C1-C2haloalkoxy;
R36 is independently selected from the group consisting of tetrazolyl, (phenyl)C0-C2alkyl, (phenyl)C1-C2alkoxy, phenoxy, and 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently chosen from N, O, B, and S, each of which R36 is unsubstituted or substituted with one or more substituents independently chosen from the group consisting of halogen, hydroxyl, nitro, cyano, C1-C6alkyl, C2-C6alkenyl, C2-C6alkanoyl, C1-C6alkoxy, (mono- and di-C1-C6alkylamino)C0-C4alkyl, C1-C6alkylester, —C0-C4alkyl(C3-C7cycloalkyl), —SO2R9, —OSi(CH3)2C(CH3)3, —Si(CH3)2C(CH3)3, C1-C2haloalkyl, and C1-C2haloalkoxy;
R48 is independently selected from the group consisting of hydrogen, halogen, hydroxyl, nitro, cyano, amino, C1-C6alkyl, C1-C6haloalkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6thioalkyl, C1-C6alkoxy, -JC3-C7cycloalkyl, —B(OH)2, -JC(O)NR9R23,_-JOSO2O R21, —C(O)(CH2)1-4S(O)R21, —O(CH2)1-4S(O)NR21R22, -JOP(O)(OR21)(OR22), -JP(O)(OR21)(OR22), -JOP(O)(OR21)R22, -JP(O)(OR21)R22, -JOP(O)R21R22, -JP(O)R21R22, -JSP(O)(OR21)(OR22), -JSP(O)(OR21)(R22), -JSP(O)(R21)(R22), -JNR9P(O)(NHR21)(NHR22), -JNR9P(O)(OR21)(NHR22), -JNR9P(O)(OR21)(OR22), -JC(S)R21, -JNR21SO2R22, -JNR9S(O)NR10R22, -JNR9SO2NR10R22, -JSO2NR9COR22, -JSO2NR9CONR21R22, -JNR21SO2R22, -JC(O)NR21SO2R22, -JC(NH2)?NR22, -JCH(NH2)NR9S(O)2R22, -JOC(O)NR21R22, -JNR21C(O)OR22, -JNR21OC(O)R22, —(CH2)1-4C(O)NR21R22, -JNR9C(O)R21, -JC(O)R21, -JNR9C(O)NR10R22, —CCR21, —(CH2)1-4OC(O)R21, -JC(O)OR23; and SC1-C6alkyl(O)?NH;
R52 is independently selected from the group consisting of halo, hydrogen, and C1-C6alkyl;
J is independently chosen at each occurrence from the group consisting of a covalent bond, C1-C4alkylene, —OC1-C4alkylene, C2-C4alkenylene, and C2-C4alkynylene;
R37 is hydrogen, C1-C6alkyl, or —(C0-C2alkyl)(C3-C6cylcoalkyl); and
R38 and R39 are independently selected from the group consisting of hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6alkoxy, (C3-C6cycloalkyl)C0-C4alkyl-, (aryl)C0-C2alkyl-, and (heteroaryl)C0-C2alkyl-.

US Pat. No. 10,919,883

TREATMENT OF IMMUNE-RELATED AND INFLAMMATORY DISEASES

Celgene Corporation, Sum...

1. A method for inhibiting IgG or IgM in a patient suffering from a disease, comprising: a) identifying a patient suffering from the disease as having overproduction of IgG or IgM; and b) administering to the patient an effective amount of a compound to inhibit the overproduction of IgG or IgM, wherein the compound is (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione of the formula:
or a pharmaceutically acceptable salt thereof, and wherein the disease is lupus erythematosus or scleroderma.

US Pat. No. 10,919,882

COMPOUNDS FOR USE IN SYNTHESIS OF PEPTIDOMIMETICS

THE FEINSTEIN INSTITUTES ...

12. A method of preparing an azapeptide comprisinga step of activating a compound according to claim 1; and
a step of coupling the activated compound with N-terminal of an amino acid, N-terminal of an aza-mino acid;
wherein the azapeptide is a compound of Formula (V):
whereinis at the N-terminus and/or the C-terminus of the compound of Formula (V), is adjacent to the N-terminus and/or the C-terminus of the compound of Formula (V) or hydrolysis site of the compound of Formula (V);B is selected from the group consisting of hydrogen, —NH2, —NNH2, —CONH2, —COOR3, —COOH, —COH, —COC1-C4 alkyl, —COC1-C4 haloalkyl, —OH, an amino acid, an aza amino acid, a 2 to 60-mer peptide, a 2 to 60-mer aza peptide, a 2 to 60-mer azatide,
D is selected from the group consisting of —OR4, —OH, —NH2, —NNH2, —NHCOCH3, —NHCH3, —N(CH3)2, —CONH2, —COOH, —COH, —COC1-C4 alkyl, —COC1-C4 haloalkyl, an amino acid, an aza amino acid, a 2 to 60-mer peptide, a 2 to 60-mer aza peptide, a 2 to 60-mer azatide,
R3 and R4 is each independently selected from the group consisting of C1-C6 alkyl, methoxyl, ethoxyl, propoxyl, a C1-C6 haloalkyl and protecting groups,
R is selected from the group consisting of side chain radicals of aspartic acid, phenylalanine, alanine, histidine, glutamic acid, tryptophan, valine, leucine, lysine, methionine, tyrosine, isoleucine, arginine, glycine, asparagine, serine, threonine, cysteine, and glutamine.

US Pat. No. 10,919,881

CRYSTALLINE FORMS OF A 4-PYRIMIDINESULFAMIDE DERIVATIVE APROCITENTAN

IDORSIA PHARMACEUTICALS L...

1. A crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide:
characterized by:
the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2?: 17.8°, 20.0°, and 23.5°; or
the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2?: 9.7°, 15.7°, and 22.0°; or
the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2?: 4.6°, 16.8°, and 20.1°; or
the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2?: 9.5°, 16.5°, and 18.2°; wherein said crystalline form is an acetonitrile solvate; or
the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2?: 4.0°, 16.1°, and 21.9°; or
the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2?: 16.9°, 19.3°, and 24.8°; wherein said crystalline form is a dimethylsulfoxide solvate; or
the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2?: 11.3°, 16.4°, and 20.3°; wherein said crystalline form is an ethanol solvate;
wherein said X-ray powder diffraction diagram is obtained by using combined Cu K?1 and K?2 radiation, without K?2 stripping; and the accuracy of the 2? values is in the range of 2?+/?0.2°.

US Pat. No. 10,919,880

ORGANIC MOLECULES, IN PARTICULAR FOR USE IN OPTOELECTRONIC DEVICES

CYNORA GMBH, Bruchsal (D...

1. An organic molecule, comprising a structure of Formula I,
wherein
T=is selected from the group consisting of RA and R1;
V=is selected from the group consisting of RA and R1;
W=is the binding site of a single bond linking the first chemical moiety to one of the two second chemical moieties or is selected from the group consisting of RA and R2;
X=is the binding site of a single bond linking the first chemical moiety to one of the two second chemical moieties or is R2;
Y=is the binding site of a single bond linking the first chemical moiety to one of the two second chemical moieties or is R2;
RT=is selected from the group consisting of CN and RI;
RV=is selected from the group consisting of CN and RI;
RW=is the binding site of a single bond linking the first chemical moiety to one of the two second chemical moieties or is selected from the group consisting of CN and RI;
RX=is the binding site of a single bond linking the first chemical moiety to one of the two second chemical moieties or is RI;
RY=is the binding site of a single bond linking the first chemical moiety to one of the two second chemical moieties or is RI;
and
two second chemical moieties, each independently of one another comprising a structure of Formula II,

wherein
the first chemical moiety is linked to each of the two second chemical moieties via a single bond;
#=represents the binding site of a single bond linking the second chemical moieties to the first chemical moiety;
Z=is at each occurrence independently from another selected from the group consisting of a direct bond, CR3R4, C?CR3R4, C?O, C?NR3, NR3, O, SiR3R4, S, S(O) and S(O)2;
wherein
RA is selected from the group consisting of a structure of Formula A1 and a structure of Formula A2,

wherein $ represents the binding site of the single bond connecting RA and the first chemical moiety;
R1, identically or differently at each occurrence, is selected from the group consisting of:
hydrogen, deuterium,
C1-C5-alkyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;
C2-C8-alkenyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;
C2-C8-alkynyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium; and
C6-C18-aryl,
which is optionally substituted with one or more substituents R6;
R2, identically or differently at each occurrence, is selected from the group consisting of:
hydrogen, deuterium,
C1-C5-alkyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;
C2-C8-alkenyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;
C2-C8-alkynyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium; and
C6-C18-aryl,
which is optionally substituted with one or more substituents R6;
RI, identically or differently at each occurrence, is selected from the group consisting of:
hydrogen, deuterium,
C1-C5-alkyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;
C2-C8-alkenyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium;
C2-C8-alkynyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium; and
C6-C18-aryl,
which is optionally substituted with one or more substituents R6;
RTz, identically or differently at each occurrence, is selected from the group consisting of
hydrogen,
deuterium,
C1-C5-alkyl,
wherein one or more hydrogen atoms are optionally substituted by deuterium; and
C6-C18-aryl,
which is optionally substituted with one or more substituents R6;
Ra, R3 and R4, identically or differently at each occurrence, are selected from the group consisting of: hydrogen, deuterium, N(R5)2, OR5, Si(R5)3, B(OR5)2, OSO2R5, CF3, CN, F, Br, I,
C1-C40-alkyl,
which is optionally substituted with one or more substituents R5 and
wherein one or more non-adjacent CH2-groups are optionally substituted by R5C?CR5, C?C, Si(R5)2, Ge(R5)2, Sn(R5)2, C?O, C?S, C?Se, C?NR5, P(?O)(R5), SO, SO2, NR5, O, S or CONR5;
C1-C40-alkoxy,
which is optionally substituted with one or more substituents R5 and
wherein one or more non-adjacent CH2-groups are optionally substituted by R5C?CR5, C?C, Si(R5)2, Ge(R5)2, Sn(R5)2, C?O, C?S, C?Se, C?NR5, P(?O)(R5), SO, SO2, NR5, O, S or CONR5;
C1-C40-thioalkoxy,
which is optionally substituted with one or more substituents R5 and
wherein one or more non-adjacent CH2-groups are optionally substituted by R5C?CR5, C?C, Si(R5)2, Ge(R5)2, Sn(R5)2, C?O, C?S, C?Se, C?NR5, P(?O)(R5), SO, SO2, NR5, O, S or CONR5;
C2-C40-alkenyl,
which is optionally substituted with one or more substituents R5 and
wherein one or more non-adjacent CH2-groups are optionally substituted by R5C?CR5, C?C, Si(R5)2, Ge(R5)2, Sn(R5)2, C?O, C?S, C?Se, C?NR5, P(?O)(R5), SO, SO2, NR5, O, S or CONR5;
C2-C40-alkynyl,
which is optionally substituted with one or more substituents R5 and
wherein one or more non-adjacent CH2-groups are optionally substituted by R5C?CR5, C?C, Si(R5)2, Ge(R5)2, Sn(R5)2, C?O, C?S, C?Se, C?NR5, P(?O)(R5), SO, SO2, NR5, O, S or CONR5;
C6-C60O-aryl,
which is optionally substituted with one or more substituents R5; and
C3-C57-heteroaryl,
which is optionally substituted with one or more substituents R5;
R5, identically or differently at each occurrence, is selected from the group consisting of hydrogen, deuterium, N(R6)2, OR6, Si(R6)3, B(OR6)2, OSO2R6, CF3, CN, F, Br, I, C1-C40-alkyl,
which is optionally substituted with one or more substituents R6 and
wherein one or more non-adjacent CH2-groups are optionally substituted by R6C?CR6, C?C, Si(R6)2, Ge(R6)2, Sn(R6)2, C?O, C?S, C?Se, C?NR6, P(?O)(R6), SO, SO2, NR6, O, S or CONR6;
C1-C40-alkoxy,
which is optionally substituted with one or more substituents R6 and
wherein one or more non-adjacent CH2-groups are optionally substituted by R6C?CR6, C?C, Si(R6)2, Ge(R6)2, Sn(R6)2, C?O, C?S, C?Se, C?NR6, P(?O)(R6), SO, SO2, NR6, O, S or CONR6;
C1-C40-thioalkoxy,
which is optionally substituted with one or more substituents R6 and
wherein one or more non-adjacent CH2-groups are optionally substituted by R6C?CR6, C?C, Si(R6)2, Ge(R6)2, Sn(R6)2, C?O, C?S, C?Se, C?NR6, P(?O)(R6), SO, SO2, NR6, O, S or CONR6;
C2-C40-alkenyl,
which is optionally substituted with one or more substituents R6 and
wherein one or more non-adjacent CH2-groups are optionally substituted by R6C?CR6, C?C, Si(R6)2, Ge(R6)2, Sn(R6)2, C?O, C?S, C?Se, C?NR6, P(?O)(R6), SO, SO2, NR6, O, S or CONR6;
C2-C40-alkynyl,
which is optionally substituted with one or more substituents R6 and
wherein one or more non-adjacent CH2-groups are optionally substituted by R6C?CR6, C?C, Si(R6)2, Ge(R6)2, Sn(R6)2, C?O, C?S, C?Se, C?NR6, P(?O)(R6), SO, SO2, NR6, O, S or CONR6;
C6-C60-aryl,
which is optionally substituted with one or more substituents R6; and
C3-C57-heteroaryl,
which is optionally substituted with one or more substituents R6;
R6, identically or differently at each occurrence, is selected from the group consisting of:
hydrogen, deuterium, OPh, CF3, CN, F,
C1-C5-alkyl,
wherein one or more hydrogen atoms are optionally, independently from each other substituted by deuterium, CN, CF3, or F;
C1-C5-alkoxy,
wherein one or more hydrogen atoms are optionally, independently from each other substituted by deuterium, CN, CF3, or F;
C1-C5-thioalkoxy,
wherein one or more hydrogen atoms are optionally, independently from each other substituted by deuterium, CN, CF3, or F;
C2-C5-alkenyl,
wherein one or more hydrogen atoms are optionally, independently from each other substituted by deuterium, CN, CF3, or F;
C2-C5-alkynyl,
wherein one or more hydrogen atoms are optionally, independently from each other substituted by deuterium, CN, CF3, or F;
C6-C18-aryl,
which is optionally substituted with one or more C1-C5-alkyl substituents;
C3-C17-heteroaryl,
which is optionally substituted with one or more C1-C5-alkyl substituents;
N(C6-C18-aryl)2,
N(C3-C17-heteroaryl)2, and
N(C3-C17-heteroaryl)(C6-C18-aryl);
wherein the substituents Ra, R3, R4 or R5 optionally form, independently from each other, a mono- or polycyclic, aliphatic, aromatic and/or benzo-fused ring system with one or more substituents Ra, R3, R4 or R5;
wherein
exactly one substituent selected from the group consisting of T, V and W is RA,
exactly one substituent selected from the group consisting of RT, RV and RW is CN,
exactly one substituent selected from the group consisting of W, Y and X represents the binding site of a single bond linking the first chemical moiety and one of the two second chemical moieties and
exactly one substituent selected from the group consisting of RW, RY and RX represents the binding site of a single bond linking the first chemical moiety and one of the two second chemical moieties.

US Pat. No. 10,919,878

MCT4 INHIBITORS AND USES THEREOF

CHARLES R. DREW UNIVERSIT...

1. A pharmaceutical composition comprising a compound having the structure of formula Ill, or a salt thereof:
wherein X and Y are independently selected from hydrogen, chlorine, fluorine, bromine and iodine, and the pharmaceutical composition comprises one or more pharmaceutically acceptable excipients or additives.

US Pat. No. 10,919,877

MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME

THE REGENTS OF THE UNIVER...

1. A compound having a structure:
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,919,876

TLR7/8 ANTAGONISTS AND USES THEREOF

Merck Patent GmbH, Darms...

1. A compound of formula I-e,
or a pharmaceutically acceptable salt thereof, wherein:
R1 is —CF3 or —CN;
each R2 is independently —H, —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
each R3 is independently —H, —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
R4 is C1-6 aliphatic, —C(O)R, —C(O)N(R)2, —C(NH)NR2, —NRC(O)R, —N(R)2; or 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
each R5 is independently C1-6 aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
each R is independently hydrogen, C1-6 aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or
two R groups on the same atom are taken together with the atom to which they are attached to form a 3-7 membered heterocyclic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
k is 1;
n is 0, 1, or 2;
p is 0;
r is 0; and
t is 1 or 2.

US Pat. No. 10,919,875

SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES

89BIO LTD, Herzliya (IL)...

1. A compound according to Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
A is —C(?O)— or —SO2—;
R1 is selected from —H, —(C1-C10)hydrocarbyl, substituted —(C1-C10)hydrocarbyl, 3-7 membered heterocyclyl, substituted 3-7 membered heterocyclyl, —(C6-C10)aryl, substituted —(C6-C10)aryl, 5-6 membered heteroaryl, substituted 5-6 membered heteroaryl, —NR7R8, —N(OR8)R7, —SR7, —N(SR8)R7, —C(?O)—(C1-C6) alkyl and —(C1-C6) heteroalkyl;
a and b are 1;
each R2 and each R3 is independently selected from —H and —(C1-C4) alkyl;
R4 is —H, —C1-C6 alkyl, —OH, ?O, —O(C1-C6) alkyl, halogen or —CN;wherein one of the R3 groups can be structurally connected to one of the R2 groups to form an alkylene bridge to produce a bicyclic ring; orone of the R3 groups can be structurally connected to the R1 group to form a 5 to 7 membered heterocyclyl ring fused to the 1-2 face of the piperidine ring;
R5 is selected from —H, —C1-C7 hydrocarbyl, —C3-C6 heterocyclyl; halogen, —(C1-C3) haloalkyl, —CN, —NR7aR8a, —O(CH2)nNR7aR8a, —O(CH2)nOR8a, —NR8a(CH2)nNR7aR8a, —NR8a(CH2)nOR8a, —C(?O)NR7aR8a, —C(?O)OR7a, 5-6 membered heteroaryl, and substituted 5-6 membered heteroaryl; wherein n is an integer selected from 1, 2, 3, and 4;
W is an sp3 hybridized carbon atom bonded to a Rw substituent, or is an sp2 hybridized carbon atom, and no Rw substituent is present;
signifies that the designated bond is a carbon-carbon single bond or a carbon-carbon double bond;
signifies that the designated bond is a C—Rw single bond when is a carbon-carbon single bond, i.e., W is an sp3 hybridized carbon atom, and a Rw substituent is present, and that the bond is not present bond when is a carbon-carbon double bond, i.e., W is an sp2 hybridized carbon atom, and there is no 1r substituent;
R6 is selected from 9-10 membered bicyclic heteroaryl, and substituted 9-10 membered bicyclic heteroaryl; provided that, when R6 is a 9-membered bicyclic heteroaryl or a substituted 9-membered bicyclic heteroaryl, the point of attachment of R6 is on a 6-membered ring portion of the 9-membered bicyclic heteroaryl or substituted 9-membered bicyclic heteroaryl;
R7 is selected from —H, —(C1-C7) hydrocarbyl, substituted —(C1-C7) hydrocarbyl, —C(?O)R8, and —(C1-C6) heteroalkyl;
R8 is selected from —H, and —(C1-C6) alkyl, wherein R7 can be structurally connected to R8 to form a 5 to 7 membered heterocyclyl ring;
R7a is selected from —H, —(C1-C7) hydrocarbyl, substituted —(C1-C7) hydrocarbyl, —C(?O)R8, and —(C1-C6) heteroalkyl;
R8a is selected from —H, and —(C1-C6) alkyl, wherein R7a can be structurally connected to R8a to form a 5 to 7 membered heterocyclyl ring;
X is selected from CH2, CHR9, C(R9)2, C?C(R11)2, C(?O), C(?NO—(C1-C7) hydrocarbyl), and C(?NO—C(?O)—(C1-C7) hydrocarbyl);
each R9 is independently selected from halogen, —(C1-C7) hydrocarbyl, —O—(C1-C7) hydrocarbyl, —NH—R11, —O—(CH2)m-(5-6 membered heterocyclyl), and —(C1-C6) heteroalkyl; or the two R9 groups can together form a spirofused heterocyclic ring or carbocyclic ring; wherein m is an integer selected from 1, 2, 3 and 4;
Rw is selected from —H, halogen, —CN, —OH, —(C1-C7) hydrocarbyl, and substituted —(C1-C7) hydrocarbyl;
each R10 is independently selected from halogen, —CN, —OH, —(C1-C7) hydrocarbyl, and substituted —(C1-C7) hydrocarbyl; p is an integer selected from 0, 1 and 2; and
R11 is selected from —H and —(C1-C7) hydrocarbyl.

US Pat. No. 10,919,874

METALLOENZYME INHIBITOR COMPOUNDS

NQP 1598, LTD., Grand Ca...

1. A compound having the formula:
or an ester prodrug thereof.

US Pat. No. 10,919,872

METHOD FOR PRODUCING 2-ALKYLCARBONYLNAPHTHO[2,3-B]FURAN-4,9-DIONE-RELATED SUBSTANCE, AND SAID RELATED SUBSTANCE

SUMITOMO DAINIPPON PHARMA...

1. A compound of formula (I):or a tautomer thereof, or an optionally pharmaceutically acceptable salt thereof, wherein Y is a group represented by the following formula (Ya), (Yb), or (Yc):
wherein
* denotes a bonding position;
P1 and P2 are identical or different, and each independently is selected from the group consisting of:
(1) a hydrogen atom,
(2) an optionally substituted C1-10alkyl group,
(3) a silyl group, wherein the silyl group is substituted with three substituents independently selected from the group consisting of an optionally substituted C1-10alkyl group, an optionally substituted C1-10alkoxy group, and an optionally substituted C6-10aryl group,
(4) an optionally substituted C6-10aryl group,
(5) an optionally substituted C1-10alkylcarbonyl group,
(6) an optionally substituted C6-10arylcarbonyl group, and
(7) an optionally substituted C3-10cycloalkyl group; and
wherein
when P1 and P2 are identical or different, and each independently an optionally substituted C1-10alkyl group, an optionally substituted C6-10aryl group, an optionally substituted C1-10alkylcarbonyl group, or an optionally substituted C3-10cycloalkyl group, or they may be taken together to form an optionally substituted cyclic ketal, wherein P1 and P2 are not both hydrogen atoms;
P3 is selected from the group consisting of:
(1) a substituted C1-10alkyl group,
(2) a silyl group, wherein the silyl group is substituted with three substituents independently selected from the group consisting of an optionally substituted C1-10alkyl group, an optionally substituted C1-10alkoxy group, and an optionally substituted C6-10aryl group,
(3) an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, wherein in the heterocyclic group, a carbon atom adjacent to a heteroatom in the ring is bound to the oxygen atom to which P3 in the formula (Yb) is attached,
(4) an optionally substituted C2-10alkenyl group,
(5) an optionally substituted C6-10aryl group,
(6) an optionally substituted C1-10alkylcarbonyl group,
(7) an optionally substituted C6-10arylcarbonyl group,
(8) an optionally substituted C1-10alkyloxycarbonyl group,
(9) an optionally substituted C6-10aryloxycarbonyl group,
(10) an optionally substituted C2-10alkenyloxycarbonyl group,
(11) an optionally substituted aminocarbonyl group,
(12) an optionally substituted C1-10alkylsulfonyl group,
(13) an optionally substituted C6-10arylsulfonyl group, and
(14) a formyl group;
P4 is selected from the group consisting of:
(1) an optionally substituted C1-10alkyl group,
(2) a silyl group, wherein the silyl group is substituted with three substituents independently selected from the group consisting of an optionally substituted C1-10alkyl group, an optionally substituted C1-10alkoxy group, and an optionally substituted C6-10aryl group,
(3) an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, wherein in the heterocyclic group, a carbon atom adjacent to a heteroatom in the ring is bound to the oxygen atom to which P4 in the formula (Yc) is attached,
(4) an optionally substituted C2-10alkenyl group,
(5) an optionally substituted C6-10aryl group,
(6) an optionally substituted C1-10alkylcarbonyl group,
(7) an optionally substituted C6-10arylcarbonyl group,
(8) an optionally substituted C1-10alkyloxycarbonyl group,
(9) an optionally substituted C6-10aryloxycarbonyl group,
(10) an optionally substituted C2-10alkenyloxycarbonyl group,
(11) an optionally substituted aminocarbonyl group,
(12) an optionally substituted C1-10alkylsulfonyl group,
(13) an optionally substituted C6-10arylsulfonyl group, and
(14) a formyl group;
R2 is an optionally substituted C1-10alkyl group;
R3 is an optionally substituted C1-10alkyl group; and
R4 and R5 are identical or different, and each independently a hydrogen atom, or an optionally substituted C1-10alkyl group,with the proviso that 2-(2-methyl-1,3-dioxolane-2-yl)naphtho[2,3-b]furan-4,9-dione and 1-(4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-2-yl)ethyl acetate are excluded.

US Pat. No. 10,919,871

METHOD OF TREATMENT OF AQUEOUS EFFLUENT

BASF SE, Ludwigshafen am...

1. A method of treatment of an aqueous effluent stream by subjecting the aqueous effluent stream containing at least one organic solvent, furfural and water to azeotropic distillation to obtain a distillate stream and a treated effluent stream, wherein the at least one organic solvent is selected from the group consisting of cyclic ketones, dialkyl ketones, and benzene derivatives.

US Pat. No. 10,919,868

BENZOTRIAZOLE DERIVATIVE COMPOUND

SHIPRO KASEI KAISHA, LTD....

1. A benzotriazole derivative compound represented by the following general formula (1):
wherein R1 in the above general formula (1) a branched alkyl group whose carbon number is 3 to 8,
wherein R2 in the above general formula (1) is an alkyl group whose carbo number is 1 to 8, and
wherein R3 in the above general formula (1) is a hydrogen atom, an alkyl group whose carbon number is 1 to 8, an acryloyl oxyalkyl group whose alkyl carbon number is 1 to 2, or a methacryloyl oxyalkyl group whose alkyl carbon number is 1 to 2.

US Pat. No. 10,919,867

SUBSTITUTED BENZOTRIAZOLE PHENOLS

3M INNOVATIVE PROPERTIES ...

1. A composition comprising a substituted benzotriazole phenol with the structure of Formula I:
wherein if R1 is an —O—R9, a —N—R9R10, a —B(OR18)(OR19) group, or a —SiR203 group wherein R9 is selected from an alkyl group, or an aryl group, and R10 is selected from a hydrogen atom, an alkyl group, an alkenyl group, an aryl group, or a heteroatom-containing group comprising one or more oxygen, nitrogen, sulfur, or phosphorous atoms, or R9 and R10 together with the atoms connecting form a heterocyclic ring structure, each R18 and R19 is independently a hydrogen atom, an alkyl group, an aryl group, or R18 and R19 together with the atoms connecting form a heterocyclic ring structure, each R20 group is an alkyl group; and
each R2, R3, R4, R5, R6, R7, and R8, independently is a hydrogen atom, an alkyl group, an alkenyl group, an aryl group, or a halogen atom; and R3 is an alkyl group with 8 carbon atoms.

US Pat. No. 10,919,865

SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH

SIGNAL PHARMACEUTICALS, L...

1. A method for preparing a compound of formula (I):
the method comprising contacting a compound of formula (Ia)

with R1NH2 in a solvent, in the presence of an organic base, wherein:
R1 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted saturated or partially saturated cycloalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted alkyl-(saturated or partially saturated cycloalkyl), or substituted or unsubstituted alkylheterocyclyl, provided that R1 is not 2 aminocyclohexyl;
R2 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted saturated C5-10 cycloalkyl, substituted or unsubstituted alkyl-(saturated or partially saturated cycloalkyl, substituted or unsubstituted non-aromatic heterocyclyl;
Rx is a C1-2 alkyl; and
m is 1 or 2,
wherein when a C1-8 alky group is substituted, the C1-8 alkyl group is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, B(OH)2, or O(alkyl)aminocarbonyl;
wherein when a group, other than a C1-8 alkyl group, is substituted, the group is substituted with halogen, alkyl, hydroxyl, alkoxy, alkoxyalkyl, amino, alkylamino, carboxy, nitro, cyano, thiol, thioether, imine, imide, amidine, guanidine, enamine, aminocarbonyl, acylamino, phosphonato, phosphine, thiocarbonyl, sulfonyl, sulfone, sulfonamide, ketone, aldehyde, ester, urea, urethane, oxime, hydroxyl amine, alkoxyamine, aralkoxyamine, N-oxide, hydrazine, hydrazide, hydrazone, azide, isocyanate, isothiocyanate, cyanate, thiocyanate, oxo, B(OH)2, O(alkyl)aminocarbonyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aryloxy, aralkyloxy, heterocyclyloxy or heterocyclylalkoxy.

US Pat. No. 10,919,864

5-FLUORO-4-IMINO-3(ALKYL/SUBSTITUTED ALKYL)-1-(ARYLSULFONYL)-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE AND PROCESSES FOR THEIR PREPARATION

Adama Makhteshim Ltd., B...

1. A compound of Formula III:wherein R1 isandR2 is selected from the group consisting ofor a tautomer, an optical isomer, or a salt thereof.

US Pat. No. 10,919,863

COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS

Vectus Biosystems Limited...

1. A compound of the formula:
or a pharmacologically acceptable salt, stereoisomer, diastereomer, enantiomer, racemate, hydrate and/or solvate thereof,
wherein:
B is selected from the group consisting of:

R1, R3 and R4 are independently C, CH, CH2, O, N, NH or S,
R2 is C, CH, CH2, N, NH, C—CF3, CH—CF3 or C?O;
R5 to R9 are independently C or N;
Q is independently selected from halo, alkyl, hydroxy, amino and substituted amino;
n is 0, 1, 2, 3, 4 or 5;
D is:

R10 to R14 are independently C, N, O or S;
T is independently selected from C1-6alkyl, halo, C0-6alkyl carboxylic acid, amino, hydroxy and C1-6alkoxy; and
m is 0, 1, 2, 3 or 4,
wherein D cannot be unsubstituted phenyl, and Q cannot be hydroxy when n is 1 and R5 to R9 are all C.

US Pat. No. 10,919,862

FUSED IMIDAZOLES AS MIDH1 INHIBITORS

BAYER PHARMA AKTIENGESELL...

18. A pharmaceutical composition comprising a compound of formula (I), or a stereoisomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same, according to claim 1, and a pharmaceutically acceptable diluent or carrier.

US Pat. No. 10,919,860

BACKFUNCTIONALIZED IMIDAZOLINIUM SALTS AND NHC CARBENE-METAL COMPLEXES

United States of America ...

1. An ionic liquid having comprising the formula:
R being a hydrogen or a methyl group;
R? being selected from the group consisting of hydrogen, an ester group, an amide group, and an aromatic group;
R? being selected from the group consisting of an alkyl group and an aromatic group;
the subscript m ranging from 0 to 10;
the subscript n ranging from 0 to 10;
X being a halide or an anion; and
Y being oxygen, sulfur, or NR?.

US Pat. No. 10,919,859

BENZYLAMINOPYRIDYLCYCLOPROPANECARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Boehringer Ingelheim Inte...

1. A compound of formula (I)
wherein
R is selected from the group consisting of
H, F, Cl, Br, I, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-6-cycloalkyl, NC—, HNRN—C(?O)—, C1-4-alkyl-NRN—C(?O)—, C3-6-cycloalkyl-NRN—C(?O)—, heterocyclyl-NRN—C(?O)—, heteroaryl-NRN—C(?O)—, HOOC—, C1-4-alkyl-O—C(?O)—, O2N—, HRNN—, C1-4 alkyl-RNN—, C1-4-alkyl-C(?O)NRN—, C3-6-cycloalkyl-C(?O)NRN—, heterocyclyl-C(?O)NRN—, heteroaryl-C(?O)NRN, C1-4-alkyl-S(?O)2NRN—, C3-6-cycloalkyl-S(?O)2NRN—, heterocyclyl-S(?O)2NRN—, heteroaryl-S(?O)2NRN—, HO—, C1-6-alkyl-O—, HOOC—C1-3-alkyl-O—, C3-6-cycloalkyl-C1-3-alkyl-O—, heterocyclyl-C1-3-alkyl-O—, phenyl-C1-3-alkyl-O—, C3-6-cycloalkyl-O—, heterocyclyl-O—, heteroaryl-O—, C1-4-alkyl-S—, C3-6-cycloalkyl-S—, heterocyclyl-S—, C1-4-alkyl-S(?O)—, C3-6-cycloalkyl-S(?O)—, heterocyclyl-S(?O)—, C1-4-alkyl-S(?O)2—, C3-6-cycloalkyl-S(?O)2—, heterocyclyl-S(?O)2—, phenyl-S(?O)2—, heteroaryl-S(?O)2—, HNRNS(?O)2—, C1-4-alkyl-NRN—S(?O)2—, heterocyclyl, phenyl, and heteroaryl,
wherein each alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groups forming R is optionally substituted with 1 or more F atoms and optionally substituted with 1 to 3 groups independently selected from Cl, C1-3-alkyl, NC—, (RN)2N—, HO—, C1-3-alkyl-O—, and C1-3-alkyl-S(?O)2—; and
wherein each phenyl and heteroaryl group or sub-group within the groups forming R is optionally substituted with 1 to 5 substituents independently selected from F, Cl, C1-3-alkyl, HF2C—, F3C—, NC—, (RN)2N—, HO—, C1-3-alkyl-O—, F3C—O—, and C1-3-alkyl-S(?O)2—;
wherein each heterocyclyl group or sub-group within the groups forming R is selected from
a cyclobutyl group wherein 1 CH2 group is replaced by —NRN— or —O—;
a C5-6-cycloalkyl group wherein 1 CH2 group is replaced by —C(?O)—, —NRN, —O—, —S— or —S(?O)2— and/or 1 CH group is replaced by N;
a C5-6-cycloalkyl group wherein 1 CH2 group is replaced by —NRN— or —O—, a second CH2 group is replaced by —NRN—, —C(?O)— or —S(?O)2— and/or 1 CH group is replaced by N; and
a C5-6-cycloalkyl group wherein 2 CH2 groups are replaced by —NRN— or 1 CH2 group by —NRN—and the other by —O— and a third CH2 group is replaced by —C(?O)— or —S(?O)2— and/or 1 CH group is replaced by N;
wherein each heteroaryl group or sub-group within the groups forming R is selected from
tetrazolyl and a 5- or 6-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently of each other selected from ?N—, —NRN—, —O—, and —S—, wherein in heteroaromatic groups containing a —HC?N— unit this group is optionally replaced by —NRN—C(?O)—;
wherein in heteroaryl and heterocyclyl rings with one or more NH groups, each of said NH groups is replaced by NRN;
R1 is selected from the group consisting of H, F, Cl, C1-4-alkyl, C3-6-cycloalkyl-, HO—C1-4-alkyl, C1-4-alkyl-O—C1-4-alkyl, NC—, HO—, C1-4-alkyl-O—, C3-6-cycloalkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(O)—, and C1-4-alkyl-S(O)2—,
wherein any alkyl and cycloalkyl group or sub-group within the groups forming R1 is optionally substituted with 1 or more F atoms, and wherein multiple R1 may be identical or different if m is 2, 3 or 4;
m is an integer selected from 1, 2, 3, and 4;
R2 is selected from the group consisting of H, F, Cl, C1-4-alkyl, NC—, and C1-4-alkyloxy, wherein any alkyl group or sub-group within the groups forming R2 is optionally substituted with 1 or more F atoms, and wherein multiple R2 may be identical or different if n is 2 or 3;
R3 is selected from the group consisting of H, F, Cl, C1-4-alkyl, NC—, and C1-4-alkyl-O—, wherein each alkyl group or sub-group within the groups forming R3 is optionally substituted with 1 or more F atoms;
n is an integer selected from 1, 2, and 3;
RN is independently of each other selected from the group consisting of H, C1-4-alkyl, HO—C1-4-alkyl-(H2C)—, C1-3-alkyl-O—C1-4-alkyl-, C1-4-alkyl-C(?O)—, C1-4-alkyl-NH—C(?O)—, C1-4-alkyl-N(C1-4-alkyl)-C(?O)—, C1-4-alkyl-O—C(?O)—, and C1-4-alkyl-S(?O)2—,
wherein each alkyl group or sub-group within the groups forming RN is optionally substituted with 1 or more F atoms;
wherein in any definition mentioned hereinbefore, if not specified otherwise, any alkyl group or sub-group may be straight-chained or branched,
or a salt thereof.

US Pat. No. 10,919,858

THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Ardea Biosciences, Inc, ...

1. A method of reducing serum uric acid levels in a human with diabetes, comprising administering to the human an effective amount of a compound of formula:
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,919,857

OLIGO-GUANIDINES BASED CELLULAR TRANSPORTER COMPRISING HETEROCYCLIC RINGS WITH HYDROPHOBIC AND/OR LIPOPHILIC GROUPS AT N-TERMINAL FOR EFFECTIVE DELIVERY OF NONPENETRABLE CARGOS IN-VITRO AND IN-VIVO

INDIAN ASSOCIATION FOR TH...

1. An oligo-guanidine as a cell penetrating agent or a carrier, represented by the following formula:
wherein R1 is selected from the group consisting of hydrophobic and lipophilic groups of tert-butyloxycarbonyl (t-BOC), hexafluoro-iso-propyloxycarbonyl [i-Pr(F)], n-octyloxycarbonyl (n-OOC), 2-hexyl-1-decyloxycarbonyl (HDOC), methoxycarbonyl (MeOC), ethoxycarbonyl (EtOC), propoxycarbonyl (POC), and iso-propoxycarbonyl (IPOC);
R is a molecule selected from the group consisting of fluorophore, peptide, a diagnostic agent, a probe, an antisense agent, or a cancer drug; and
n is an integer from 1 to 4.

US Pat. No. 10,919,856

CYCLOHEXENE COMPOUNDS AND USE THEREOF

GUANGZHOU HENOVCOM BIOSCI...

1. A cyclohexene compound having a structural formula II or a pharmaceutically acceptable salt, a stereoisomer thereof:
wherein,
m is selected from 0 or 1;
R is selected from H;
R1 is selected from amino, or guanidyl;
R2 is selected from C1-C4 alkyl;
R3 and R4 are independently selected from H;
R5 is absent, or R5 is selected from H, C1-C4 alkyl, substituted C1-C4 alkyl, C3-C6 cycloalkyl, substituted C3-C6 cycloalkyl, C3-C6 heterocyclyl, or substituted C3-C6 heterocyclyl;
n is selected from 2;
X is selected from O, NHCOO, or OCONR9R10; and
R9 and R10 are independently selected from H, C1-C4 alkyl, substituted C1-C4 alkyl, C3-C6 cycloalkyl, or substituted C3-C6 cycloalkyl, or R9 and R10 together with the atom to which they are attached form a C3-C6 heterocyclic ring containing O and NH.

US Pat. No. 10,919,854

MONO- OR DI-SUBSTITUTED INDOLE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS

Janssen Pharmaceuticals, ...

1. A compound of formula (I)
wherein R1, R2 and R3 are selected from the group consisting of:
R1 is H, R2 is F and R3 is H or CH3,
R1 is H, CH3 or F, R2 is OCH3 and R3 is H,
R1 is H, R2 is OCH3 and R3 is CH3,
R1 is CH3, R2 is F and R3 is H,
R1 is CF3, R2 is H and R3 is H,
R1 is OCF3, R2 is OCH3 and R3 is H, and
R1 is OCF3, R2 is H and R3 is CH3,
or a stereoisomer, pharmaceutically acceptable salt, solvate or polymorph thereof.

US Pat. No. 10,919,853

CROSS-LINKING AGENT(S)

GL CHEMTEC VISION INC., ...

1. A compound of formula II:
R1-R11 are the same or different, and are each independently selected from H, halo, hydroxyl, a substituted or unsubstituted hydrocarbon group, a substituted or unsubstituted heterogeneous group, a substituted or unsubstituted carbocyclic group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or NRaRb, wherein Ra and Rb are the same or different, and are independently selected from H, halo, hydroxyl, amino, a substituted or unsubstituted hydrocarbon group, a substituted or unsubstituted heterogeneous group, a substituted or unsubstituted carbocyclic group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aromatic group, or a substituted or unsubstituted heteroaromatic group;
X1 and X2 are the same or different, and are each independently selected from a direct bond, a heteroatom, C(O), a substituted or unsubstituted hydrocarbon group, a substituted or unsubstituted heterogeneous group, a substituted or unsubstituted carbocyclic group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or NRa; and
Z is selected from a heteroatom, C(O), a substituted or unsubstituted hydrocarbon group, a substituted or unsubstituted heterogeneous group, a substituted or unsubstituted carbocyclic group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, NRa, or [SiR12R13O]wSiR12R13, wherein R12 and R13 are the same or different, and are independently selected from H, halo, hydroxyl, amino, a substituted or unsubstituted hydrocarbon group, a substituted or unsubstituted heterogeneous group, a substituted or unsubstituted carbocyclic group, a substituted or unsubstituted heterocyclic group, a substituted or unsubstituted aromatic group, or a substituted or unsubstituted heteroaromatic group, and w is from 0 to 60.

US Pat. No. 10,919,852

IMMUNOMODULATOR COMPOUNDS

ChemoCentryx, Inc., Moun...

1. A compound of Formula (I)
or a pharmaceutically acceptable salt thereof wherein:each of R1a, R1b, R1c, R1d is independently selected from the group consisting of H, halogen, CF3, CN, C1-4 alkyl and —O—C1-4 alkyl, wherein the C1-4 alkyl and —O—C1-4 alkyl are optionally further substituted with halogen, hydroxyl, methoxy or ethoxy;L is a linking group selected from the group consisting of:wherein each of the subscripts q is independently 1, 2, 3 or 4, and L is optionally further substituted with one or two members selected from the group consisting of halogen, hydroxy, C1-3 alkyl, —O—C1-3 alkyl, C1-3 hydroxyalkyl, C1-3 haloalkyl and —CO2H;Z is piperidinyl optionally substituted with from 1 to 4 groups independently selected from halogen, CN, hydroxy, oxo, C1-4 alkyl, —NH2, —NHC1-3 alkyl, —N(C1-3 alkyl)2, —O—C1-3 alkyl, C1-3 hydroxyalkyl, C1-3haloalkyl, —OC(O)(C1-4 alkyl), —CO2(C1-4 alkyl) and —CO2H;each R2a, R2b and R2c is independently selected from the group consisting of H, halogen, —CN, —Rd, —CO2Re, —CONReRf, —OC(O)NReRf, —NRfC(O)Re, —NRfC(O)2Rd, —NRe—C(O)NReRf, —NReRf, —ORe, —X2—OR, —X2—NReRf, —X2—CO2Re, —SF5, and —S(O)2NReRf, wherein each X2 is a C1-4 alkylene; each Re and Rf is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl, each Rd is independently selected from the group consisting of C1-8 alkyl, C2-8 alkenyl, and C1-8 haloalkyl;R3 is selected from the group consisting of —NRgRh;Rg is selected from the group consisting of H, C1-8 haloalkyl and C1-8 alkyl;Rh is selected from —C1-8 alkyl, C1-8 haloalkyl, C1-8 hydroxyalkyl, C1-8alkyl-CO2Rj, C1-8alkyl—CONRjRk, and C1-8alkyl-CONHSO2Rj, C1-8 alkyl-SO2NRjRk, C1-8alkyl-SO3Rj, C1-8 alkyl—B(OH)2, C1-8 alkyl-PO3H2, C1-8 alkyl-C(O)NHOH, C1-8 alkyl-NRh1Rh2, —C(O)Rj, C3-10 cycloalkyl, —C3-10 cycloalkyl-COORj, —C3-10 cycloalkyl-ORj, C1-8 alkyl—C6-10 aryl, —C1-8alkyl C?O)C6-10 aryl, —CO2—C1-8 alkyl-O2C—C1-8 alkyl, —C1-8 alkyl-NH(C?O)—C2-8 alkenyl, —C1-8 alkyl-NH(C?O)—C1-8 alkyl, —C1-8 alkyl-NH(C?O)—C2-8 alkynyl, —C1-8 alkyl-(C?O)—NH—C1-8 alkyl-COORj, and —C1-8 alkyl-(C?O)—NH—C1-8 alkyl-ORj optionally substituted with CO2H; wherein each Rj and Rk is independently selected from hydrogen, C1-8 alkyl optionally substituted with 1 to 2 substituents selected from OH, SO2NH2, CONH2, C(O)NHOH, PO3H2, COO—C1-8alkyl or CO2H, and C1-8 haloalkyl optionally substituted with 1 to 2 substituents selected from OH, SO2NH2, CONH2, C(O)NHOH, PO3H2, COO—C1-8alkyl or CO2H; orRh1 and Rh2 are each independently selected from the group consisting of H, C1-6 alkyl, and C1-4 hydroxyalkyl;
the C1-8 alkyl portions of Rh are optionally further substituted with from 1 to 3 substituents independently selected from OH, COOH, SO2NH2, CONH2, C(O)NHOH, COO—C1-8 alkyl, and PO3H2,
the C6-10 aryl portions of Rh are optionally substituted with 1 to 3 substituents independently selected from OH, B(OH)2, COOH, SO2NH2, CONH2, C(O)NHOH, PO3H2, COO—C1-8 alkyl, C1-4alkyl-OH, C1-4alkly-SO2NH2, C1-4alkyl CONH2, C1-4alkyl-C(O)NHOH, C1-4alkyl- PO3H2, C1-4alkyl-COOH, and phenyl and the C3-10 cycloalkyl portions of Rh are optionally substituted with 1 to 4 Rw substituents;each Rw substituent is independently selected from C1-4 alkyl, C1-4 alkyl-OH, C1-4 alkyl-COOH, C1-4 alkyl-SO2NH2, C1-4 alkyl CONH2, C1-4 alkyl-C(O)NHOH, C1-4 alkyl-PO3H, OH, COO—C1-8 alkyl, COOH, SO2NH2, CONH2, C(O)NHOH, PO3H2 and oxo;R4 is selected from the group consisting of —O—C1-4 alkyl-pyridyl optionally substituted with 1 to 5 R4a;each R4a is independently selected from the group consisting of halogen, —CN, —CO2Rn, —CONRnRp, —C(O)Rn, —OC(O)NRnRp, —NRnC(O)Rp, —NRnC(O)2Rn, —NRn—C(O)NRnRp, —NRnRp, —ORn, —O—X4—ORn, —O—X4—NRnRp, —O—X4—CO2Rn, —O—X4—CONRnRp, —X4—ORn, —X4—NRnRp, —X4—CO2Rn, —X4—CONRnRp, —SF5, —S(O)2RnRp, —S(O)2NRnRp, and C3-7 cycloalkyl, wherein the cycloalkyl ring is optionally substituted with 1 to 5 Rt, wherein each Rt is independently selected from the group consisting of C1-8 alkyl, C1-8haloalkyl, —CO2Rn, —CONRnRp,—C(O)Rn, —OC(O)NRnRp, —NRnC(O)Rp, —NRnC(O)2Rm, —NRn—C(O)NRnRp, —NRnRp, —ORn, —O—X4—ORn, —O—X4—NRnRp, —O—X4—CO2Rn, —O—X4—CONRnRp, —X4—ORn, —X4—NRnRp, —X4—CO2Rn, —X4—CONRnRp, —SF5, and —S(O)2NRnRp;wherein each X4 is a C1-6 alkylene; each Rn and Rp is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl; each Rm is independently selected from the group consisting of C1-8 alkyl, C2-8 alkenyl, and C1-8 haloalkyl; and optionally when two R4a substituents are on adjacent atoms, they are combined to form a fused five or six-membered carbocyclic ring optionally substituted with oxo;n is 0, 1, 2 or 3;each R5 is independently selected from the group consisting of halogen, —CN, —Rq, —CO2Rr, —CONRrRs, —C(O)Rr, —OC(O)NRrRs, —NRrC(O)Rs, —NRrC(O)2Rq, —NR—C(O)NRrRs, —NRrRs, —ORr, —O—X5—ORr, —O—X5—NRrRs, —O—X5—CO2Rr, —O—X5—CONRrRs, —X5—ORr, —X5—NRrRs, —X5—CO2Rr, —X5—CONRrRs, —SF5, —S(O)2NRrRs, wherein each X5 is a C1-4 alkylene; each Rr and Rs is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl; each Rq is independently selected from the group consisting of C1-8 alkyl, and C1-8 haloalkyl;R6a is selected from the group consisting of H, C1-4 alkyl and C1-4 haloalkyl;m is 0, 1, 2, 3 or 4;each R6b is independently selected from the group consisting of F, C1-4 alkyl, O—Ru, C1-4 haloalkyl, and NRuRv, wherein each Ru and Rv is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl.

US Pat. No. 10,919,851

2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS

ABAC THERAPEUTICS, S.L., ...

1. A compound of formula (I):or a pharmaceutically acceptable salt or solvate thereof,whereinR1 and R2 are independently selected from hydrogen, C1-4alkyl, haloC1-4alkyl and hydroxyC1-4alkyl;R3, R4, R5, R6 and R7 are independently selected from hydrogen, —OH, halogen, C1-6alkoxy, haloC1-4alkoxy, —OC3-6cycloalkylC0-4alkyl, C1-6alkyl, C3-6cycloalkylC0-4alkyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-4alkoxyC1-6alkyl, C1-4alkoxyC1-4alkoxy, —OCOR11, —OS(O2)R11, —NR11R12, —NR11COR12, —NR11CO2R12, —NR11S(O2)R12, —OCONR11R12, —CONR11R12, —S(O2)NR11R12, —S(O2)R11, —CN and —CO2R11; or two of R3 to R7 attached to adjacent carbon atoms are connected to form a 5- or 6-membered cycloalkyl, wherein 1 or 2 methylene groups of the cycloalkyl are optionally replaced by O, said cycloalkyl can be optionally substituted by one or more C1-4alkyl or haloC1-4alkyl;R8 is selected from —OH, C1-6alkyl, haloC1-6alkyl, hydroxyC1-4alkyl, C1-4alkoxyC0-4alkyl, C3-6cycloalkylC0-4alkyl, —C(O)C1-4alkyl, —C(O)C3-6cycloalkylC0-2alkyl, —CONR13R14, —C(NR15)NR11R12 and —CO2R11;R9 is selected from hydrogen, C1-4alkyl and haloC1-4alkyl;n is 0, 1, 2 or 3;each R10, if present, is independently selected from —OH, halogen, C1-6alkyl, haloC1-6alkyl, C1-6alkoxy, C1-4alkoxyC1-6alkyl, —OC3-6cycloalkylC0-4alkyl, —SR11, —NR11R12, —OCOR11, —OS(O2)R11, —NR11COR12, —NR11CO2R12, —NR11S(O2)R12, —OCONR11R12, —CN, phenyl, 5- or 6-membered heteroaryl ring comprising 1 or 2 heteroatoms selected from N, O and S; wherein said phenyl and said heteroaryl rings are optionally substituted by one or more C1-4alkyl or haloC1-4alkyl; or two R10 attached to a common carbon atom form an oxo; or two R10 attached to a common carbon atom form a spiro C3-6cycloalkyl, or two R10 attached to adjacent carbon atoms are connected to form a 3- to 6-membered cycloalkyl, said cycloalkyl is optionally substituted by one or more substituents independently selected from C1-4alkyl, haloC1-4alkoxy, haloC1-4alkyl and halogen;each R11 and R12 are independently selected from hydrogen, C1-4alkyl, haloC1-4alkyl and C3-6cycloalkylC0-4alkyl;each R13 and R14 are independently selected from hydrogen, C1-4alkyl, C3-6cycloalkylC0-4alkyl and Het3-6, wherein each C1-4alkyl and C3-6cycloalkylC0-4alkyl are optionally substituted by one or more R16, and wherein each C1-4alkyl are optionally substituted by one or more Het3-6; or R13 and R14 form, together with the N atom to which they are attached, a 4- to 6-membered saturated heterocycle, which optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C1-4alkyl, haloC1-4alkyl and —C(O)C1-4alkyl;R15 is selected from hydrogen, C1-6alkyl, haloC1-6alkyl, —CN, —CONR11R12, —S(O2)R11, —SOR11 and —S(O2)NR11R12;each R16 is independently selected from alkyl, halogen, —CN, —CO2R11, —OR11, —SR11, —NR17R18, —CONR17R18 and —OCOR11;Het3-6 is a 3- to 6-membered saturated monocyclic heterocyclic ring containing one heteroatom selected from O, S and N, wherein said ring is bonded to the rest of the molecule through any available C atom and wherein said ring is optionally substituted by one or more substituents independently selected from C1-4alkyl and haloC1-4alkyl; andeach R17 and R18 are independently selected from hydrogen, C1-4alkyl and haloC1-4alkyl, or R17 and R18 form, together with the N atom to which they are attached, a 4-to 6-membered saturated heterocycle, which can optionally contain one additional heteroatom selected from N, S and O, said heterocycle can be optionally substituted by one or more substituents independently selected from C1-4alkyl and haloC1-4alkyl;and wherein the following are excluded:tert-butyl (S)-2-(2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxylate,tert-butyl (R)-2-(1-methyl-2-phenylhydrazine-1-carbonyl)pyrrolidine-1-carboxylate,tert-butyl (2S,4S)-4-mercapto-2-(2-(3-sulfamoylphenyl)hydrazine-1-carbonyl) pyrrolidine-1-carboxylate,3-(2-((2S,4S)-1-(tert-butoxycarbonyl)-4-mercaptopyrrolidine-2-carbonyl)hydrazinyl) benzoic acid,tert-butyl (2S,4S)-4-mercapto-2-(2-(2-(trifluoromethyl)phenyl)hydrazine-1-carbonyl) pyrrolidine-1-carboxylate, andtert-butyl (2S,4S)-2-(2-(2-chloro-5-(trifluoromethyl)phenyl)hydrazine-1-carbonyl)-4-mercaptopyrrolidine-1-carboxylate.

US Pat. No. 10,919,850

COVALENT INHIBITORS OF KRAS G12C

ARAXES PHARMA LLC, San D...

1. A method for treating a cancer mediated by a K-Ras G12C, H-Ras G12C or N-Ras G12C mutation, the method comprising administering an effective amount of a compound having the following structure (VI):or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, to a subject in need thereof, wherein:A is CR37b, N or NR38a;
B is CR37c, N, NR38b or S;
C is CR37d, N, NR38c or S;
G3 and G4 are each independently N or CR, wherein R is H, cyano, halo or C1-C6alkyl;
L1a is a bond, —NH—, alkylene or heteroalkylene;
L2 is a bond or alkylene;
R32a and R32b are, at each occurrence, independently H, —OH, —NH2, —CO2H, cyano, cyanoalkyl, C1-C6alkyl, C3-C8cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R32a and R32b join to form a carbocyclic or heterocyclic ring; or R32a is H, —OH, —NH2, —CO2H, cyano, C1-C6alkyl, C3-C8cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R32b joins with R33b to form a carbocyclic or heterocyclic ring;
R33a and R33b are, at each occurrence, independently H, —OH, —NH2, —CO2H, cyano, cyanoalkyl, C1-C6alkyl, C3-C8cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl; or R33a and R33b join to form a carbocyclic or heterocyclic ring; or R33a is H, —OH, —NH2, —CO2H, cyano, C1-C6alkyl, C3-C8cycloalkyl, hydroxylalkyl, aminoalkyl, carboxylalkyl or aminocarbonyl and R33b joins with R32b to form a carbocyclic or heterocyclic ring;
R37a, R37b, R37c, R37d and R37e are each independently H, halo, oxo, hydroxyl, cyano, aminocarbonyl, formyl, C1-C6alkyl, C1-C6alkylsulfonyl, C1-C6haloalkyl, C3-C8cycloalkyl, C1-C6alkoxy, C1-C6hydroxylalkyl, C1-C6alkoxyalkyl, C1-C6aminoalkyl, heterocyclyl or aryl;
R38a, R38b and R38c are each independently H, C1-C6alkyl or aryl;
n3 and n4 are each independently 1, 2 or 3;
m is 0 or 1;
is a single or double bond such that all valences are satisfied; and
E is an electrophilic moiety capable of forming a covalent bond with the cysteine residue at position 12 of a K-Ras, H-Ras or N-Ras G12C mutant protein.

US Pat. No. 10,919,849

ONLINE CONTINUOUS FLOW PROCESS FOR THE PREPARATION OF ORGANIC PEROXIDES DIRECT FROM ALCOHOLS OR ALKANES

SHANGHAI HYBRID-CHEM TECH...

1. An online continuous flow production method for the preparation of organic peroxides direct from alcohols or alkanes, comprising:feeding reaction substrate, oxidant and condensation agent into inlets of an integrated continuous flow reactor; and
obtaining an organic peroxide by oxidation condensation and workup;
wherein the organic peroxides are selected from the group consisting of carboxylate peroxide, carbonate peroxide, and ketal peroxide;
the reaction substrate is alcohol or alkane, and the condensation agent is alkali liquor and acyl compound during the production of carboxylate peroxide and carbamate peroxide;
in the production of ketal peroxide, the reaction substrate is acid solution and condensation raw material, and the condensation raw material is alcohol or ketone;
the general formula of a production process in the integrated continuous flow reactor is as follows:

wherein, A1 is alcohol or alkane; A2 is selected from the group consisting of acyl chloride, chloroformate, alcohol and ketone, oxidant is selected from the group consisting of hydrogen peroxide and oxygen; C is selected from the group consisting of carboxylate peroxide, carbonate peroxide and ketal peroxide.

US Pat. No. 10,919,848

PROCESS FOR PREPARING METHIONINE

Evonik Operations GmbH, ...

1. A process for preparing methionine, comprising:alkaline hydrolyzing of 5-(2-methylmercaptoethyl)-hydantoin in an aqueous process solution, comprising alkali metal hydroxide, alkali metal carbonate, and/or alkali metal hydrogen carbonate to form methionine alkali metal salt,
treating the methionine alkali metal salt with carbon dioxide to yield precipitated methionine,
separating the precipitated methionine from the aqueous process solution which was treated with carbon dioxide,
concentrating an aqueous process solution from which methionine has been removed, and
recycling of a concentrated aqueous process solution in the alkaline hydrolyzing of 5-(2-methylmercaptoethyl)-hydantoin to the aqueous process solution,
wherein alkali metal cations in the aqueous process solution of alkaline hydrolyzing are potassium and sodium, having a K/Na molar ratio range from 99/1 to 20/80.

US Pat. No. 10,919,847

PROCESS FOR THE PREPARATION OF ARYLSULFONYLPROPENENITRILES BY PHOTOCATALYTIC REACTIONS

Kemira Oyj, Helsinki (FI...

1. A process for a preparation of a compound of a general formula (I)
wherein R1, R2 and R3 independently represent a hydrogen atom, a halogen atom, a hydroxy group, an amino group, an alkylamino group, an alkyl group, a hydroxyalkyl group, a haloalkyl group or an alkoxy group having 1 to 4 carbon atoms, or an acylamido group having 1 to 10 carbon atoms, said process comprising steps of:
i) mixing a sulfonyliodide and acrylonitrile in a solvent;
ii) initiating a radical reaction after step i) by irradiation with visible light;
iii) quenching the reaction; and
iv) adding a base to eliminate an iodide to form a desired product,
wherein the solvent is propylene carbonate and comprises 3% to 10% (V/V) water and the reaction is performed at a temperature of 25° C.-50° C.

US Pat. No. 10,919,846

UREA PRODUCTION PROCESS AND PLANT WITH HEAT INTEGRATION IN LOW PRESSURE RECOVERY SECTION

Stamicarbon B.V., Sittar...

1. A urea production process comprising:A) subjecting ammonia and carbon dioxide to urea-forming conditions in a high pressure reaction zone thereby forming a first urea solution which also comprises carbamate,
B) subjecting the first urea solution to high pressure stripping to decompose carbamate using heat, thereby forming a gas stream and a second urea solution also containing carbamate, and subjecting said gas stream to condensation in a high pressure carbamate condenser, thereby forming a first carbamate-containing solution and releasing heat of condensation, wherein the carbamate-containing solution is supplied to the high pressure reaction zone,
C) subjecting said second urea solution to low pressure carbamate decomposition, or first processing said second urea solution at medium pressure and subjecting the processed second urea solution to low pressure decomposition, wherein said low pressure carbamate decomposition involves heating in a low pressure decomposer the urea solution containing carbamate using said heat of condensation from the high pressure carbamate condenser to decompose carbamate, thereby giving a first vapor and a third urea solution also containing carbamate, and expanding the third urea solution to a sub-atmospheric pressure thereby obtaining an expanded third urea solution,
D) subjecting said first vapor to condensation in a first low pressure carbamate condenser, thereby obtaining a second carbamate-containing solution and second vapor and releasing additional heat of condensation, wherein the first low pressure carbamate condenser has an outlet for the second carbamate-containing solution in liquid communication with an inlet of the high pressure reaction zone,
and subjecting said expanded third urea solution to decomposition of carbamate in a sub-atmospheric decomposer using said additional heat of condensation from said first low pressure carbamate condenser by heat transfer through a heat-exchanging wall between said first low pressure carbamate condenser and said sub-atmospheric decomposer, thereby obtaining a fourth urea solution and a third vapor, and
E) subjecting said third vapor to condensation in a sub-atmospheric carbamate condenser, in indirect heat exchange with cooling fluid, thereby obtaining a fourth carbamate-containing solution.

US Pat. No. 10,919,845

CLEANING DEVICE FOR GAS FLOWS FROM ISOCYANATE PRODUCTION

Covestro Deutschland AG, ...

1. A cleaning apparatus for separating an organic isocyanate prepared by reacting an organic amine with a stoichiometric excess of phosgene in the gas phase from the gaseous crude product obtained in the reaction, comprising a first separating unit having at leasta crude product inlet for a gaseous crude product stream containing at least the isocyanate, hydrogen chloride and unconverted phosgene,
a first liquid inlet for a liquid stream containing at least a quench liquid and
a first liquid outlet for a liquid stream containing at least some of the quench liquid and at least some of the isocyanate,wherein a first gas conduit for conveying a gas stream containing at least hydrogen chloride, evaporated quench liquid and phosgene departs from the first separation unit, andwherein at least one addition unit for direct introduction of at least one cooling fluid for an at least partial condensation and/or absorption of the gas stream conductible through the first gas conduit is assigned to the first gas conduit.

US Pat. No. 10,919,844

ANTIBACTERIALS AND/OR MODULATORS OF BIOFILM FORMATION AND METHODS OF USING THE SAME

Indiana University Resear...

1. A method for reducing the growth of bacteria, comprising the steps of:treating bacteria with at least one compound of the formula:

wherein:
R1 is selected from the group consisting of: benzyl substituted with 1 to 3 halogens, C1-C6 alkyl, C1-C6 alkoxy, —NH2, —NO2, —CN, or —CF3, and phenyl substituted with 1 to 3 halogens, C1-C6 alkyl, C1-C6 alkoxy, —NH2, —NO2, —CN, or —CF3;
R2 is NR3R4;
R3 is H;
R4 is —(CH2)n—R5;
R5 is methyl, —OH, —CF3, morpholinyl, pyridinyl, or phenyl substituted with 1 to 3 halogen, C1-C6 alkyl, C1-C6 alkoxy, —OH, —NH2, —NO2, —CN, or —CF3; and
n is 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,919,843

CANNABIDIOL DERIVATIVES AS INHIBITORS OF THE HIF PROLYL HYDROXYLASES ACTIVITY

Emerald Health Pharmaceut...

1. A method of treating a condition that benefits from the inhibition of the hypoxia-inducible factor (HIF) propyl hydroxylases (PDHs) activity, wherein the condition that benefits from the inhibition of the HIF PHDs activity is independently selected from the group consisting of stroke, traumatic injuries, anemia, myocardial ischaemia-reperfusion injury, acute lung injury, diabetic and chronic wounds, organ transplantation, acute kidney injury, and arterial diseases; the method comprising administering a compound of Formula (I), or pharmaceutically acceptable salts thereof,
to a subject in need thereof,
wherein R is the carbon atom of a group, represented by aryl, linear or branched alkenyl, linear or branched alkynyl, acyl, or alkoxycarbonyl groups; or
wherein R is the nitrogen atom of a group, represented by linear or branched alkylamine, an arylamine, a linear or branched alkenylamine or a linear or branched alkynylamine.

US Pat. No. 10,919,842

CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE

THE UNITED STATES OF AMER...

1. A crystalline form of (2R,6R)-hydroxynorketamine hydrochloridewherein the crystalline form of (2R,6R)-hydroxynorketamine hydrochloride is characterized byexhibiting a XRPD spectra with characteristic peaks at any combination of at least 5, at least 8, at least 10, or at least 12 of the following (2?) values: 12.1, 13.6, 14.1, 15.1, 15.6, 16.9, 18.0, 19.2, 19.5, 20.8, 22.1, 23.5, 24.0, 24.3, 24.6, 24.8, 25.2, 26.4, 27.0, 27.4, 27.7, 28.1, 29.9, 30.2, 31.5, 31.9, 32.4, 32.7, 33.5, 34.7, 36.5, 37.1, 37.7, 38.3, 38.7, 39.1, and 39.6.

US Pat. No. 10,919,841

MONOAMINE REUPTAKE INHIBITORS

Research Triangle Institu...

1. A compound according to the structure:
wherein:
R1-R5 Are each independently selected from H, OH, optionally substituted C1-4 alkyl, optionally substituted C1-3 alkoxy, optionally substituted C2-4 alkenyl, optionally substituted C2-4 alkynyl, halo, amino, acylamido, CN, CF3, NO2, N3, CONH2, CO2R12, CH2OR12, NR12R13, NHCOR12, NHCO2R12, CONR12R13; C1-3 alkylthio, R12SO, R12SO2, CF3S, and CF3SO2;
R8 is methyl or ethyl and R9 is H or optionally substituted C1-10 alkyl;
R10 is optionally substituted cyclobutyl and R11 is H or optionally substituted C1-10 alkyl;
R12 and R13 are each independently H or optionally substituted C1-10 alkyl,
or a pharmaceutically acceptable ester, amide, salt, solvate, prodrug, or stereoisomer thereof.

US Pat. No. 10,919,840

DIAMINE CROSSLINKING AGENTS, CROSSLINKED ACIDIC POLYSACCHARIDES AND MEDICAL MATERIALS

SEIKAGAKU CORPORATION, T...

1. A crosslinked acidic polysaccharide obtained by forming crosslinks by amide bonding between primary amino groups in a diamine or a polyamine crosslinking agent and carboxyl groups in an acidic polysaccharide;wherein the crosslinking agent has the general formula (I) below:

where the number of atoms in the linear chain between the primary amino groups at both terminals is 5 to 12, X and Y are each independently a single bond, a substituted or unsubstituted alkanediyl group, a substituted or unsubstituted alkenylene group, or a substituted or unsubstituted alkynylene group, with the proviso that X and Y are not single bonds at the same time;
Z is an oxygen atom or a sulfur atom;
R1 is a hydrogen atom, a CONR3R4 group, a COOR5 group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, or a substituted or unsubstituted alkynyl group;
R2 consists of a hydrogen atom, a —CONR3R4 group, a —COOR5? group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, or a substituted or unsubstituted alkynyl group, wherein R5? is an alkyl group optionally substituted with phenyl group;
any —CH2— in X or Y, if present, is optionally substituted with one or more groups selected from the group consisting of an amide group (—CONH—), an ester group (—C(?O)—O—), an ether group (—O—), an imino group (—NH—) and a phenylene group, wherein the ester group, the amide group, the ether group or the imino group present in X or Y is not directly adjacent to —CO—Z— in the formula (I);
any —CH2— in R1 or R2, if present, is optionally substituted with one or more groups selected from the group consisting of >C?O, —CONH—, arylene, —O—, —NR6— and —S—;
R3, R4, R5 and R6 are each independently a hydrogen atom or an alkyl group optionally substituted with phenyl group;
the substituent in X and Y is selected from the group consisting of an hydroxyl group, an alkyl group having 1 to 6 carbon atom and a halogen atom;
the substituent in R1 and R2 is selected from the group consisting of a hydroxyl group, an alkyl group having 1 to 6 carbon atom, a phenyl group, an indolyl group, a diazolyl group, a —(CH2)n—NHMe group, a —(CH2)n—NMe2 group, a —(CH2)n—CONR3R4 group, a —(CH2)n—COOR5 group, a —S-Me group, and a —SH group, wherein n is, independently, an integer of 0 to 4, and
wherein the polyamine crosslinking agent has a structure in which at least one of the substituents in X and Y or at least one of R1 and R2 in the general formula (I) comprises a biodegradable site and a terminal primary amino group.

US Pat. No. 10,919,839

SILICON-CONTAINING COMPOSITIONS AND THEIR METHODS OF USE

Aditya Birla Chemicals (U...

1. A compound of Formula (I-A-iv)
or a salt thereof, wherein:
z is an integer from 1 to 6;
t is an integer from 0 to 1;
q1 is an integer from 1 to 4;
q2 is an integer from 1 to 3;
each of R4A, R4B, R4C, and R4D is independently for each occurrence hydrogen or alkyl; and each occurrence of R5A is independently alkyl, cycloalkyl, aryl, or —ORC, wherein RC is alkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, cycloalkenyl, aryl or heteroaryl, provided that the sum of t, q1, and q2 is 4.

US Pat. No. 10,919,838

PRODUCTION OF TRI-METHYL BENZENE DERIVATIVES

RHODIA OPERATIONS, Auber...

1. A process for the preparation of a compound of Formula (I)
wherein
X and Y independently are optionally substituted heteroatoms;
each R2 independently is H, alkyl, alkenyl or aryl;
R3 and R4 independently are H or —CN, provided that at least one of R3 and R4 is —CN; the process comprising
a.) dehydration/aromatization of a compound of the Formula (II)

wherein
X and Y independently are optionally substituted heteroatoms;
R is a C1-4 alkylene group which may optionally be substituted with one or more R1;
R1 is a linear, branched and/or cyclic, saturated or unsaturated hydrocarbon group which optionally bears one or more functional groups;
R2 independently is H, alkyl, alkenyl or aryl; and
R3 and R4 independently are H or —CN, provided that at least one of R3 and R4 is —CN;
to obtain a compound of the Formula (III)

wherein X, Y, R, R2, R3 and R4 are defined as above;
followed by deprotection of the compound of Formula (III);
or
b.) carrying out the dehydration/aromatization and the deprotection of the compound of Formula (II) in a single step.

US Pat. No. 10,919,837

PRODUCTION OF AMINES UTILIZING ZEOLITE CATALYSTS

RHODIA OPERATIONS, Auber...

1. A process for forming a primary or a secondary amine, comprising reacting:A first reactant having 5-30 carbon atoms and one or two primary hydroxyl functionalities, with
A second reactant being NH3 or a reactant having primary amine functionality,
in the presence of at least one zeolite comprising a transition metal selected from the group consisting of Ru, Rh, Pd, and any combination thereof, and
wherein the reaction is conducted on a gas-liquid-solid tri-phase reactor connected with a condense column and a collection tank, and wherein the gas pressure is from 0 barg to 10 barg.

US Pat. No. 10,919,835

COMPOUNDS AND SYNTHETIC METHODS FOR THE PREPARATION OF RETINOID X RECEPTOR-SPECIFIC RETINOIDS

Io Therapeutics, Inc., H...

1. A method of making Compound 38,
or a pharmaceutically acceptable salt thereof,comprising a synthetic process of preparing intermediate compound 8, (Z)-3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)but-2-en-1-ol, of Formula (XII),
or a solvate thereof,by reacting compound 4, sodium (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)boronate of Formula (XVI),
or a solvate thereof,with compound 7, (Z)-3-iodobut-2-en-1-ol, of Formula (XVII),
or a solvate thereof,in the presence of Pd/C and a base, such that the compound of Formula (XII) or a solvate thereof is prepared.

US Pat. No. 10,919,827

PROCESS FOR RECOVERING 3-METHYLBUT-3-EN-1-OL

BASF SE, Ludwigshafen am...

1. A process for recovering 3-methylbut-3-en-1-ol from a feed stream F1 comprising 3-methylbut-3-en-1-ol, one or more solvents selected from the group consisting of 1-pentanol, 2-hexanol, 2-methyl-hexanol, 4-methyl-hexanol, 3-methyl-hexanol, 3-ethylhexanol, 4-heptanol, 2-methyl-2-heptanol, 3-heptanol, 2-heptanol, 3-ethyl-3-hexanol, 3-methyl-2-heptanol, 2-methyl-4-heptanol, 4-ethyl-4-heptanol, 2-octanol, 2-ethylhexanol, propanediol, glycol, 1,4-butanediol, cyclo-2-penten-1-one, cyclohexanone, cycloheptanone, methanol, ethanol, tert-butanol, 2-propanol, 1-propanol, 2-methyl-2-butanol, isobutanol, 3-pentanol, 1-butanol, 2-pentanol, acetone, 2-butanone, 2-pentanone, ethyl acetate, and acetonitrile, water, and isobutene, the process comprising(i) subjecting a feed stream F1 to distillation in a first distillation unit (K1200), obtaining a bottoms stream B1 (Su K1200) comprising 3-methylbut-3-en-1-ol, one or more solvents and water, and a top stream T1 (De K1200) comprising isobutene;
(ii) subjecting the bottoms stream B1 (Su K1200) to distillation in a second distillation unit (K1300), obtaining a bottoms stream B2 (Su K1300) comprising 3-methylbut-3-en-1-ol and one or more solvents and a top stream T2 (De K1300) comprising water;
(iii) subjecting the bottoms stream B2 to distillation in a third distillation unit (K1500), obtaining a top stream T3 (De K1500) comprising 3-methylbut-3-en-1-ol and a bottoms stream B3 (Su K1500) comprising one or more solvents;
wherein the bottoms stream B1 (Su K1200) is enriched in methylbut-3-en-1-ol, in the one or more solvents and in water relative to the feed stream F1, wherein the bottoms stream B2 (Su 1300) is enriched in methylbut-3-en-1-ol relative to the bottoms stream B 1, wherein the top stream T3 (De K1500) is enriched in methylbut-3-en-1-ol relative to the bottoms stream B2(Su K1300).

US Pat. No. 10,919,826

PROCESS FOR THE CONVERSION OF SYNTHESIS GAS TO ISOBUTANOL

UOP LLC, Des Plaines, IL...

1. A method of making isobutanol comprising:introducing a first synthesis gas stream into a first reaction zone in the presence of a first heterogeneous catalyst to produce a reaction mixture comprising a mixture of alcohols comprising methanol and a substantial amount of ethanol and propanol, wherein a weight ratio of ethanol and propanol to methanol is greater than 0.2:1 thereof;
separating the reaction mixture into at least a first stream consisting essentially of the methanol, and a second stream consisting essentially of the ethanol and propanol; and
introducing a second synthesis gas stream and at least a portion of the second stream into a second reaction zone in the presence of a second heterogeneous catalyst to produce isobutanol.

US Pat. No. 10,919,825

MEMBRANE-BASED PROCESS FOR BUTANOLS PRODUCTION FROM MIXED BUTENES

SAUDI ARABIAN OIL COMPANY...

1. A system of separately producing tert-butanol and sec-butanol, the system comprising:a reaction membrane unit, the reaction membrane unit comprising:
a membrane, the membrane configured to allow selective gases in a mixed butenes stream to permeate through from a tube side of the membrane to a shell side of the membrane, wherein retentate gases remain on the tube side of the membrane, wherein the mixed butenes stream comprises butene gases,
the tube side of the membrane, defined by the membrane such that the tube side is enclosed within the membrane, the tube side comprising a TBA catalyst, wherein the tube side operates at a SBA reaction temperature, wherein the retentate gases react with water in a TBA reactor water feed in the presence of the TBA catalyst to produce tert-butanol, wherein the retentate gases comprise isobutene, wherein the tert-butanol exits the tube side as a TBA reactor effluent; and
the shell side of the membrane, the shell side comprising an SBA catalyst, wherein the selective gases react with water in an SBA reactor water feed in the presence of the SBA catalyst to produce sec-butanol, wherein the shell side operates at an SBA reaction temperature, wherein the selective gases are selected from the group consisting of 1-butene, 2-butene, and combinations of the same, wherein the sec-butanol is collected by a sweep gas to produce a SBA reactor effluent, wherein the sweep gas is selected from the group consisting of nitrogen, argon, other noble gases, and combinations of the same.

US Pat. No. 10,919,824

COMPOSITIONS OF CHROMIUM OXYFLUORIDE OR FLUORIDE CATALYSTS, THEIR PREPARATION AND THEIR USE IN GAS-PHASE PROCESSES

ARKEMA FRANCE, Colombes ...

1. A process for modifying the fluorine distribution in a hydrocarbon compound in the presence of a catalyst, the catalyst being a solid composition containing at least one component containing chromium oxyfluoride or fluoride of empirical formula CrxM(1-x)OrFs,wherein
2r+s is greater than or equal to 2.9 and less than 6,
M is a metal chosen from the group consisting of Zn, Mg, Co, Mn and Ni,
x has a value from 0.9 to 0.999,
s is greater than 0 and less than or equal to 6,
and r is greater than or equal to 0 and less than 3,
wherein the solid composition has a crystallinity of less than 20% by weight; and
wherein the fluorine content of the hydrocarbon compound is increased by reacting the hydrocarbon compound with hydrogen fluoride in the gas phase in the presence of the solid composition, the hydrocarbon compound being a saturated halogenated hydrocarbon or an unsaturated halogenated hydrocarbon or an unsaturated hydrocarbon.

US Pat. No. 10,919,822

DUAL CATALYST PROCESSES AND SYSTEMS FOR PROPYLENE PRODUCTION

Saudi Arabian Oil Company...

1. A multiple-stage catalyst system for producing propylene from butene, the multiple-stage catalyst system comprising a feed stream, a metathesis reaction zone and a cracking reaction zone directly downstream of the metathesis reaction zone, where:the metathesis reaction zone comprises a metathesis catalyst comprising a mesoporous silica-alumina catalyst support impregnated with at least one metal oxide, the mesoporous silica-alumina catalyst support comprising from 5 weight percent to 50 weight percent alumina;
the cracking reaction zone comprises a cracking catalyst comprising an MFI structured silica-containing catalyst, where the MFI structured silica-containing catalyst directly cracks a metathesis product stream to form a cracking product stream comprising propylene; and
the feed stream to the multiple-stage catalyst system comprises from 20 wt. % to 60 wt. % of cis- or trans-2-butene, or both, from 10 wt. % to 20 wt. % of 1-butene, and from 5 wt. % to 20 wt. % n-butene.

US Pat. No. 10,919,821

PROCESS AND PLANT FOR PRODUCING AN OLEFIN

LINDE AKTIENGESELLSCHAFT,...

1. Process for producing an olefin in which a reaction input stream containing at least one paraffin, oxygen and water, is formed and in which a portion of the paraffin and of the oxygen in the reaction input stream is converted into the olefin by oxidative dehydrogenation using a catalyst to obtain a process gas, wherein the process gas contains at least the unconverted portion of the paraffin and of the oxygen, the olefin and the water from the reaction input stream, characterized in that at least one parameter is determined and that an amount of the water in the reaction input stream is adjusted on the basis of the at least one determined parameter, wherein said at least one parameter is acitvity of the catalyst.

US Pat. No. 10,919,820

PROCESS TO PREPARE PROPYLENE

GASOLFIN B.V., Amersfbor...

1. A process for preparing propylene from a hydrocarbon feedstock fraction comprising between 5 and 50 wt % olefin hydrocarbon compounds having 4 or more carbon atoms, the process comprising:isolating the hydrocarbon feedstock from an effluent of a fluid catalytic cracking process;
contacting the hydrocarbon feedstock fraction with a mixture of a heterogeneous cracking catalyst and a heterogeneous dehydrogenation catalyst obtain propylene and other reaction products;
wherein the heterogeneous cracking catalyst and the heterogeneous dehydrogenation catalyst are present as separate particles in one or more packed beds in an in-series configuration, each packed bed comprising the heterogeneous cracking catalyst and the heterogeneous dehydrogenation catalyst;
wherein the hydrocarbon feedstock fraction, the propylene, and the other reaction products flow from an up-flow region to a down-flow region following a flow path;
wherein in the direction of the flow path a concentration of the heterogeneous dehydrogenation catalyst in the one or more packed beds gradually or step-wise increases compared to the heterogeneous cracking catalyst; and
wherein a content in the volume percent of the heterogeneous dehydrogenation catalyst particles relative to the total volume of catalyst particles varies from between 0% to 50% at a start of the flow path to between 20% and 100% at an end of the flow path.

US Pat. No. 10,919,819

OLIGOMERIZATION OF ETHYLENE

SK Innovation Co., Ltd., ...

1. A method for oligomerization of ethylene, the method comprising:mixing an aluminoxane and an alkyl aluminum compound to prepare a cocatalyst mixture;
introducing the cocatalyst mixture and a oligomerization catalyst including a transition metal into a reactor;
introducing ethylene into the reactor; and
reacting the oligomerization catalyst, the cocatalyst mixture, and the ethylene in the reactor with each other,
wherein the oligomerization catalyst is a complex in which the transition metal and a heteroatom ligand represented by Chemical Formula 2 below are coordinated to each other

where, in Chemical Formula 2, R11 to R14 are each independently substituted or unsubstituted hydrocarbyl or substituted or unsubstituted heterohydrocarbyl; and
R15 and R16 are each independently substituted or unsubstituted hydrocarbyl, or R15 and R16 may be bonded to each other to form a ring.

US Pat. No. 10,919,818

AUTO-IGNITION COMPOSITION

Joyson Safety Systems Acq...

1. An auto-ignition composition consisting of:a nonmetal perchlorate as a first oxidizer;
a secondary oxidizer selected from the group consisting of metal oxides, alkali metal nitrates, alkaline earth metal nitrates, and mixtures thereof, provided at about 12.5-30 weight percent of the total composition;
a first fuel selected from the group consisting of maleic hydrazide and salts thereof, and mixtures thereof, said first fuel provided at about 5-15 weight percent of the total composition; and
a second nitrogen-containing fuel selected from the group consisting of acidic tetrazoles, acidic triazoles, guanidine, nitroguanidines, guanidine salts, guanidine derivatives, and mixtures thereof,
wherein the composition has an auto-ignition temperature of 200° C. or less.

US Pat. No. 10,919,817

PROCESS AND EQUIPMENT FOR HIGH-SPEED RECYCLING AND TREATMENT OF ORGANIC WASTES AND GENERATION OF ORGANIC FERTILIZER THEREBY

1. A method for producing organic fertilizers from organic solid waste material, comprising(1) pre-treating waste material, the pretreatment further comprising the steps of storing the waste material comprising one or mixtures of municipal solid wastes, restaurant wastes, gardening wastes, agricultural wastes, and dead animals,
mechanically pretreating the waste material,
wet pulping the stored waste material,
recovering metals, glass, sands, bones, and plastics from the mechanically pretreated and wet pulped waste material,
recovering wet pulps and food slurries from the mechanically pretreated and wet pulped waste material and forming wet pulps and food slurries, and
storing the wet pulps and food slurries in a storage tank;
(2) stabilizing and activating the wet pulps and food slurries and organic waste material that do not need pretreatment, the organic waste material that do not need pretreatment comprising one or mixtures of sludge, animal wastes, night soils, anaerobic digesting residues, and landfill leachates, by
mixing and adjusting temperature and moisture in the wet pulps and food slurries and the organic waste material that do not need pretreatments to obtain mixed and adjusted organic waste material,
multi-conditioning the mixed and adjusted organic waste material to obtain multi-conditioned organic waste material, wherein the mixed and adjusted organic waste material are treated for solubilization and destruction of easily degradable organics, loosening of lignocellulose fibers, sterilization of pathogens, destruction of weed seeds, dissolution of heavy metals, and conditioning for organic radical generation,
waste curing the multi-conditioned organic waste material to obtain cured organic waste material, wherein the multi-conditioned organic waste material are treated for release of nutrients, generation of heat energy, destruction of toxic organics, generation of humic substances, and plant-grow-stimulating agents, and
dewatering the cured organic waste material, wherein solid and liquid contents in the organic waste material are separated, to generate solid and liquid organic fertilizers, and
(3) refining the solid and liquid organic fertilizers, the refining process further comprising the steps of
activating and steam exploding, and nutrients adjustments of solid fertilizers, and
concentrating, catalytic oxidizing and nutrient adjustments of liquid fertilizers,
wherein refined organic solid and liquid fertilizers are generated.

US Pat. No. 10,919,815

METHOD AND SYSTEM FOR COMPOUNDING FERTILIZER FROM MANURE WITHOUT NUTRIENT EMISSION

Dari-Tech, Inc., Lynden,...

21. A method for compounding fertilizer from liquid manure without releasing nutrients into the ambient environment, the method comprising:centrifugally separating liquid manure into nutrients as a liquid centrate and a generally organic matter cake:
evaporating a vapor containing ammonia from the liquid centrate by means of mechanical vapor recompression (MVR) to produce a nutrient sludge; and
producing a combustible gas by either one of digesting or gasifying the generally organic matter cake.

US Pat. No. 10,919,813

SYSTEM AND METHOD FOR EXPOSED AGGREGATE ARCHITECTURAL COATING FOR EXISTING CONCRETE STRUCTURES

FIRMECRETE INC., Ontario...

1. A method for preparing and applying an exposed aggregate architectural coating, comprising:preparing a first composition by combining 41 to 50 percent sand with 50 to 59 percent cement;
preparing a second composition by combining 75 to 86 percent water with 14 to 25 percent glue;
combining the first composition with the second composition to form an exposed aggregate architectural coating;
preparing a pre-existing cement structure to create a roughened surface having a concrete surface profile of three or greater; and
applying the exposed aggregate architectural coating to the roughened surface of the pre-existing cement structure by evenly spreading the exposed aggregate architectural coating onto the roughened surface to create an even thickness of the exposed aggregate architectural coating, wherein the exposed aggregate architectural coating forms a thickness of between 1/32nd of an inch and one-fourth of an inch above the roughened surface, wherein combining the first composition with the second composition to form the exposed aggregate architectural coating occurs prior to applying the exposed aggregate architectural coating to the roughened surface of the pre-existing cement structure.

US Pat. No. 10,919,810

CEMENTED CARBIDE AND COATED CEMENTED CARBIDE

TUNGALOY CORPORATION, Iw...

1. A cemented carbide comprising: a hard phase containing tungsten carbide as its main component; a binder phase containing an element of at least one kind selected from the group consisting of Co, Ni and Fe as its main component; and a composite compound phase, wherein:based on total contents of the hard phase, the binder phase and the composite compound phase in the cemented carbide, a content ratio of the hard phase is from 70 volume % or more to 85 volume % or less, a content ratio of the binder phase is from 7.0 volume % or more to 17.0 volume % or less, and a content ratio of the composite compound phase is from 5.0 volume % or more to 15.0 volume % or less;
the composite compound phase comprises an aggregate;
the aggregate comprises a small-diameter aggregate having a longest diameter of from 10 ?m or more to below 30 ?m and a large-diameter aggregate having a longest diameter of 30 ?m or more;
the small-diameter aggregate containing at least one kind from among a carbide, a nitride and a carbonitride of an element of one kind selected from the group consisting of Ti, Zr, Hf, V, Nb, Ta, Cr and Mo as its main component;
the large-diameter aggregate containing at least one kind from among a carbide, a nitride and a carbonitride of an element of one kind selected from the group consisting of Ti, Zr, Hf, V, Nb, Ta, Cr and Mo as its main component;
a cross-sectional structure of a surface region which ranges inward from a surface of the cemented carbide to a depth of 100 ?m satisfies a condition represented by formula (1A) below; and
a cross-sectional structure of an inner region further inward than the surface region satisfies a condition represented by formula (2A) below
0.5?SSDA?4.0  (1A)
1.0?ILDA?6.0  (2A)
SSDA refers to a ratio (unit:area %) of a surface region cross-sectional area of the small-diameter aggregate based on a total cross-sectional area of the composite compound phase,
ILDA refers to a ratio (unit:area %) of an inner region cross-sectional area of the large-diameter aggregate based on a total cross-sectional area of the composite compound phase.

US Pat. No. 10,919,809

MNZN FERRITE AND ITS PRODUCTION METHOD

HITACHI METALS, LTD., To...

1. A method for producing MnZn ferrite comprising Fe, Mn and Zn as main components, and Ca, Si and Co, and at least one selected from the group consisting of Ta, Nb and Zr as sub-components, comprisinga step of molding a raw material powder for said MnZn ferrite to obtain a green body, and
a step of sintering said green body;
said sintering step comprising a temperature-elevating step, a high-temperature-keeping step, and a cooling step;
said cooling step including a slow cooling step of cooling in a temperature range of 1100° C. to 1250° C. at a cooling speed of 0° C./hour to 20° C./hour for 1 hours to 20 hours, and
a cooling speed before and after said slow cooling step being higher than 20° C./hour;
said MnZn ferrite having a volume resistivity of 8.5 ?·m or more at room temperature, an average crystal grain size of 7 ?m to 15 ?m and core loss of 420 kW/m3 or less between 23° C. and 140° C. at a frequency of 100 kHz and an exciting magnetic flux density of 200 mT.

US Pat. No. 10,919,808

GYPSUM COMPOSITION COMPRISING UNCOOKED STARCH HAVING MID-RANGE VISCOSITY, AND METHODS AND PRODUCTS RELATED THERETO

UNITED STATES GYPSUM COMP...

1. A gypsum board comprising:a set gypsum core disposed between two cover sheets, the core formed from a slurry comprising stucco, water, and at least one uncooked non-substituted starch having a peak viscosity of from about 120 Brabender Units to about 900 Brabender Units when the viscosity is measured by putting the starch in a slurry with water at a starch concentration of 15% solids, and using a VISCOGRAPH®-E instrument set at 75 rpm and 700 cmg, where the starch is heated from 25° C. to 95° C. at a rate of 3° C./minute, the slurry is held at 95° C. for ten minutes, and the starch is cooled to 50° C. at a rate of ?3° C./minute.

US Pat. No. 10,919,806

DEVICE COMPRISING A CABLE OR CABLE ACCESSORY CONTAINING A FIRE-RESISTANT COMPOSITE LAYER

NEXANS, Courbevoie (FR)

1. A device having a power and/or telecommunications cable and/or a power and/or telecommunications cable accessory, wherein said cable and/or said cable accessory comprises:at least one composite layer obtained from a composite composition comprising at least one organic polymer or oligomer that is liquid at ambient temperatures; and
at least one aluminosilicate geopolymer in the form of a gel, said aluminosilicate geopolymer in the form of a gel being obtained from an aluminosilicate geopolymer composition comprising an alkali metal aluminate or an aluminosilicate, an alkali metal silicate, water and optionally an alkali metal base.

US Pat. No. 10,919,805

STRUCTURAL COMPOSITE MATERIALS

The Regents of the Univer...

1. A method of forming a composite material, the method comprising:forming a mixture comprising a binder material and a filler material; and
applying a pressure of at least 20 MPa to the mixture to form the composite material,
wherein the mixture comprises less than 9% by weight of the binder material, less than 18% by volume of the binder material, or both.

US Pat. No. 10,919,802

FERRITE COMPOSITIONS

BAE SYSTEMS plc, London ...

1. A method of manufacturing a ferrite composite structure comprising at least one glass fibre ply, the method comprising:causing heating of the at least one glass fibre ply to a softening point of the at least one glass fiber ply, thereby forming at least one softened glass fiber ply;
embedding a magnetic ferrite powder in the at least one softened glass fibre ply, wherein particles of the magnetic ferrite powder have an average longest dimension of less than 500 nm;
causing the at least one softened glass fibre ply to cool, thereby forming at least one cooled glass fibre ply;
encapsulating the at least one cooled glass fibre ply in a binder matrix, such that the binder matrix directly contacts the at least one cooled glass fibre ply; and
causing a cure of the binder matrix, thereby forming a fibre-reinforced composite.

US Pat. No. 10,919,801

DEVICE AND METHOD FOR INDUCING BY THERMAL POLING A SPATIALLY CONTROLLED REFRACTIVE INDEX GRADIENT INSIDE AN AMORPHOUS INORGANIC MATERIAL

UNIVERSITE DE BORDEAUX, ...

1. A device for inducing by thermal poling a spatially controlled refractive index gradient inside at least one amorphous inorganic material to be treated, said device comprising:a structured electrode arranged on a surface or in proximity to the surface of the material to be treated and having a structure defined by at least three geometrical parameters;
at least one dielectric material,
wherein
the structured electrode comprises at least one conductive zone and at least one non-conductive zone and the structure electrode is confined between the amorphous inorganic material to be treated and the dielectric material, the refractive index gradient being controlled in three directions of space by the at least three geometrical parameters defining the structure of the structured electrode, and wherein a value of each of the at least three geometrical parameters is selected to induce said spatially controlled refractive index gradient inside said amorphous inorganic material.

US Pat. No. 10,919,800

PLANARISATION OF A COATING

Pilkington Group Limited,...

1. A method of planarising a surface of a coating on a glass pane comprising:providing a glass pane that is directly or indirectly coated on a major surface thereof with a rough underlayer, and
depositing at least one layer based on one or more silazane or polysilazane on said underlayer; wherein
the method further comprises partially or completely converting the at least one layer based on one or more silazane or polysilazane to at least one layer based on silica and/or an organo silica, and
wherein the rough underlayer comprises at least one layer based on a transparent conductive coating (TCC), wherein the TCC is a transparent conductive oxide (TCO), and wherein the TCO is one or more of fluorine doped tin oxide (SnO2:F), zinc oxide doped with aluminium, gallium or boron (ZnO:Al, ZnO:Ga, ZnO:B), indium oxide doped with tin (ITO), cadmium stannate, ITO:ZnO, ITO:Ti, In2O3, In2O3ZnO (IZO), In2O3:Ti, In2O3:Mo, In2O3:Ga, In2O3:W, In2O3:Zr, In2O3:Nb, In2-2xMxSnxO3 with M being Zn or Cu, ZnO:F, Zn0.9Mg0.1O:Ga, (Zn,Mg)O:P, ITO:Fe, SnO2:Co, In2O3:Ni, In2O3:(Sn,Ni), ZnO:Mn, and/or ZnO:Co, and
wherein each layer of the at least one layer based on a TCC has a thickness of at least 20 nm, but at most 600 nm, and
wherein a surface of the at least one layer based on silica and/or an organo silica has an arithmetical mean height of the surface value, Sa, of at most 3 nm, and
wherein after depositing the layer based on one or more polysilazane or silazane, and/or after partially or completely converting the layer based on one or more polysilazane or silazane to at least one layer based on silica and/or an organo silica, said pane exhibits a haze value measured in accordance with the ASTM D 1003-61 standard of from 0.2% to 1.0%.

US Pat. No. 10,919,799

METHODS AND APPARATUS FOR PROCESSING GLASS

Corning Incorporated, Co...

1. An apparatus for coating a glass sheet comprising:a fog chamber comprising a first enclosure and a second enclosure;
a fog generator to provide fog to the first enclosure and the second enclosure, wherein the fog generator comprises an atomizer fog generator;
a first passage in the first enclosure from which fog can exit the first enclosure to contact a first major surface of the glass sheet,
a second passage in the second enclosure from which fog can exit the second enclosure to contact a second major surface of the glass sheet; and
a conveyor extending along the first passage, wherein the conveyor is positioned external to the fog chamber and configured so the glass sheet is in a vertical orientation as the glass sheet travels internally and laterally through the fog chamber during the coating;
wherein the first passage is spaced a predetermined distance from the second passage, and the predetermined distance defines a lateral travel path for the glass sheet to travel through the fog chamber during the coating.

US Pat. No. 10,919,798

ARTICLES WITH PATTERNED COATINGS

Corning Incorporated, Co...

1. An article, comprising: a continuous patterned coating with a bimodal distribution of coating thickness, the bimodal distribution comprising a lower-mode thickness in a range from 10 nm to 90 nm, and a higher-mode thickness in a range from about 50 nm to about 5000 nm,wherein the lower-mode thickness comprises a full-width-at half-maximum (FWHM) of about 1 nm or less and the higher-mode thickness comprises a FWHM greater than the FWHM of the lower-mode thickness.

US Pat. No. 10,919,797

DAMAGE RESISTANT GLASS WITH HIGH COEFFICIENT OF THERMAL EXPANSION

CORNING INCORPORATED, Co...

1. A glass, the glass comprising SiO2, from 6 mol % to 17 mol % Al2O3, greater than 5 mol % P2O5, and greater than 1 mol % K2O, wherein the glass has a coefficient of thermal expansion of greater than 95×10?7° C.?1, wherein the glass has a liquidus temperature TL, a 160 kP temperature T160kP, a 35 kP temperature T35kP, and a zircon breakdown temperature Tbreakdown, wherein TLT35kP.

US Pat. No. 10,919,796

METHOD FOR PRODUCING GLASS PLATE

NIPPON ELECTRIC GLASS CO....

1. A manufacturing method for a glass sheet, the manufacturing method comprising:a scribing step of forming a main scribe line along a preset cutting line on a glass original sheet, and forming a first auxiliary scribe line, a second auxiliary scribe line, a third auxiliary scribe line, and a fourth auxiliary scribe line on the glass original sheet; and
a cutting step of cutting the glass original sheet along the preset cutting line to obtain a glass sheet having an outer peripheral contour conforming to the preset cutting line,
wherein the main scribe line comprises:
a first straight line portion;
a second straight line portion;
a first connection portion, which connects one end point of the first straight line portion and one end point of the second straight line portion to each other, and comprises a curved line; and
a second connection portion, which connects another end point of the first straight line portion and another end point of the second straight line portion to each other,
wherein the first auxiliary scribe line is located on a straight line extended from the one end point of the first straight line portion along the first straight line portion,
wherein the second auxiliary scribe line is located on a straight line extended from the another end point of the first straight line portion along the first straight line portion,
wherein the third auxiliary scribe line is located on a straight line extended from the one end point of the second straight line portion along the second straight line portion,
wherein the fourth auxiliary scribe line is located on a straight line extended from the another end point of the second straight line portion along the second straight line portion,
wherein the first auxiliary scribe line, the second auxiliary scribe line and the first straight line portion are arranged on a same straight line,
wherein the third auxiliary scribe line, the fourth auxiliary scribe line and the second straight line portion are arranged on a same straight line, and
wherein the cutting step comprises:
a straight line portion cutting step of cutting the glass original sheet along the first straight line portion, the first auxiliary scribe line, and the second auxiliary scribe line by a single break cutting, and cutting the glass original sheet along the second straight line portion, the third auxiliary scribe line, and the fourth auxiliary scribe line by a single break cutting; and
a connection portion cutting step of cutting the glass original sheet, which has been subjected to the straight line portion cutting step, along the first connection portion, and cutting the glass original sheet along the second connection portion.

US Pat. No. 10,919,795

GLASS PLATE BEND-BREAKING MACHINE

BANDO KIKO CO., LTD., To...

2. A machine for bend-breaking a glass plate comprising:a flexible member on which the glass plate with a cut line formed thereon is placed;
a supporting mechanism having a supporting surface for supporting through said flexible member the glass plate at a central portion of a lower surface of the glass plate in a region surrounded by the cut line on the glass plate in a plan view;
a glass plate receiving device disposed below said flexible member and having an annular glass plate receiving surface for receiving the glass plate from a lower side of the glass plate through said flexible member and a recess surrounded by the annular glass plate receiving surface;
a first moving device for moving the glass plate receiving surface of said glass plate receiving device;
a press-breaking device disposed above said flexible member and having a pressing surface for press-breaking along a cut line the glass plate with the cut line formed thereon; and
a second moving device for moving the pressing surface of said press-breaking device,
wherein said first moving device is adapted to dispose the glass plate receiving surface such that, at the time of press-breaking of the glass plate by the pressing surface, the pressing surface of said press-breaking device can press that part of the glass plate that opposes the recess surrounded by the glass plate receiving surface,
said second moving device is adapted to dispose the pressing surface such that, at the time of press-breaking of the glass plate by the pressing surface, the pressing surface can press that part of the glass plate that opposes the recess surrounded by the glass plate receiving surface which has been moved by said first moving device, and
said machine further includes a controller programmed to cause the pressing surface of said press-breaking device to press-break the glass plate along the cut line by causing the pressing surface to press against that part of the glass plate that is outside a region surrounded in plan view by the cut line and opposes the recess surrounded by the glass plate receiving surface.

US Pat. No. 10,919,794

METHOD OF CUTTING GLASS USING A LASER

GENERAL ATOMICS, San Die...

1. A system for cutting a glass sheet having a front surface, a reverse surface, and a thickness, comprising:a sacrificial substrate, wherein the glass sheet is placed onto the sacrificial substrate such that the reverse surface faces the sacrificial substrate;
a laser, wherein the glass sheet is interposed between the sacrificial substrate and the laser;
a pulsing system coupled to the laser, wherein the pulsing system pulses a beam from the laser at a frequency of from between 10 kHz and 30 kHz; and
a laser control apparatus coupled to the laser, wherein the laser control apparatus is adapted to:
direct a beam from the laser at the front surface of the glass sheet and through the glass sheet onto the sacrificial substrate;
move the beam across the glass sheet at a rate of between 30 millimeters per second and 90 millimeters per second;
ablate the sacrificial substrate with the beam;
generate a superheated vapor in response to the ablating of the sacrificial substrate; and
ablate the reverse surface of the glass sheet with the superheated vapor in response to the superheated vapor being generated, whereby the glass sheet is cut.